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" . . .  a miraculous disease, that is not very prevalent. The disease is chronic 
and it takes a long time to manifest itself. Then the patient lives short and 
life is terrible and painful. An insuppressible thirst; extreme drinking, which 
is totally disproportionate to the large quantity of urine. This thirst cannot be 
taken away . . .  " 
Demetrius of Apameia, 300 B .C. l;Z 
The current definition of diabetes is : "a metabolic disorder of multiple 
aetiology characterized by chronic hyperglycaemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action or both. "3 
The effects of diabetes mellitus include long-term damage to and the 
dysfunction and failure of various organs. Diabetes mellitus may present 
with characteristic symptoms such as thirst, polyuria, blurring of vision, and 
weight loss. Often the symptoms are not severe, or may even be absent, and, 
consequently, hyperglycaemia sufficient to cause pathological and 
functional changes may be present for a long time before the diagnosis is 
made. The long-term effects of diabetes mellitus include progressive 
development of the specific complications of retinopathy with potential 
blindness, nephropathy that may lead to renal failure, and/or neuropathy 
with a risk of foot ulcers, amputation, Charcot joints, and features of 
autonomic dysfunction, including sexual dysfunction. There is an increased 
risk of cardiovascular, peripheral vascular, and cerebrovascular disease: 
people with diabetes have a two to threefold increased risk of cardiovascular 
disease compared with those who do not have diabetes.4 Patients with 
diabetes have significantly higher all-cause mortality rates than the general 
population, with the most common cause of death cardiovascular disease 
(almost 50% versus 36% in the non-diabetic population). 5-7 
Several pathogenetic processes are involved in the development of 
diabetes. These include processes which destroy the beta cells of the 
pancreas with consequent insulin deficiency, and others, such as obesity and 
physical inactivity, which result in a resistance to insulin action. The 
abnormalities of carbohydrate, fat, and protein metabolism are due to the 
deficient action of insulin on target tissues resulting from an insensitivity to 
or lack of insulin. 
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Type 2 diabetes mellitus is the more common form of diabetes and results 
from a defect in insulin secretion, usually accompanied by insulin 
resistance. Type 2 diabetes is a term used to describe a relative (rather than 
an absolute) insulin deficiency. People with this type of diabetes are 
frequently resistant to the action of insulin.8;9 At least initially, and often 
throughout their lifetimes, these individuals do not need treatment with 
insulin to survive. The majority of these patients are obese, and obesity 
itself may cause or aggravate insulin resistance.10;11 Insulin sensitivity may 
be improved with weight reduction, increased physical activity, and/or 
pharmacological treatment of hyperglycaemia, though it does not return to 
normal.12;13 This form of diabetes frequently remains undiagnosed for many 
years because the hyperglycaemia is often not severe enough to cause 
noticeable symptoms of diabetes.14;15 Nevertheless, such patients are at an 
increased risk of developing macrovascular and microvascular 
complications. The risk of developing �e 2 diabetes increases with age, 
obesity, and lack of physical activity.1 ;!7 It occurs more frequently in 
women with prior gestational diabetes and in individuals with hypertension 
or dyslipidaemia. It is often associated with a strong familial, likely genetic, 
predisposition.18-20 
Reason for this thesis 
Type 2 diabetes mellitus has a long history. Because of recent 
developments, type 2 diabetes is becoming a world-wide epidemic in the 
first quarter of the 21st century with serious consequences for the quality of 
life of affected persons and substantial implications -with rising demands­
for health care. 
The prevalence of diabetes in adults world-wide was estimated to be 
4.0% in 1995 and is expected to increase to 5.4% by the year 2025. The 
number of adults with diabetes will rise from 135 million in 1995 to 300 
million in the year 2025. There will be a 42% increase, from 51 to 72 
million, in developed countries where the majority of people with diabetes 
are aged >65 years.21 Following the initial phase of the type-2-diabetes 
epidemic, macro- and microvascular complications will emerge as a major 
threat to public health world-wide with huge economic and social costs.22 
Type 2 diabetes is no longer an isolated disorder of glucose metabolism. 
Often a person with diabetes will be found to have at least one or more other 
cardiovascular disease (CVD) risk components?3 This clustering has been 
labeled variously as Syndrome X,23 the Insulin Resistance Syndrome, 17 or 
3 
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the Metabolic Syndrome. 17 The diabetic person with hypertension, central 
(upper body) obesity, and dyslipidaemia presents a diagnostic and 
therapeutic challenge. This group of people is at high risk for developing 
macrovascular disease.23 People with diabetes are two to three times more 
likely to develop cardiovascular disease than the non-diabetic population.4 
Evidence is accumulating that insulin resistance may be the common 
aetiological factor res�onsible for the individual components of the 
Metabolic Syndrome. 17; 4;25 Alone, each component of the cluster conveys 
increased CVD risk, but in combination they become much more 
powerful.26 This can be illustrated by the increase in relative risk for CVD 
when combining different risk factors, as was done for the Framingham 
population (Figure 1).27 Consequently, the management of persons with 
diabetes and other features of the Metabolic Syndrome should focus not 
only on blood glucose control but should also include strategies for the 
reduction of other CVD risk factors.28 In other words, type 2 diabetes has 
changed from being an isolated disorder of glucose metabolism into an 
important cardiovascular risk factor. 
Much as is seen in other countries, there is an ongoing shift from 
secondary to primary care in The Netherlands. 29;3° Consequently, the care 
for patients with type 2 diabetes is concentrated in primary care.31-34 
Concomitantly, there is a growing shortage of primary health care 
providers. 35-38 
To improve the quality of diabetes care, guidelines for clinical 
practice have been developed in many countries.34;3941 However, the 
implementation of these guidelines has proven not to be 
straightforward.42;43;4447 The reasons causing the problems in 
implementation are multiple: lack of time, lack of staff, lack of recall 
facilities and lack of diabetes registers, poor quality of documentation, 
unavailability of diabetes nurses, patient failure to keep referrals and missed 
appointments, inadequate reimbursement, lack of physician consultative 
assistance, the obligatory active approach, and waiting lists for 
ophthalmologists. 48-56 
In light of the above developments, which make type 2 diabetes into 
a large health-care problem, solutions need to be found which address the 
quality of care and the manageability of the disease. 
4 
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Figure 1. Estimated 1 0-year risk of coronary heart disease in hypothetical 
55-year-old men and women according to levels of various risk factors. 
Lipid units are in mg/dL. 27 
Improving the quality of care means that findings from clinical research 
settings need to be translated to real-world practice.57 The challenge is 
determining how to translate findings from an ideal setting to the frequently 
less-than-optimal situations that face typical clinicians, who care for diverse 
communities with finite resources and face many competing demands.58 
Structured shared care can help solve the above problems and can 
improve quality of care. 59 Multifaceted complex interventions targeting 
different barriers to change are most effective. Successful interventions 
include applying organizational strategies, using multifaceted professional 
interventions, facilitating generalist-specialist communication, delegating 
5 
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tasks to practice assistants or nurses, and using specialist diabetes nurse 
facilitators. Nurses can play an important role in facilitating compliance and 
educating patients. In certain conditions, thel can even replace physicians in 
delivering many aspects of diabetes care.48-5 ;s9-6 1 
The aim of this thesis is to study the current magnitude of type 2 
diabetes as a health care problem, to study the effectiveness of different 
organizational strategies to improve the quality of care for type 2 diabetes, 
and to identify future directions for further improvement strategies. 
Research questions 
The aims of this thesis lead to three research questions that are addressed in 
the ZODIAC-study (Zwolle Outpatient Diabetes project Integrating 
Available Care). 
1 .  What is the magnitude of the health care problem surrounding type 2 
diabetes in The Netherlands as we enter the 2 1st century? 
2.  How effective are two different organizational strategies, in the form of 
shared care with task delegation, in improving quality of care for type 2 
diabetes? 
3 .  What should be the aims of future improvement strategies with respect to 
the treatment of patients with type 2 diabetes in primary care? 
Outline of this thesis 
The first research question, regarding the magnitude of the health care 
problem surrounding type 2 diabetes, is primarily addressed in chapter 2, 
but also in chapters 3 and 5-8. Chapter 2 addresses the epidemiology of type 
2 diabetes. In chapter 3 and in chapters 5-8, data on the implementation of 
different aspects of the national guidelines of the Dutch College of General 
Practitioners (shortly: National GP Guidelines) are presented, and in 
chapters 3 and 6-8, data on the prevalence and the management of 
glycaemic regulation, hypertension, and lipid profile abnormalities, as well 
as the prevalence of microalbuminuria and micro- and macrovascular 
complications are shown. 
Chapter 2 describes the epidemiology of type 2 diabetes in the 
Zwolle region of The Netherlands during the years 1 998 through 2000. 
Prevalence, incidence, and mortality data are extrapolated to national 
estimates for The Netherlands. 
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The second research question, regarding the effectiveness of different 
organizational strategies for type 2 diabetes in primary health care, in the 
form of shared care with task delegation is addressed in chapters 3 and 4. 
Chapter 3 describes the longitudinal effects of two different shared­
care interventions with task delegation and compares these interventions 
with standard care. Outcome variables are the implementation of 
measurements and examinations according to the guidelines34, glycaemic 
regulation, and the regulation of blood pressure and the lipid profile. 
The third research question, regarding the aim of future improvement 
strategies for the care of patients with type 2 diabetes in primary health care, 
is addressed in chapters 4 through 9. 
Chapter 4 describes the responsiveness of general practitioners to 
advice, given within the shared care project concerning individual patients. 
We studied direct (in writing) recommendations from nurses specialized in 
diabetes concerning referrals to dieticians, chiropodists, or podiatrists, and 
indirect (checkbox format) recommendations concerning blood pressure, 
lipid profile, and glycaemic regulation. 
Chapter 5 describes a survey of 1 79 general practitioners about the 
organisation of diabetes care in primary health care, with an emphasis on 
task delegation; the findings were compared to what is recommended in the 
National GP Guidelines.34 
Chapter 6 describes an analysis of the prevalence, treatment, and 
treatment success of cardiovascular risk factors. Additionally, the influence 
of patient factors (age, gender, smoking, having a history of cardiovascular 
disease, and glycaemic regulation) and the registration of the different risk 
factors in the patient record by general practitioners was studied. 
Chapter 7 describes the prevalence and treatment of micro- and 
macroalbuminuria, a risk factor for cardiovascular disease and nephropathy, 
in different age categories. Recent literature is reviewed to answer the 
question whether the National GP Guidelines in this area need to be 
reviewed. 34 
Chapter 8 describes a study comparing the prevalence and treatment 
of hypertension in patients with type 2 diabetes in primary care with those in 
secondary care. 
Chapter 9 describes a study into associations of body mass index and 
smoking habits between patients and their physicians, and the role of other 




To be able to interpret the presented results, an exact understanding of the 
methods used is essential. To avoid an overly lengthy description of the 
methods in the separate chapters, the design is described here in detail. 
Study design 
The Zwolle Outpatient Diabetes project Integrating Available Care 
(ZODIAC)-study investigates the effects of structured shared care for type 2 
diabetes within the primary care setting. Zwolle is located in the east of The 
Netherlands. The Zwolle region had, before the introduction of the shared 
care project, a classical organisation of diabetes care. The majority of type 2 
diabetes patients were treated in primary care only. Treatment in secondary 
care was restricted to patients with complications or patients with glycaemic 
dysregulation, who would possibly need insulin therapy. Diabetes specialist 
nurses, who are employed by the hospital, could (and can, except within the 
shared care project) only be consulted through a referral to an internist, in 
the secondary care setting. As a consequence of developments in recent 
years, at this moment initiation of insulin therapy can be done (outside the 
project setting) by GPs themselves, with support from a practice nurse or a 
nurse from a home care organization, or through a formal referral to 
secondary care as described. There was and is no GP laboratory. The Zwolle 
region does have a long tradition of extra attention for diabetes care though. 
Even before the introduction of the first national guideline for type 2 
diabetes, there was a consensus between primary and secondary care about 
the main elements of treatment of type 2 diabetes. Retinal screening by an 
ophthalmologist was only possible by referring the patient, there were and 
are no possibilities for retinal photography except within the shared care 
project. Easy accessibility for secondary (outpatient) diabetes care was and 
is pursued, but capacity problems gave rise to growing waiting lists. The 
MCC-K.lik shared-care project, in which the ZODIAC-study was embedded, 
was started in 1 998, in order to further improve diabetes care in the region. 
Eight GP-working groups were invited to participate. A GP-working group 
consists of GPs -with practices in the same town or city- collaborating 
mainly with respect to delivering medical service during out-of-office hours. 
After generating a list of all GP-groups in the target region, the GP­
coordinator of the project started to contact these groups in alphabetical 
order and asked them to participate. When the line was busy, or the group 
could not be contacted at that moment, the coordinator moved further down 
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the list. The first eight groups that could be reached (64 GPs) all agreed to 
participate. Allocation to intervention A , B, or standard care was, for 
pragmatic reasons, done according to the preference of the GP-working 
groups as a whole. Although randomisation was seriously discussed, 
extending the co-operation between primary and secondary care had proven 
not to be straightforward in the initial phase of the project. Therefore, a 
higher priority was given to further extension of the regional co-operation 
than to the ransomisation for the benefit of the study. Three GPs were 
excluded: two because they were starting a new practice and one due to 
retirement. 
The GPs were each allocated to one of three groups: the first group 
(intervention A -annual check-up by DSNs-, 32 GPs) received extensive 
support from nurses specialized in diabetes (DSNs) who were hospital­
based, but who worked for the project within the primary health care setting. 
The second group (intervention B -on demand consultation with DSNs 
only-, 21 GPs) received limited support from these DSNs and the third 
group (intervention C, 8 GPs ), the standard-care group, delivered standard 
care, receiving no extra support at all. In total, 1.6 full time equivalent (fte) 
DSNs were employed in the project, approximately 1.4 fte for intervention 
A and 0.2 fte for B. 
Interventions 
Extensive support (Intervention A: annual check-up according to National 
GP Guidelines by DSNs) 
Extensive support means that DSNs -instead of the GPs- performed the 
annual check-up according to the National GP Guidelines, in all patients 
with type-2-diabetes treated within the primary health care setting. Fundus 
photographl2 was included in this check-up, where normally each patient 
would have to be referred to an ophthalmologist. GPs were responsible for 
the tri-monthly check-up themselves. Additionally, the DSNs gave one-on­
one counseling which was tailored to the needs of the individual patient. If 
necessary (according to retinal photography results, or in cases of newly 
diagnosed diabetes) a referral to the ophthalmologist was arranged by the 
DSN. The 45-minute appointments with the DSN took place outside the 
hospital, in the primary health care setting, in the village or city where the 
patient lived. Patients who missed an appointment were contacted and 
rescheduled. Patients who were housebound with serious co-morbidity were 
visited at home. 
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A comprehensive structured report (appendix 1) of the results was sent to 
the GP within three weeks. If necessary, the results were accompanied by 
comments and/or recommendations from the DSN and/or an internist. The 
(written) comments from the DSN included recommendations concerning 
referrals to dieticians, chiropodists, and/or podiatrists. The (written) advice 
from the internist concerned treatment according to the National GP 
Guidelines. The report also included indirect (checkbox) recommendations 
with respect to the regulation of blood pressure, lipid profile, and HbA1c 
which were judged as being 'good', 'acceptable', or 'poor'. 'Poor' 
regulation could (should) be seen as a recommendation to initiate or 
intensify therapy. Regulation was defined as 'poor' for blood pressure if it 
exceeded 160/90 mmHg, for HbAlc if it exceeded 8,5%, for BMI if it 
exceeded 30, and for the lipid profile if the total cholesterol to HDL­
cholesterol ratio was more than 6. 
The GPs were therefore able to dedicate their consultation time to 
discussing the results with the patient in detail and to decide, together with 
the patient, how to act upon them. The GPs maintained the full 
responsibility for patient care and were under no obligation to follow the 
recommendations given. 
A second part of the extensive support was the possibility of sending 
individual patients directly (without -as in standard care- referral to 
secondary care) to the DSN for an on-demand consultation within the 
primary health-care setting. 
Limited support (Intervention B: on-demand consultations with DSNs only) 
Intervention B was restricted to the possibility of direct on-demand 
consultations with the DSN (without -as in standard care- referral to 
secondary care). Reasons for on-demand consultations included: education, 
instruction on self-monitoring, or instruction on insulin injection therapy. 
The GPs remained responsible for determining the initial insulin dosages 
and for making changes in insulin dosages if consulting the DSN for 
switching to insulin therapy. 
The GPs were themselves responsible for the annual and tri-monthly 
check-ups, including referrals to the ophthalmologist. The GPs received 
reports on individual patients who had been sent to the DSNs for on-demand 
consultation. 
Benchmarking 
All participating GPs from intervention groups A, B, and standard-care 
group C received benchmarking (appendix 2) about their baseline 
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performance, which was discussed within the GP-working-group in the 
presence of an internist. Data from their own patients were compared to 
pooled anonymous data from their colleagues. These data concerned the 
characteristics of the diabetes population, glycaemic control, body mass 
index, blood pressure regulation, lipid profile regulation, diabetes-related 
therapy, and performance with regard to working according to the National 
GP Guidelines. The mean HbA1c, blood pressure, and cholesterol values for 
the GPs' diabetes population were compared to the mean values for all the 
patients from the other participating GPs, as were the percentages of 
patients with a 'good', 'acceptable', and 'poor' regulation of these variables. 
Patients 
The target population consisted of patients with type 2 diabetes, treated 
within the primary health care setting. In contrast with many other studies in 
this area, and in contrast with clinical trials, our objective was to keep the 
target population as unselected as possible, because this is what GPs see in 
daily practice. Patients with type 1 diabetes, defined by an age at diagnosis 
of <40 years and requiring insulin within one month of diagnosis, were 
excluded. Patients were also excluded if they had been (co )treated in 
secondary care by an internist during the past year, if they were terminally 
ill, or if they had been diagnosed with dementia. All other patients were 
invited to participate, resulting in a highly unselected primary-care type-2-
diabetes patient population. 
Data collection 
Lists naming all patients known with type 2 diabetes mellitus, as defined by 
the National GP Guidelines,34 were provided annually by the GPs. In The 
Netherlands, virtually all citizens are registered with a GP. On these lists 
GPs indicated patients who were being (co )treated in secondary care by an 
internist, who were terminally ill, or who had a diagnosis of dementia. All 
other patients on the list were potential participants. 
As outcome measures we chose the set of variables that has to be 
collected during the annual check-up according to the revised 1999 national 
guidelines?4 We had been given the opportunity to view the contents of the 
revised guidelines before publication. The reason for this choice was the 
existing consensus about the relevance of these variables for diabetes care 
and because the Guidelines of The Dutch College of General Practitioners 
are widely accepted among the Dutch GPs. 
11 
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Effects of interventions were measured by changes in three quality 
indicators. We studied process control ( 1 ) :  the percentage of patients with 
examinations and measurements performed according to the guidelines, and 
outcome control (2) :  the percentage of patients that achieved target values 
(HbA1c  < 7.0%, blood pressure < 1 50/85 mm Hg, total cholesterol < 5 
mmoVL). Expressing the number of patients known to have achieved target 
values -based on available data- as a percentage of the total target 
population, results in a quality indicator (3) that combines process and 
outcome control. Feasibility of the interventions was valued based on 
participation rates of patients and GPs and patient and provider satisfaction. 
Data were collected on these patients through different methods. 
Firstly, for intervention groups A, B, and the standard-care group C, data on 
medication use and medical history were provided for each individual 
patient by their treating GPs. Secondly, for intervention groups A, B, and the 
standard-care group C, retrospective and prospective data were collected 
manually for each individual patient from the GPs' registrations (electronic 
or paper medical record, including specialist correspondence) by the 
primary investigator of the study. Data were collected for patients who 
entered the project between February 1 998 and February 2001 on: complete 
medical history, diabetes and general medication use, diabetes duration, foot 
examination, smoking status, eye-examination/retinal screening, blood 
pressure, weight, length, body mass index, fasting blood glucose, blood 
glucose profiles, HbAl c, total cholesterol, HDL-cholesterol, triglycerides, 
serum creatinine, urinary creatinine, and (micro-)albumin. Retrospective 
data collection covered a period of one year for all variables except for eye 
examinations for which a two year period was used as a biennial visit to the 
ophthalmologist is all that is recommended in the National Guidelines for 
patients with uncomplicated diabetes. All laboratory measurements 
retrieved from the patients' records had been performed in a single 
laboratory, except for glucose levels. Glucose may also have been measured 
using ambulant devices from the GPs' practices. Thirdly, for intervention 
group A, data were collected prospectively for each patient by the DSNs. 
For intervention group B this was only applicable for patients who were 
referred to the DSN for an on-demand consultation. 
All participating patients in intervention group A received, together 
with their invitation, a laboratory form and a quality-of-life questionnaire. 
Quality of life was assessed annually with the Rand 36-Item Health Survey 
(Rand-36),63 a validated generic quality-of-life questionnaire. Patients were 
asked to complete this questionnaire and have their blood drawn and urine 
12  
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collected before the consultation with the DSN. The DSNs collected data 
during their consultations with the patient. The nurse checked the data on 
medication use and the medical history provided by the treating GPs with 
the patient. Blood pressure, weight, and height were measured: blood 
pressure with a Welch Allyn Sphygmomanometer (annually gauged) in 
supine position after at least 5 minutes of rest, and weight and height both 
with Seca scales. The feet were examined thoroughly for wounds. Any loss 
of sensation was tested with a 5 .07 Semmes Weinstein monofilament on 
three sites of each foot, which is a reasonably sensitive and specific 
assessment for diagnosing diabetic polyneuropathy.64 The BMI was 
calculated from weight and length (kg/m2). Data on smoking were obtained 
by questioning the patient directly. In the laboratory, HbAl c  (reference 
value 4.0-6.0%) was measured with a Primus CLC-385 using the principle 
of boronate affinity chromatography and high pressure liquid 
chromatography (HPLC). A Roche/Hitachi MODULAR Analyzer was used 
to measure serum creatinine (kinetic colorimetric assay), non-fasting total 
cholesterol (Cholesterol CHOD-PAP, enzymatic colorimetric test), non­
fasting HDL-cholesterol (HDL-Cholesterol plus, homogeneous enzymatic 
colorimetric test), non-fasting triglycerides {Triglycerides GPO-PAP, 
enzymatic colorimetric test), and urine micro albumin {Tina-quant® 
Albumin, immunoturbidimetric assay). Creatinine clearance was calculated 
using the Cock croft and Gault formula. 65 
The Medical Ethics Committee of the Isala Clinics (formerly 
Weezenlanden Hospital) approved this study. 
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Prevalence, incidence and mortality 
Abstract 
Background: To present actual data to estimate prevalence, incidence and 
mortality of known type 2 diabetes mellitus in all age categories in The 
Netherlands. 
Methods: Prospective population-based study between 1998 and 2000 in 
The Netherlands. Baseline population of 1 55,774 patients, registered with 
6 1  general practitioners participating in the Zwolle Outpatient Diabetes 
project Integrating Available Care (ZODIAC)-study. 
Results: Age- and sex-adjusted prevalence of type 2 diabetes was 2 .2% at 
baseline and 2.9% after two years of follow-up; for women and men it was 
3 . 1% and 2.7% at follow-up, respectively. Patients aged >70 years account 
for almost 50% of all type 2 diabetes patients. Age- and sex- adjusted mean 
annual incidence per 10,000 over three years was 22.7 overall; for women 
23 . 1  and for men 22.2. Incidence -even though high- decreases after the age 
of 70 years. The mortality rate was 47.9/1 ,000 and standardised mortality 
ratio 1 .40. Based on these results, the estimated total number of subjects 
known with type 2 diabetes was 466,000 for The Netherlands in 2000; the 
number of patients with newly diagnosed diabetes 36,000. 
Conclusions: Prevalence and incidence rates exceed all estimates regarding 
known type 2 diabetes for The Netherlands. Elderly patients, aged 70 years 
and over, account for 50% of the type 2 diabetic population. These results 




Type 2 diabetes mellitus is a chronic disease, leading to considerable 
morbidity and premature mortality. 1 ;2 The prevalence is high, especially in 
the elderly, and increasing.3 Accurate information about the prevalence of 
known type 2 diabetes and the number of newly diagnosed cases in the 
community is essential for health-care planning. 
In The Netherlands, estimates on current and future incidence, 
prevalence and mortality are available, based on various studies.4-9 
However, the data used originate from 1 993 or earlier, estimates on 
incidence and prevalence vary considerably,8 and few studies describe older 
age categories in detail. This variation in estimates on current and future 
incidence and prevalence may be explained by the differences in models 
used for future projections, by the year the data used for these projections 
originate from, and also by differences in the design of studies supplying 
original data for these estimates. Between studies with a different study 
design -using oral glucose tolerance tests or based on self report or general 
practice registers- the large proportion of patients with type 2 diabetes that 
is presumed to be undiagnosed (and could be as high as 50%) can give rise 
to varying findings, I O; l l  especially because this proportion again may vary 
between regions or countries. 
Not only national but also international literature presents few 
publications with detailed data on the highest age categories : these 
publications are difficult to compare because of considerable differences in 
definitions and study design, and they show highly varying prevalence 
rates. 12-1 9 As the prevalence of type 2 diabetes increases quickly and is 
estimated to be highest in the eldest age categories, we consider it important 
not to ignore this age category and to present actual data on current 
prevalence, incidence and mortality of known diabetes in all age groups, 
including these eldest. These data could be used to describe temporal trends 
and can support health-care planning. 
Therefore, in the light of all the above arguments, the aim of this 
study is to present actual data from a large population in order to be able to 
estimate current prevalence, incidence and mortality of type 2 diabetes, as 
known in or identified through the normal health-care processes, in all age 
categories in The Netherlands. 
2 1  
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Methods 
The Zwolle Outpatient Diabetes project Integrating Available Care 
(ZODIAC)-study investigates the effects of a shared-care project for type 2 
diabetes. In this project general practitioners (GPs) receive support from 
diabetes specialist nurses for the practical implementation of the national 
guidelines with respect to performing the annual control and education in 
patients with known diabetes. This working protocol does not, in any way, 
aim to influence in the actual process of diagnosing diabetes and screening 
high-risk populations; so (changes in) prevalence and incidence are 
considered comparable with those found in the normal health-care process. 
In the project, 6 1  GPs from an eastern part of the country participate. These 
are all the GPs of the 8 GP-working groups covering the project target area. 
A GP-working group consists of GPs -with practices in the same town or 
city- collaborating mainly with respect to delivering medical service in out­
of-office hours. GPs could only participate in the project with their total 
working-group, and all groups invited agreed to participate. This means that 
among participating GPs there are some with a special interest and others 
with no special interest in diabetes. In The Netherlands, virtually each 
inhabitant is registered with a GP. 
As part of the ZODIAC-study, we collected cross-sectional data on 
the general population and all patients with diabetes, as registered with the 
6 1  GPs, in three consecutive years: 1 998-2000. Lists naming all patients 
known with type 2 diabetes, as defined by the national guidelines of the 
Dutch College of General Practitioners of 1 989 and 1 999 (based on the 
1 985 World Health Organisation (WHO) and 1 997 American Diabetes 
Association (ADA) criteria, respectively), were provided annually by the 
GPs and checked for each individual practice by the principal investigator. 
These lists were composed combining information on glucose 
measurements, HbA 1 c, use of diabetes medication and special markers for 
signalling diabetes in the patient files. A manual check, consisting of a 
review of the complete paper and/or electronic patient file, for the validity 
of the diagnosis, the type of diabetes, and the date of diagnosis was 
performed by the principal investigator of the study for each individual 
patient with diabetes in each practice. Patients with type 1 diabetes, defined 
by age at diagnosis as <40 years and requiring insulin within one month of 
diagnosis, were removed from the lists. The validity of the diagnosis type 2 
diabetes was checked in the individual patient files by looking up the 
glucose measurements the diagnosis was based upon, and comparing these 
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measurements with the criteria for diabetes in the national guideline at the 
time of diagnosis for each patient. Incident cases (newly diagnosed cases) 
were defined as having a diabetes duration of <1  year at baseline or in the 
first or second study year. The total general population, registered with the 
participating 6 1  GPs at baseline, consisted of 1 55,774 persons. The practices 
had computerised patient lists and all supplied the total number and age- and 
sex- distribution of the total general population registered with their practice 
in each study year. 
To extrapolate our findings for the Dutch population, we used 
national data on age- and sex- distribution from the Central Bureau for 
Statistics for each year corresponding with the study years.20 To check the 
external validity of the data, the age- and sex- distribution of the study 
population and national population were compared. Prevalence rates were 
calculated as percentages per 5- and 10-year age category. The 95% 
confidence intervals (CI) for differences between observed proportions were 
calculated for each age category. Incidence rates were calculated per 10,000 
per 5- and 1 0-year age category. Standardised mortality ratios (SMRs) were 
calculated for patients with known type 2 diabetes, dividing the observed 
number of diabetic deaths by the number of expected deaths in the general 
population, using the Dutch 1 998 population as the reference population.20 
Expected numbers were calculated per 5-year age category. Statistical 
analyses were performed using the Statistical Package for Social Sciences 
(SPSS, version 8.0 . 1 ). This study was approved by the Medical Ethics 
Committee of the Isala Clinics (formerly Weezenlanden Hospital). 
Results 
The age and sex distribution of the total general population studied was 
marginally different from the national population, mainly in the age 
categories 20-29 and 65-69 years (Figure 1 ) .  In these categories the 
difference between the proportions of the age categories from the total study 
population and the national population was 2.2% and 0.4%, respectively. 
Prevalence 
At baseline, 3369 patients known with type 2 diabetes were identified in the 
total population of 1 55,774 persons. The mean age of the diabetic 
population was 67.7 years (Standard Deviation (SD): 1 2 .6) overall, and 69.7 
(SD: 1 2.3) versus 65 . 1  (SD: 1 2.3) for women and men, respectively. Age 
ranged from 1 9  to 1 02 years. 
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Figure 1 .  Age and sex distribution of the study population and national 
population. 
Prevalence 
At baseline, 3369 patients known with type 2 diabetes were identified in the 
total population of 1 55,774 persons. The mean age of the diabetic 
population was 67.7 years (Standard Deviation (SD): 1 2.6) overall, and 69.7 
(SD: 12.3) versus 65. 1 (SD: 1 2.3) for women and men, respectively. Age 
ranged from 19  to 102 years. 
The overall crude prevalence was 2. 1 6%; the age- and sex-adjusted 
prevalence for The Netherlands was 2.2 1% (95% CI = 2. 1 3-2.28). 
Prevalence for women was 2 .4% versus 2.0% in men. The prevalence per 
age category is presented in Table 1 and Figures 2 and 3 .  The highest 
prevalence was found in the age category 70-79 for both women and men. 
After two years of follow-up, the population on the lists of participating GPs 
consisted of 1 56.074 persons; the number of participating GPs did not 
change, but the general population of the practices had grown in the study 
period, as in the rest of The Netherlands. Because of this change, data on 
age and sex distribution of the general population of each specific study 
year were used for the age- and sex- adjustment. In this general population, 
4423 patients were known with type 2 diabetes after two follow-up years. 
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Crude prevalence had increased to 2.83% overall, age- and sex-adjusted 
prevalence to 2.94% overall, to 3 . 1%  for women and to 2.7% for men. For 
the diabetes population this meant an increase of 33% (women 30%, men 
37%) in two years. The age distribution for known type 2 diabetes for the 
male population shifted towards the pattern of the female population. The 
number of patients in The Netherlands in 2000, according to the prevalence 
found, is estimated to be 466,000. 
Table 1. Prevalence per 5- and 1 0-year age categories for men and 
women. 
Baseline Follow-up year 2 2-year increase in 
l!revalence 
Prevalence (%} 
-"' � -� = � ·c ._, = 0 � ._, � � CJ � CJ - = - � CJ = 4J � � - 4J = - = 4J -� -; 4J = 4J "C � CJ -; -; -; e - ... = t: 4J .... = � �  � = �  - 4J - - 0 4J = 0 -� 0 ... 0 0 � � .,Q =  � u .S  < E- � E- � < -c  
0-4 0 0.0 0 0.0 0.0 0.0 0.00 0.00 -0.00 
5-9 0 0.0 0 0.0 0.0 0.0 0.00 0.00 -0.00 
10-14 0 0.0 0 0.0 0.0 0.0 0.00 0.00 -0.00 
15-19 1 0.0 1 0.0 0.0 0.0 0.00 -0.03 -0.03 
20-29 8 0.0 8 0.0 0.0 0.0 0.00 -0.04 -0.03 
30-39 63 0.3 76 0.3 0.3 0.3 0.05 -0.04 -0. 1 4  
40-49 249 1 .2 3 14  1.5 1 .3 1 .6 0.29 0.08 -0.50 
50-59 587 3.2 778 4.3 3.6 4.9 1 .05 0.67 - 1 .43 
60-64 370 5.8 480 7.5 7.0 8. 1 1 .73 0.9 1 -2.56 
65-69 477 8.6 576 10.4 10.4 10.4 1.77 0.75 -2.79 
70-79 109 1  10.7 1437 14.0 14. 1 13.9 3.35 2.43 - 4.27 
80-89 466 10.7 667 15.3 15 .4 15. 1  4.59 3.17 -6 .02 
>90 57 8.2 86 12.3 12.6 1 1 . 1  4.05 0.8 1 - 7.30 
Total 3369 2.16 4423 2.83 3.08 2.57 0.67 0.56 -0.78 
Incidence 
The number of patients with newly diagnosed type 2 diabetes at baseline 
and in year one and two are shown in Table 2. The overall crude mean 
annual incidence was 22.0/10,000 and the age-and sex-adjusted incidence 
22.7/10,000 (95% CI: 22.5-22.9). For women this was 23 . 1  and for men 
22.2/ 10,000. The highest incidence for both women and men was found in 
the age category 65-69, where it was 87 and 97/10,000 per year, 
25 
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respectively. Based on the incidence found, the annual number of patients 
with newly diagnosed diabetes is estimated to be approximately 36,000 per 
year in The Netherlands. 
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Figure 2. Prevalence of type 2 diabetes at baseline. 
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Table 2. Incidence per 10, 000 for 5- and 1 0-year age categories for men 
and women. 
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Total 290 376 364 22.0 2 1 .8 -22.2 22.5 
CI: Confidence Interval 
Mortality 
- -u u 
� c � 0 � 0 tn :2: tn e'l e'l 
0 - 0 0 0 - 0 
0 - 0 0 0 -0 
0 -0 0 0 -0 
1 - 1  0 0 -0 
1 - 1  1 I - 1  
3 - 3 3 2 - 3 
1 3  - 14 12 12 - 12 
40 -43 47 46 -49 
64 - 72 72 68 - 76 
82 - 92 97 9 1  - 103 
76 - 83 96 9 1  - 10 1  
69 - 78 84 76 - 9 1  
3 1  -4 1  0 0 -0 
22.2 - 22.7 2 1 .6 2 1 .3 - 2 1 .8 
From the baseline population (n=3369), 323 (9.6%) patients died during the 
two-year follow-up period. The mean age of these patients was 79.3 years 
(SD: 1 0.5, range 38- 104 years), for women (54.2%) this was 8 1 .5 and for 
men 76.8 years. The mortality rate was 47.9/1000 for the diabetic 
population and 8.8/ 1000 for the total general population in 1 998. The SMR 
for the total diabetic population is 1 .40, for women 1 .4 1  and for men 1 .44, 
as compared to the general population. The relative mortality risks per age 
category are shown in Table 3 .  
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Table 3. Standardised mortality ratios per 5-year age category. 
Diabetic Standardised mortality ratio 
deaths in two 
follow-up 
"' years (n) Q,j 
•t: = tlJ) Q,j - = = - - -cos u u u u Q,j Q,j 
Q,j e = -; e � = � -; � tlJ) = Q,j - = c Q,j c - c 
< � � = � In :; In = In E-< Cl'\ Cl'\ E-< Cl'\ 
35-39 1 1 0.00 0.0 -0.0 26.46 -46.9 - 99.8 14.20 -25.2 -53.6 
40-44 1 1 2 8.36 - 14.8 - 3 1 .5 6.13 - 10.9 - 23. 1 7.09 -6.8 -2 1 .0 
45-49 2 0 2 8.77 -8.4 - 26.0 0.00 0.0 -0.0 2.69 -2.6 - 8.0 
50-54 0 2 2 0.00 0.0 -0.0 1.51 - 1 .5 -4.5 1 .05 - 1 .0 - 3. 1  
55-59 2 9 1 1  1 .32 - 1 .2 - 3.9 3.48 0.2 -6.7 2.68 0.4 - 4.9 
60-64 5 7 12  1 .73 -0.4 - 3.9 1 .50 -0. 1  - 3. 1  1 .56 0.3 - 2.8 
65-69 7 10 17 1.15 -0. 1  - 2 .4 0.97 0. 1 - 1 .8 1 .02 0.3 - 1 .7 
70-74 24 29 53 1.86 0.8 - 2.9 1 .50 0.7 - 2.3 1 .64 1 .0 - 2.3 
75-79 29 26 55 1.28 0.6 - 2.0 1.12 0.5 - 1 .7 1.16 0.7 - 1 .6 
80-84 35 34 69 1.24 0.7 - 1 .8 1 .76 0.9 - 2.6 1 .40 0.9 - 1 .9 
85-89 40 20 60 1 .47 0.8 -2 . 1  1 .42 0.5 - 2.3 1.44 0.9 - 2.0 
90-94 1 7  6 23 1 .33 0.4 - 2.2 1 .02 -0. 1 - 2.2 1 .25 0.5 - 2.0 
>95 1 3  3 16 1 .43 0.3 - 2 .5 1 .93 - 1 .2 - 5.0 1 .50 0.5 - 2.5 
Total 1 75 148 323 1 .41 1 . 1 - 1 .7 1 .44 1 . 1  - 1 .8 1 .40 1 .2 - 1 .6 
Elderly population 
In the population aged 70 years and older, prevalence is higher than in any 
other age category. Patients aged 70 years and over account for almost half 
( 49.5%) of the total type 2 diabetes population. There is an increase in 
prevalence with age until the age of 80 at baseline and until the age of 90 
after 2 years of follow-up. After the age of 90, prevalence decreases. The 
largest absolute increase in number of patients with known type 2 diabetes 
was found in the age category 70-79; the largest absolute increase in 
prevalence was found in the age category 80-89. The incidence -even 
though still high between the age of 70-90 years- decreases after a peak at 





Our study, which is limited to known type 2 diabetes, presents actual data 
from a large population to estimate current prevalence, incidence and 
mortality in The Netherlands; our main conclusion is that the prevalence is 
considerably higher than described or estimated up till now. This is the case 
for both the overall prevalence, 6;2 1  and for the prevalence in all different age 
categories. 1 1 ;22-24 Incident cases explain a part of the rise in prevalence. The 
incidence we found is also higher than what has been published for The 
Netherlands up to now, overall as well as for the different age categories,6;25 
except for 30-39 and 80-89 years.4 From the original population 4.8% died 
annually. In the elderly population, aged 70 years and over, prevalence is 
higher than in any other age category; this patient category accounts for 
almost 50% of all type 2 diabetes patients. Incidence -even though still high 
between the age of 70-89 years- decreases after a peak at the age of 65-69. 
The current detailed data on prevalence and incidence of known type 2 
diabetes in general, and specifically in the elderly, are new for The 
Netherlands and can support health care planning in our ageing population. 
The detailed data on the eldest patients are also important for international 
comparisons as data on these specific age categories are scarcely available. 
Limitations 
The main limitation of our study is the lack of knowledge regarding 
undiagnosed diabetes. The number of undiagnosed patients may be as high 
as 50%. 10; 1 1  This group of patients explains the difference in prevalence data 
between epidemiological studies with different designs: studies using oral 
glucose tolerance tests to screen populations detect also patients with 
diabetes who were undiagnosed until that moment, and studies using 
registers from GPs or surveys don't. The size of this group of undiagnosed 
patients again might vary between regions or countries, explaining the 
differences found between studies of the same design in different locations. 
Due to the extra attention of all care providers regarding the detection of 
diabetes and the screening of high-risk populations, the percentage of 
undiagnosed diabetes may have decreased in The Netherlands the past 
years, as was found in the US as well.26;27 To get an idea of the magnitude 
of the uncertainty regarding the percentage of unknown diabetes, we 
compared our incidence rates with those from an epidemiological study 
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performed earlier elsewhere in The Netherlands, using oral glucose 
tolerance tests. They found a cumulative incidence of 6. 1 -6.9% in the 
population aged 50-75 at baseline (according to WH0-85 criteria), with a 
mean follow-up duration of 6.4 years.28 Our data show a mean annual 
incidence for this age category which is 3 1 -44% lower. This suggests that 
there may still be a large group of patients with undiagnosed type 2 diabetes 
in our population, even though this group may be decreasing. 
Another limitation is that the rise in prevalence may partly be 
explained by the introduction of the revised guidelines of the Dutch College 
of General Practitioners in 1 999.29 In these guidelines the 1 997 ADA 
criteria are used for the diagnosis of type 2 diabetes instead of the 1 985 
WHO criteria in the guidelines used until that moment.30 Given these 
criteria, the prevalence of diabetes mellitus among the general Dutch 
population will change only slightly, but the number of persons to be 
classified in a different category after their introduction is considerable: 
39% of the ADA diabetics are not diabetics according to the current WHO 
classification, while 38% of the WHO diabetics are not diabetics according 
to the ADA criteria. 31 The latter group may still be registered as having 
diabetes in the GP registers, causing a higher prevalence. 
Another explanation for the high prevalence of known type 2 
diabetes found in our region, as compared to other data derived from GP 
registers, may be the long-standing attention for diabetes care in the area 
studied. Moreover, the increase in prevalence may be explained by the extra 
attention for diabetes care because of the shared-care project. Part of the 
data used for this study was collected within the scope of this project. On 
the other hand, over 70 shared-care diabetes initiatives have been described 
in The Netherlands: the above effect on prevalence of known type 2 
diabetes may be found in other places as well.32 A finding supporting the 
above theory is that the increase in prevalence is partly explained by the 
improvement in GP-registrations during the follow-up years. Patients who 
were diagnosed, but not yet registered correctly up until that moment, 
explained almost 40% of the rise in prevalence (in the first follow-up year 
40% and in the second 38%). This phenomenon was also found in another 
Dutch study that showed that it took 10  years of continuous attention for the 
disease and its registration before the reservoir of unregistered patients was 
empty.33 In our opinion, after three years of annually composing diabetes 
lists, combining information on glucose measurements, HbA1c, use of 
diabetes medication, and special markers for signalling diabetes in the 
patient files, and after annual extensively checking the lists manually in 
30 
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each practice, the proportion of unregistered known patients with diabetes 
will be reduced to a minimum. Moreover, the patients with diabetes we 
found, are all true cases of type 2 diabetes: by checking all individual 
patient files, we know that no false positive cases were included. 
Comparison to other national and international studies 
Prevalence 
As already stated, our main conclusion is that the prevalence of known type 
2 diabetes is higher than described for The Netherlands up till now for both 
the overall prevalence,6;2 1  and for the prevalence in all different age 
categories. 1 1 ;22-24 The most recent prevalence estimate from Baan et al.6 was 
2.7-3 .2% for the population aged >30, whereas we find 4.7% for this age 
category. However, our prevalence rates of known type 2 diabetes do not 
yet reach the prevalence of combined diagnosed and undiagnosed diabetes, 
as found in earlier epidemiological studies, showing that undiagnosed 
diabetes is still present. Our prevalence is a�proximately 75% of the 
prevalence found in Hoom1 1  and in Rotterdam.2 The estimated number of 
466,000 patients with known type 2 diabetes in 2000 exceeds all current and 
future projections for The Netherlands.6;7;9;23 Projections from the nineties 
regarding the increase in the next 1 5-20 years, vary between 20% and 50%. 
We found an increase of 33% in 2 years. The overall prevalence of known 
type 2 diabetes is higher in women than in men, as shown in other 
studies, 1 1 ;22 but lower for women aged <64 which was also shown by Mooy 
et al. 1 1  and Han et al.34 Prevalence rises sharply in the two follow-up years. 
The largest absolute increase in known type 2 diabetes is found in the age 
group 70-79 and not between 45-65 as was predicted.7 
As compared to international prevalence rates we find a higher 
overall prevalence (2.9%) in The Netherlands than in Italy (2.5%) and the 
United Kingdom (UK) (2.0%),35;36 and this also applies for the different age 
categories in these countries.37;38 In the United States (US), the overall 
prevalence among white non-Hispanics is higher in most publications: for 
the population aged >20, Harris et al.27 found a prevalence of 4.8% and 
Mokdad et a1.39 found 5 .9%, versus 3 .9% in this age category in our results. 
Incidence 
Incident cases explain a part of the rise in prevalence. The incidence we 
found is higher than what has been published up till now for The 
3 1  
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Netherlands, overall as well as for the different age categories,6;25 except for 
30-39 and 80-89 years.4 
As compared to international incidence rates we find a higher overall 
incidence (2.27/1 ,000) than in the UK ( 1 .63/1 ,000).36 Compared to our data, 
the numbers found for the US are too divergent to allow for a valid 
conclusion. 40;4 1  
Mortality 
From the original population 4.8% died annually. Baan et al.5 estimated the 
number of diabetic deaths as a percentage of the total number of deaths to 
be 1 8. 1 %  for women and 1 1 .9% for men. According to our results this is 
lower: 1 3 . 1  and 1 1 .4%. This might be explained by the fact that the 
estimates from Baan et al. 5 are based on mortality ratios from the Verona 
Study (Italy) : these are higher for every age category than the mortality 
ratios we observed, especially for women.35 In a Dutch study, De Grauw et 
al.42 found a mortality ratio of 1 .62 and 1 .56 for women and men, 
respectively, as compared to 1 .4 1  and 1 .44 in our results. This might be 
explained by the difference in study design: we compared to the total 
general population (including patients with diabetes) whereas they 
compared to matched cases from the non-diabetic population. 
As compared to international data, we find a higher mortality rate 
(47.9/1 ,000) than in the UK (41 .8/1 ,000).43 In the US mortality rates for the 
population aged >65 years are comparable to ours.44 In an international 
meta-analysis the percentage of patients dying annually was found to be 
lower (3 .8%) than in our results (4.8%).45 
Elderly 
No detailed Dutch data on prevalence in the age category >90 years were 
found but up until the age of 90 the prevalence rates of known diabetes we 
found are a lot higher than in earlier research, even though the pattern of an 
initially increasing prevalence that decreases in the eldest patients is 
similar. 1 1 ;22 Compared with the US, we found a higher prevalence in the 
eldest age categories (>70 and >75 years for different studies, 
respectively).27;39 ;46 
Incidence -even though high between the age of 70-90 years­
decreases after a peak at the age of 65-69. For women between 80-89 years, 
we found a lower incidence than others did: 73/10,000 versus an estimated 
103/10,000 by Barendregt et al. The Dutch Sentinel Practice Network found 
32 
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a peak between 65-79 years?5 The estimated incidence by others shows a 
continuous rise without a peak.4;6 
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Shared care with task delegation to nurses 
Abstract 
Background: To study the feasibility and the effects of two different 
structured shared-care interventions, tailored to local needs and resources, in 
an unselected patient population with type 2 diabetes mellitus. 
Methods: A 3-year prospective observational study of two interventions 
and standard care. The interventions involved extensive (A) or limited (B) 
task delegation from general practitioners to hospital-liaised nurses 
specialized in diabetes, and included a diabetes register, structured recall, 
facilitated generalist-specialist communication, audit and feedback, patient­
specific reminders, and emphasized patient education. The target population 
consisted of 2,660 patients with type 2 diabetes treated in the primary care 
setting. Patients who were terminally ill or who had been diagnosed with 
dementia were excluded from the study. 
Results: The participation rates were high (90%) for patients, and none of 
the 6 1  GPs discontinued their participation in the study. Longitudinal 
analyses showed significant improvements in quality indicators for both 
intervention groups (process parameters and achieved target values on the 
individual patient level); in standard care, performance remained stable or 
deteriorated. Both the patients and the caregivers appeared satisfied with the 
project. 
Conclusions: This study shows that structured shared care with tasks being 
delegated to nurses, targeted at a large unselected general practice 
population, is feasible and can positively affect the quality of care for 




Type 2 diabetes mellitus (type 2 DM) is a chronic disease, which leads to 
considerable morbidity and premature mortality. 1 ;2 The prevalence of type 2 
DM is high and is increasing.3 Since most patients with diabetes die from 
complications of atherosclerosis, they should receive intensive preventive 
interventions to reduce their cardiovascular risk.4 Guidelines for clinical 
practice have been developed in many countries to optimise diabetes care. 5;6 
However, the implementation of these guidelines has not been 
straightforward.7;8 There are many reasons for this, including: a lack of time, 
staffing problems, recall facilities, diabetes registers, poor quality of 
documentation, the unavailability of qualified nurses, problems with patient 
compliance, inadequate reimbursement, lack of physician consultative 
assistance, and long waiting lists for ophthalmologists.9; 1 0  
As in other countries, in The Netherlands the care for type 2 DM 
patients is concentrated in the primary care setting, 6; 1 1  and there is a growing 
shortage of primary health care providers. 1 2; 1 3 
Structured shared care can partially resolve the aforementioned 
problems and may also improve the quality of care for patients with 
diabetes. 14 Multifaceted complex interventions, which target different 
barriers preventing change, are the most effective. Successful interventions 
include applying organizational strategies that increase structured recall, 
protecting time which has been reserved for diabetes care, using 
multifaceted professional interventions, facilitating generalist-specialist 
communication, delegating tasks to practice assistants or nurses, and using 
specialist diabetes nurse facilitators. Nurses can play an important role in 
encouraging compliance and educating patients. In certain situations, they 
can even replace physicians in delivering many aspects of diabetes 
care.9; I O; I 4- 16 
Previous studies on diabetes care in general practice have tended to 
include highly selected populations of practitioners and patients. 
Our aim was to study the effects of two different forms of structured 
shared care -tailored to local needs and resources- and of standard care, in 
an unselected type 2 DM patient population in a prospective observational 
study. 
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Materials and methods 
Study design 
The Zwolle Outpatient Diabetes project Integrating Available Care 
(ZODIAC)-study investigated the effects of a shared-care project for type 2 
DM. In The Netherlands, general practitioners (GPs) collaborate in GP­
working groups. A GP-working group consists of several GPs who practice 
in the same area or town, and cover for each other in the delivery of medical 
services during out-of-office hours. Eight GP-working groups (64 GPs) in 
the eastern Netherlands agreed to participate in the study. Three GPs were 
excluded from the study: two because they had recently started a new 
practice and one due to retirement. For pragmatic reasons, allocation to the 
two intervention groups and to the standard-care group was assigned 
according to the preference of the GP-working groups as a whole. As 
Greenhalgh mentioned, it is important to recognize that the different ways in 
which GPs organize their diabetes care and in which they interface with 
specialist services is a function of both the particular needs of their practice 
populations and their individual skills and confidence. 1 4 Moreover, for 
interventions to work, the methods must be acceptable to the target groups. 1 7 
The 32 GPs who participated in intervention A received extensive 
support from nurses specialized in diabetes (DSNs) who were hospital­
based, but who worked for the project in the primary care setting. The 
second group (intervention B, 2 1  GPs) received limited support from DSNs, 
and the third group (intervention C, 8 GPs), the standard-care group, 
delivered standard care and received no extra support. 1 .6 full time 
equivalent DSNs were employed by the project. 
Interventions 
Extensive support (intervention A) means that DSNs -instead of the GPs­
performed the annual examination according to the national guidelines of 
the Dutch College of General Practitioners for all the type 2 DM patients 
treated in the primary health-care setting. The GPs were responsible for the 
check-ups, which should occur every three months. On top of this, the DSNs 
gave one-on-one education, tailored to the needs of the individual patients. 
Fundus photography1 8 was integrated into the consultation as well, where 
normally each patient would have been referred to an ophthalmologist. If 
necessary (according to retinal photography results, or in the case of a newly 
diagnosed diabetes) a referral to the ophthalmologist was arranged by the 
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DSN. The appointments with the DSNs took place outside the hospital in 
the primary health-care setting in the village or city where the patient lived. 
Any patient who missed his or her appointment was rescheduled. Patients 
who were housebound with serious co-morbidity were visited at home. A 
comprehensive structured report of the results was sent to the GP within 
three weeks. If necessary, the results were accompanied by 
recommendations from the DSN concerning referrals to a dietician, 
chiropodist, and/or podiatrist, and by a recommendation from an internist 
concerning treatment (according to the guidelines). This process allowed the 
GPs to dedicate their consultation time to discussing the results with the 
patient in detail, and to decide how to act upon them. The GPs kept the full 
responsibility for the care of the patients and had no obligation to follow any 
of the recommendations they were given. A second part of the extensive 
support structure was the possibility of sending individual patients directly 
to the DSN for an on-demand consultation within the primary health-care 
setting (without -as in standard care- a formal referral to secondary care) . 
Possible reasons for requesting such a consultation could be: for patient 
education, instruction on self-monitoring, or instruction on insulin injection. 
The GPs were responsible for determining the initial insulin dosages and for 
making any dosage changes. 
The only extraneous support the GPs in intervention group B 
received was having direct access to on-demand consultations with the 
DSN, without the need for a formal referral to secondary care. They 
performed the annual and three-monthly check-ups themselves, including 
making any necessary referrals to the ophthalmologist. 
In the standard-care group (8 GPs ), patient care was delivered as 
usual, with no extra support. Consultation with a DSN was only possible 
through a formal referral to the internist in the secondary health-care setting. 
All participating GPs received one-time feedback about their 
baseline performance, which was discussed within the GP-working-group in 
the presence of an internist. 
Patients 
The target population consisted of patients with type 2 diabetes who were 
being treated in the primary care setting, and the aim was to have an 
unselected population. Virtually all citizens of The Netherlands are 
registered with a GP. Annually, the GPs provided lists with the names of all 
the patients with known type 2 diabetes, as defined by the National GP 
Guidelines.6 Patients with type 1 diabetes were excluded. Type 1 diabetes 
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was defined by age at diagnosis <40 years and a requirement for insulin 
within one month of diagnosis. 1 55,774 persons were registered with the 6 1  
participating GPs, 3 ,362 of whom had been diagnosed with type 2 diabetes 
mellitus. Patients were only excluded if they were being treated in 
secondary care by an internist, if they were terminally ill, or if they had been 
diagnosed with dementia. 
Data collection 
We collected data on all the eligible patients with type 2 DM, who were 
registered with and had been treated by the 6 1  GPs, during the three 
consecutive years from 1 998 through 2000. The data were collected 
annually for all patients from the (electronic and/or paper) patient records in 
the general practice (including correspondence with specialists) by the 
principal investigator of the study. Additionally, the data were collected by 
the investigator from the reports on the consultations by the DSNs in the 
intervention groups A and B. 
The data were collected on full medical history, micro- and 
macrovascular complications, diabetes and other medication(s), referrals for 
ophthalmologic examination, measurements of blood pressure and weight, 
foot examination, smoking status, and laboratory measurements: HbA1c, 
total cholesterol, HDL-cholesterol, triglycerides, creatinine, 
microalbuminuria, and albumin-creatinine ratio in urine (reference value for 
HbAtc: 4,0-6,0%). The blood pressure was measured by the DSN in 
intervention group A, and by the GP in intervention group B and in the 
standard-care group. The blood pressure was measured twice with a Welch 
Allyn Sphygmomanometer in the supine position after at least five minutes 
of rest. Renal clearance was calculated by the Cockcroft and Gault 
formula. 1 9 The data on patient and provider satisfaction were collected by 
asking the GP "How do you judge the shared-care project" and "How do 
your patients judge the shared-care project". 
The Medical Ethics Committee of the Isala Clinics (formerly 
Weezenlanden Hospital) approved this study. 
Outcome measurements 
The effects of the interventions were measured by changes in three quality 
indicators. We studied ( 1 ): process control (the percentage of patients with 
examinations and measurements performed according to the guidelines), 
and (2) outcome control: the percentage of patients that achieved target 
values (HbA1c  < 7.0%, blood pressure < 1 50/85 mm Hg, total cholesterol < 
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5 mmol/L ). Expressing the number of patients known to have achieved 
target values -based on available data- as a percentage of the total target 
population, results in a quality indicator (3) that combines process and 
outcome control. The feasibility of the interventions was evaluated based on 
the participation rates of the patients and the GPs and patient and provider 
satisfaction. 
Analysis 
Statistical analyses were performed using SPSS for Windows. For baseline 
cross-sectional analyses we used Student's T -test, and the One-way Anova 
for variables with a normal distribution, Mann-Whitney-U test for non­
normal variables, and the Chi-square test for categorical variables. For 
longitudinal analyses we performed an ' intention-to-treat analysis' and used 
the McNemar. The different groups were not directly compared with each 
other because of the possible bias resulting from the non-randomized design 
Results 
The prevalence of diabetes in the study area was representative for a larger 
area, and the size of the practice population and the percentage of GPs 
working in solo-practices were similarly representative for the population of 
The Netherlands. None of the GPs discontinued their participation in the 
study. 
Among the 2,660 patients with type 2 diabetes treated in the primary 
care setting (figure 1 ), 1 74 (6.5%) were excluded by their GPs for reasons of 
terminal illness or dementia. 2,486 patients were eligible for the study: 
1 ,244 were assigned to intervention group A, 842 to group B, and 400 to the 
standard-care group. 
Baseline data are shown in table 1 .  The three groups differed 
significantly at baseline with respect to age, diabetes duration, glycaemic 
control, cardiovascular risk factors, and treatment. Patients who were 
excluded were older (77.3 vs. 68.4 years), had more cerebrovascular 
complications (23% vs. 1 1  %), used significantly less diabetes, 
antihypertensive, and lipid-lowering medication, and had their eyes (26% 
vs. 55%) and feet examined less frequently compared to participants (22% 
vs. 36%). 
2,048 (82%) out of 2,486 patients were available for follow-up after 
two years. 2 1 7  (8.7%) patients died, 1 54 (6.2%) were referred to an 
internist, 66 (2. 7%) moved, and 2 patients were lost to follow-up. The 
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referral percentages to secondary care were 7% for group A, 4% for B, and 
9% for the standard-care group. The follow-up for the different groups was 
77% for intervention A, 88% for intervention B and 79% for the standard­
care group. In intervention A, 1 ,  1 2 1  (90 . 1%) of patients responded to the 
invitation for a consultation with the DSN at some point during the three 





with type 2 diabetes 
6 1  GPs 
2660 patients Excluded 1 74: 
-terminally ill 
invited population -severe dementia 
2486 patients 
I 
I I I 
intervention A intervention B standard care (C) 
extensive support limited support no support 
by DSNs by DSNs by DSNs 
32 GPs 2 1  GPs 8 GPs 
1244 patients 842 patients 400 patients 
I I I 
follow-up 963 follow-up 737 follow-up 3 14 
-additionally -died 49 -died 3 7  
excluded 33 -moved 23 -moved 13 




Figure 1. Patient selection, group assignment, and follow-up. 
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Table 1. Baseline data from patients in intervention groups A and B, and 
standard-care group C (means or percentages). 
Intervention Standard Total P-value* 
group care group 
A B 
Practice characteristics 
Gender GPs male (%) 88 85 100 89 0.52 
Practice size 2612  2523 2732 2598 0.5 1 
Prevalence DM {%} 1 .9 2.3 2.4 2 . 1  0.09 
Patients (n) 1 127 842 400 2369 
Gender female (%) 58 54 60 57 0.07 
Age (years) 68.7 67.3 70.3 68.5 <0.00 1 
Diabetes duration (�ears} 7.7 6.7 6.5 7.2 0.002 
HbAtc (%) 7.5 7.3 7.3 7.4 0.0 1 
BMI (kglm2) 28.9 28.0 26.7 28.8 0.0 1 
Systolic blood pressure (mmHg) 155 150 152 153 <0.00 1 
Diastolic blood pressure (mmHg) 84 83 84 84 0. 15 
Total Cholesterol (mmoVL) 5.7 5.5 5.9 5.7 0.003 
Total-cholesterol!HD L-ratio 5.3 5.2 5.0 5.2 0.25 
Diabetes treatment 
Diet (%) 1 3  20 10 1 5  <0.001 
Oral agent (%) 70 64 75 69 
Insulin (%) 1 4  12  12  13  
Insulin and oral agent (%) 2 5 3 3 
* Single test for statistically significant differences between A, B. and C 
The opportunity to consult with a DSN on-demand was not frequently used. 
The reasons for these consultations were, in the majority of cases, for 
support with respect to education and instruction of insulin therapy within 
the primary care setting: 27/47 (57%) for group A and 1 1/ 19  (58%) for 
group B. 
The effects of the interventions are shown in tables 2 and 3. Table 2 
shows the change in process control. Performance significantly improved 
with respect to process parameters for both interventions A (extensive 
support by DSNs) and B (limited support by DSNs): at two-year follow-up, 
all examinations and measurements were performed more frequently for 
group A, and most for B. 
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Table 2. Performance with respect to process control. 
Baseline Follow-up p Direction of 
{%) {%) Significant change 
Foot exam A 44 87 < 0.001 t 
B 3 1  4 1  < 0.00 1 t 
c 16 1 1  0. 1 1  
Eye exam A 48 84 < 0.00 1 t 
B 57 67 < 0.00 1 t 
c 4 1  53 0.001 t 
HbAlc A 57 89 < 0.001 t 
B 67 75 < 0.00 1 t 
c 62 63 0.9 1 
Blood pressure A 76 88 < 0.001 t 
B 89 85 0.03 ,!, 
c 78 72 0.03 ,!, 
Total Cholesterol A 46 89 < 0.00 1 t 
B 59 63 0.06 
c 48 39 0.008 ,!, 
Creatinine A 54 89 < 0.00 1 t 
B 63 74 < 0.001 t 
c 60 63 0.33 
Body Mass Index A 0.3 88 < 0.00 1 t 
B 0.3 1 8  < 0.001 t 
c 0.6 2 0.45 
Smoking status A 5 90 < 0.001 t 
known B 25 4 1  < 0.001 t 
c 7 1 1  0.00 1 t 
In intervention A, where the DSN is responsible for the annual check-up, 
the perfonnance was very high, ranging from 84 to 90%; for intervention B 
this ranged from 1 8  to 85%. In the standard care group, the perfonnance 
regarding process parameters remained stable or decreased, ranging from 2 
to 72% for the various parameters after two years of follow-up. 
Table 3 shows the change in outcome control: perfonnance 
regarding the percentage of patients who achieved target values for the 
different groups. The percentage of patients with good glycaemic regulation 




Table 3. Quality indicators at baseline and follow-up. 
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27 (84/3 14) 
46 (439/963) 
44 (32 1 /737) 
30 (95/3 14) 
35 (34 1/963) 
3 1  (227/73 7) 
1 0  (32/3 14) 
For both blood pressure and hypercholesterolemia, outcome control 
improved in intervention groups A and B, while there was no change in the 
standard-care group. Expressing the number of patients known to have 
achieved target values -based on the available data- as a percentage of the 
total target population, results in a quality indicator that combines process 
and outcome control. It appears that the performance for this quality 
indicator was 35-46% for intervention A, 3 1 -44% for intervention B, and 
10-30% for the standard-care group. 
The GPs rated the project as good in 70 and 69% of cases and 
adequate in 30 and 25% of cases in interventions A and B, respectively; the 
patients were satisfied in 8 1% of cases according to their GPs. There was no 
mention of dissatisfaction. 
Discussion 
In this study, examining two interventions with structured shared care and 
task delegation, which was targeted at an unselected group of patients with 
type 2 diabetes treated in a primary care setting, we found improvements in 
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process and outcome control. Performance for process parameters increased 
for both interventions, as did the percentage achieved target values on the 
individual patient level for blood pressure and total cholesterol, however not 
for blood glucose control. In contrast, the standard-care group showed 
minimal improvements, and even some deterioration. The patient 
participation rate remained high throughout the study, and none of the GPs 
discontinued participation. 
Strengths and limitations 
A strong point of this study is that the results may, for the most part, be 
generalized to similar patient populations. We studied a highly unselected 
patient population, unlike many of the previous studies on this topic. The 
quality of care improved even though changes are difficult to effect in busy 
primary care environments.20 The interventions used in this study may be 
used in other primary care settings, provided the same exclusion criteria are 
applied. Excluding those terminally ill or having dementia, seems realistic 
from a clinical point of view: intensive therapy is either not useful for 
prevention of long-term complications or not possible. 2 1  
A limitation of our study is  the non-randomized design. To study 
how evidence and guidelines may be translated into daily practice, 
flexibility is necessary to deal with pragmatic issues; rigorous 
nonrandomized study designs including quasi-experimental, time-series, and 
observational studies are sometimes more appropriate.22 We chose, for 
pragmatic reasons, to assign the patients to the intervention groups 
according to the preferences of the GP-working groups. The effects of the 
interventions may have been overestimated as a consequence of the 
design, 23 and baseline values were not comparable for the three groups 
analysed. Direct comparison would consequently be difficult to interpret. 
We therefore decided to limit our analysis to independent descriptions of the 
three intervention groups, and focussed on the quality indicators at the 
individual patient level instead of on group means. At the same time, there 
was a difference in the amount of available data: in group A the data 
collected during consultations with the patients by the DSNs was nearly 
complete. In groups B and C, however, the data were collected from the 
GPs' patient records, where the availability of data was not optimal. 
Obtaining data Erovided from medical records can lead to underreporting of care delivered. 4 However, although the same lack of documentation has 
been found by others, 20;25 and intermediate outcomes may not be different 
for the patients concemed/5 the delinquent recording of risk factors reflects 
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suboptimal care, because opportunities to detect increased risk and therefore 
to start treatment are missed. Moreover, the quality of care delivered lacks 
transparency. 
Comparison with other studies 
With intervention A (extensive support by DSNs) a large increase was 
found with respect to process control, with an overall high performance rate 
between 84 and 90%, which is higher than that found in another recent 
study (41 -80%).25 This appears to be a direct effect of the central role of the 
DSNs who were responsible for performing the annual check-up. For 
intervention B (limited support by DSNs), process control improved as well, 
and was comparable to, or higher than (but still suboptimal), the findings 
reported by Goudswaard et al. 25 The standard-care group showed few 
improvements, and even some deterioration. Renders et al. reported a 
similar finding for their reference group.26 
For outcome control (achieved target values), in both intervention 
groups the percentage of patients achieving target values increased for blood 
pressure regulation and lipid control. Although difficult to compare, other 
intervention studies with a central role for DSNs showed improvement in 
blood pressure and/or lipid profile as well,27-29 whereas programs without a 
central role for DSNs found no (significant) positive effect on these 
outcomes.26;30 In the standard-care group no changes in outcome control for 
blood pressure or hypercholesterolemia were found. 
In the intervention groups we did not find an increase in the 
percentage of patients with good glycaemic regulation, whereas other 
intervention programs did.27;29-32 The percentage of patients with an HbA1c 
<7 is comparable or somewhat lower compared to that found by 
others.26;30;32 An explanation for the lack of improvement may be that the 
baseline HbA1c was already quite acceptable in this unselected �opulation, 
which may have left little room for improvement (ceiling effect). 3 The GPs 
in all three participating groups treat a higher percentage (80%) of the total 
diabetic population in primary care than in most other programs ( 6 1 -
75%),26;3 ;35 probably also including a higher percentage of patients who are 
difficult to treat. Since metabolic control tends to deteriorate with the 
duration of the disease,36 keeping glycaemic control stable could be seen as 
a positive effect of the interventions. In the standard-care group, the 
percentage of patients with good glycaemic regulation decreased, which was 
also reported by de Sonnaville et al. for their control group. 30 
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Using a quality indicator that combines process and outcome control may be 
a simple and transparent method to indicate the quality of care delivered, 
enabling benchmarking of performance at the level of the individual health 
care providers or teams. 
In intervention group A, 9.9% of patients did not visit the DSN in 
either one of the three project years. This percentage seems acceptable as it 
is within the variance (0- 1 7%) that is mentioned in a Dutch literature study 
into diabetes patients not showing up within a period of 6- 1 3  months.37 
Reasons mentioned by patients varied between 'just don't want to' and 
' long term admittance to the hospital' or 'partner to ill' or 'family 
problems' .  Many patients who could not participate in one year, resumed 
participation in the next year. 
The follow-up period may have been too short to show all the 
potential positive effects, since only after 2 years the GPs started to make 
more use of on-demand consultations. We expect that the intervention 
groups and the standard-care group will diverge further with respect to the 
quality of care, as, in intervention group A, the recommendations from the 
internists become increasingly stringent and extensive at the GPs' request. 
Moreover, we are currently seeing a large annual increase in on-demand 
consultations in intervention groups A and B. 
Implications 
Abnormal but unrecorded values deprive the GP of possible indications for 
starting or adjusting treatment, and may therefore hamper the achievement 
of optimal diabetes care at the individual patient level. Moreover, 
unrecorded values limit the transparency of the care delivered. In other 
health care settings, quality indicators have yet been included in the 
assessment of the quality of diabetes care?8 Although there have been 
proposals/9;40 in The Netherlands there is not yet an official set of quality­
indicators, whereas this would be useful for benchmarking and to compare 
effect evaluations of interventions to improve the quality of diabetes care. 
The delegation of tasks to nurses appears to improve process-control, 
as process indicators improved and reached high levels when nurses were 
responsible for performing the annual check-ups. Concomitantly, outcome­
control appears to improve at the level of individually reached target values. 
Ultimate proof of the effectiveness of these interventions can only be 
seen after analysing the development of complications as was done recently 
by Gaede et al.4 1 The ZODIAC-study has now entered its seventh year, 
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which will make the assessment of long-term effects of the presented 
interventions possible within the next several years. 
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Abstract 
Background: Within shared diabetes care, general practitioners (GPs) 
receive recommendations from various caregivers. In the literature, little has 
been reported about the advisory role of nurses. Therefore, our aim was to 
study the responsiveness of GPs to the recommendations given by nurses 
specialized in diabetes (DSNs). 
Methods: We studied the responsiveness of GPs to recommendations 
concerning individual patients, given within the first year of a shared-care 
diabetes project in the intervention group, in which DSNs perform the 
annual check-up in all patients with type 2 diabetes treated in the primary 
care setting. We studied the compliance rate at one-year for direct (in 
writing) recommendations from DSNs concerning referrals to dieticians, 
chiropodists or podiatrists; and indirect (checkbox format) recommendations 
concerning glycaemic regulation, regulation of blood pressure, and lipid 
profile. 
Results: For 1 , 149 patients, 1 , 1 54 recommendations were given, 42% of 
which were followed. There was a significant difference between 
compliance rates for the direct, written, format (49%) and the indirect, 
checkbox, format (38%).Whether or not recommendations were followed 
was independent of the consulting DSN. 
With respect to indirect recommendations, the GPs responded most often 
(64%) to an unsatisfactory HbAl c, by increasing or changing the blood 
glucose lowering therapy. The GPs responded the least often to an 
unsatisfactory regulation of the lipid profile ( 17% ) . 
Conclusion: GPs complied with less than 50% of the recommendations 
they were given within shared care. GPs may need to pay extra attention to 
the cardiovascular risk profile in addition to glycaemic regulation. Patient 




The care for patients with type 2 diabetes is changing. There has been a shift 
from secondary to primary care, and, as in other countries, the care for type 
2 diabetes mellitus in The Netherlands is becoming concentrated in primary 
health care. 1 -9 The type 2 diabetes population is growing due to an 
increasing prevalence and an aging population. IO; I I  With our expanding 
knowledge, the care for this chronic disease is becoming increasingly 
complex. Moreover, the present shortage of primary health care providers is 
growing.7-9; 1 2  This problem may be partially resolved by having nurses 
support GPs and by using specialist diabetes nurse facilitators. 1 3 ; 14 This is 
already frequently being done in the United States and in the United 
Kingdom. 15 They can, in some cases, even replace physicians in delivering 
many aspects of care for patients with diabetes. 16 
Within the MCC Klik shared care diabetes project, GPs receive 
recommendations from various caregivers. In the literature, little has been 
reported concerning the advisory role of nurses. Therefore, our aim was to 
study the responsiveness of GPs to recommendations from nurses 
specialized in diabetes (DSNs). 
Methods 
Study design 
The study design of the shared care project has been described in detail in 
the introduction. Three DSNs ( 1 .6 full time equivalents) were employed by 
the project. We used the data from patients participating in intervention 
group A. 
Three types of individual advice 
The comprehensive reports containing the results of the consultations with 
the DSNs were sent to the GPs participating in intervention group A. If it 
was deemed necessary, according to the guidelines of the Dutch College of 
General Practitioners (short form: National GP Guidelines), it contained 
comments with associated recommendations for each individual patient. 
Firstly, DSNs give the GPs recommendations regarding referrals to 
paramedical professionals: these direct recommendations (in writing) 
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concern referrals to dieticians, chiropodists, and/or podiatrists. According to 
the National GP guidelines referral to a dietician would be indicated for 
instruction of dietary advice; to a podiatrist or chiropodist specialized in 
diabetes in case of decubitus, tylosis, or position abnormalities of feet or 
toes. 
Secondly, internists give recommendations regarding pharmaco­
therapy and referrals to secondary care: direct recommendations (in writing) 
from an internist concerning treatment was included in the individual patient 
report. The follow-up of these recommendations was not studied. 
Thirdly, the report contained indirect recommendations (checkbox): 
a box is check-marked indicating whether blood pressure, HbA1 c, or lipid 
profile regulation are 'good' ,  ' satisfactory' ,  or 'poor' according to the goals 
outlined in the Guidelines of the Dutch College of General Practitioners .6 A 
'poor' regulation was defined as a recommendation to change therapy. 
Blood pressure regulation was defined as 'poor' if it was =:: 1 60/90 mmHg, 
glycaemic regulation if HbAl c  � 8,5%, and the lipid profile when the total 
cholesterol to HDL-cholesterol ratio was �6. 
We studied both the direct and the indirect recommendation formats. 
Data collection 
We collected data regarding all patients with type 2 diabetes, registered with 
and treated by the 32 GPs in intervention group A, during two consecutive 
years: 1 998 and 1 999. The data collection was performed annually by the 
principal investigator of the study using the (electronic and/or paper) patient 
files (including correspondence with specialists) for all patients with known 
type 2 diabetes. Additionally, data were collected by the same investigator 
from the reports of the consultations with the DSN. Data were collected on 
direct recommendations (in writing) given by the DSNs (referrals to 
dieticians, podiatrists, and chiropodists), indirect recommendations from the 
checkboxes (regarding regulation of blood pressure, HbAl c, and lipid 
profile), and general and diabetes medication, including dosages and dosing 
frequencies. After the initial analyses, the recommendations were checked 
for clarity and for key statements made by the nurse such as 'the patient 
refused the referral ' ,  in an attempt to determine why recommendations were 
not followed. 
Outcome measurements 
The primary outcome was the percentage of recommendations that were 
followed. Direct (in writing) recommendations were defined as being 
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followed when it became clear during follow-up that the patient had actually 
visited the health care provider (podiatrist, chiropodist, or dietician) to 
whom he or she had been referred during the previous year's appointment. 
This information was confirmed by the nurses, who asked the patients 
directly. Indirect (checkbox) recommendations were defined as being 
followed when medication for the dysregulated variable was added, when 
the dosage of existing therapy had been changed, and/or when further 
therapy was added, compared with the previous year. 
The embedded nature of the recommendations was studied in a 
random selection of 1 0% of all comments made by the DSNs. We calculated 
the percentage of words directly concerning recommendations and the 
percentage of words dealing with additional information. 
Finally we examined the influence of the patient's opinion as 
expressed by the DSN. We studied the percentage of cases in which the 
recommendations were followed when the patient 'refused referral' .  
Analysis 
Statistical analyses were performed using SPSS for Windows. We used 
Student's T -test and the chi-squared test to find differences in means and in 
the percentages of followed recommendations between the nurses, and 
between the different recommendation formats. A p-value of 0.05 or lower 
was defined as statistically significant. 
Results 
1 ,664 patients with type 2 diabetes were known to the 32 GPs. Of those, 338 
(20%) were also being treated by an internist and were therefore excluded. 
57 of the remaining patients were excluded because of terminal disease or 
dementia. Of the 1 ,269 patients invited, 1 , 1 49 (9 1 %) participated in the 
study. The baseline characteristics of the patient population are shown in 
table 1 .  During the first year, 1 02 patients dropped out of the study: 22 had 
died, 4 had moved, 38 had been referred to an internist, 1 5  had been 
excluded, and 23 refused further participation. Table 2 shows that a total of 
1 , 1 54 recommendations were given, 4 1 8  (42%) of which were followed. 
There was a significant difference between the compliance with 
recommendations about referrals which were in a direct format ( 49%) and 
those about treatment changes in an indirect format (38%). 
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Table 1. Baseline characteristics for the participating population. 
Female gender 
Age (years) 
Diabetes duration (years) 
HbAtc <%> 
Total Cholesterol (mmoVL) 
Total Cholesterol/HDL-ratio 
Triglycerides (mmol/L) 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Body mass index (kg/m2) 
Smoking 
Insulin and oral diabetes medication (%) 
Insulin (%) 
Diet (%) 
Oral diabetes medication (%) 















Mean (St. Deviation) I % 
57.6 
68.7 ( 1 1 .5) 
7.6 (7.4) 
7.5 ( 1 .3) 
5 .7 ( l . l )  
5.3 ( 1 .6) 
2.6 ( 1 .6) 
155  (25) 

















Recommendations Recommendations followed ----��==������� 
given (N) N % 
I68 63 (37.5) 
I 86 1 I6 (62.4) 
30 8 (26.7) 
I 9 1  122 (63.9) 
I29 60 (46.5) 
293 49 ( 16.7) 
997 4 1 8  (4 1 .9) 
Direct (in writing) recommendations 
A recommendation to refer a patient to a chiropodist was the most 
frequently followed (62%), contrasting with referrals to podiatrists (27%). 
The difference between these three specialty referral rates was significant 
(p<O.O l ). Whether or not the recommendation was followed was 
independent (p=0.24-0.54) of the DSN. 
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Indirect (checkbox) recommendations 
With respect to indirect recommendations, the GPs complied most 
frequently (64%) with recommendations regarding an unsatisfactory 
HbA1 c, by increasing or changing the blood glucose lowering therapy. GPs 
complied the least with recommendations concerning an unsatisfactory 
regulation of the lipid profile ( 1 7%). The follow-up of the three types of 
indirect recommendations was significantly differ�nt (p<O.Ol) .  
Embedding of recommendations concerning referral 
The recommendations from the DSNs were accompanied by a great deal of 
additional information: the recommendations making up only 1 2% of the 
comments. 
'Patient refusal' 
In a small percentage of cases the DSN s noted that "the patient refused the 
referral" which was recommended: 8% dietary, 4% chiropodist, and 1 0% 
podiatrist recommendations. It appeared that none of these 
recommendations had been complied with by the following year. 
Discussion 
In summary, we found that GPs complied with less than 50% of the 
recommendations received in shared diabetes care. Follow-up of 
recommendations may depend on the format of the recommendation. The 
dysregulation of glucose metabolism led more frequently to treatment 
changes than the dysregulation of blood pressure or lipid profiles. Patient 
refusal of referral appears non-modifiable. 
Limitations 
Some limitations need to be taken into consideration when examining these 
results. Patient compliance was not taken into account. Initiation of non­
pharmacological therapies was also not taken into account as part of 
changing therapy by GPs. The GPs were not asked for their reasons for not 
referring individual patients, and, in some cases they may have had good 
reasons. Finally, the analysis was done for the first year of the shared-care 
project, during which phase a learning curve was probably present. 
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Interpretation of the results 
A large proportion of the recommendations (>50%) were not complied with. 
We were unable to find suitable data for comparison in the (inter)national 
literature. The reasons why the GPs do not follow the recommendations 
may include patient non-compliance, insufficient availability of health care 
professionals, or individual patient-related factors. A difference in opinion 
between GPs and DSNs concerning the necessity or importance of referrals 
may also play a role. This needs further study. 
We found a significant difference between compliance with 
recommendations depending on the type of referral : GPs refer more patients 
to chiropodists than to dieticians. Possibly the GPs '  opinions differ from 
those of the DSNs with respect to the importance of referring a patient to a 
dietician. We already found (Chapter 2) that GPs did not delegate diet 
counseling as much as they could or probably should.4;6; 1 7 Referral to a 
podiatrist was the recommendation which was followed the least often; 
though the availability of podiatric consultation may have been insufficient, 
or insufficiently known by GPs. 
With regard to non-compliance, in a small percentage of cases, 
DSN s already stated the opinion of the patient as 'refusing referral ' .  It is 
questionable whether GPs or DSNs should invest time in motivating the 
patient for the referral, as we found that in none of these patients a referral 
was effectuated. However, this statement may also have demotivated the GP 
to arrange the referral to begin with. 
The format in which the recommendation was presented may also 
play a role in the unsatisfactory compliance rate for referral advice. These 
recommendations appeared embedded and therefore 'hidden' within other 
information contained in the DSNs' comments, with only 12% consisting of 
actual recommendation information. The significant difference we found 
between the follow-up of direct (in writing) and indirect (checkbox) 
recommendations may also be an indication for the role of the format in the 
compliance rates for recommendations. This hypothesis was confirmed 
during the regular discussions that we had with the participating GPs: they 
felt that a direct (in writing) recommendation, coming from a caregiver they 
knew -DSN or internist- had more impact on their treatment choices than 
an indirect (checkbox) recommendation, purely because of the personal 
aspect. However, as not only the format differed between the 
recommendations, but also the content or subject, we cannot draw any 
conclusions on this matter. This also needs further study. 
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We found that recommendations on changing therapy for dysregulated 
HbAlc is followed more often than recommendations concerning a 
dysregulated blood pressure or lipid profile. This is probably because the 
treatment of the latter two cardiovascular disease risk factors has only 
recently received more emphasis: it was only in 1 999 that the revised 
guidelines of the Dutch College of General Practitioners for type 2 diabetes, 
with more emphasis on this subject, was introduced. 
Implications and possible solutions 
Barriers to compliance with recommendations need further study. Within 
the shared care project, the recommendation format may have to be changed 
to prevent advice from being hidden within additional information in the 
DSN's commentary. The checkbox indicating unsatisfactory regulation of 
HbAlc, blood pressure, or lipid profile may have to be changed to a more 
direct, written format. Maybe a practical referral guide for GPs would be 
useful in improving the compliance with recommendations regarding 
referrals to paramedical professionals. Another consideration should 
probably be that the DSNs themselves, instead of the GPs, refer patients to 
the dietician, chiropodist, and podiatrist, changing their advisory role into an 
active referring role, comparable with other countries. 1 8 
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Abstract 
Introduction: This study aimed to describe the present status of the 
organization of care and task delegation for type 2 diabetes in primary care, 
in order to find a direction for future quality improvement strategies. 
Methods: A survey was conducted of 1 92 general practitioners (GPs) by 
mailed questionnaire. 
Results: The response rate was 72%. Diabetes-specific consultation hours 
were organized by 20% of the GPs, and 70% had diabetes-specific 
registrations. Active screening for type 2 diabetes in high-risk groups was 
performed by 4 1%. In total, 3 8% had a structural cooperation with a nurse 
specialized in diabetes (DSN). Among GPs initiating insulin treatment 
themselves (48%), 6 1% had a structural cooperation with a DSN. Patient 
education and regular check-ups were mainly performed by GPs themselves 
and were rarely delegated. Opinions varied about responsibility for follow­
up appointments for retinal screening. 
Conclusion: The conditions regarding the organization of care for patients 
with type 2 diabetes are not yet sufficiently met. The responsibility for 
certain tasks needs to be clarified. Opportunities for task delegation are not 
optimally used. Barriers preventing the implementation of task delegation 




Type 2 diabetes mellitus (type 2 DM) is a chronic disease, which leads to 
considerable morbidity and premature mortality. 1 ;2 The prevalence of type 2 
DM is high and increasing.3 In many countries the care for patients with 
type 2 DM is concentrated in primary care,4-9 with a growing shortage of 
primary health care providers. 10- 1 3 
The guidelines for clinical practice have been developed to optimise 
diabetes care.7;9; 14; 1 5  However, the implementation of these guidelines has 
proven to be somewhat troublesome. 1 6- 19 The reasons for this are multiple 
and include: lack of time, staff, recall facilities, diabetes registers, poor 
quality of documentation, insufficient availability of specialized nurses, 
patient failure to keep referrals and missed appointments, and inadequate 
reimbursement. 20-26 
Successful interventions to improve diabetes care are applying 
organizational strategies like increasing structural recall, protecting time 
reserved for diabetes care, delegating tasks to practice assistants or nurses, 
and using specialist diabetes nurse facilitators. Nurses can play an important 
role in educating patients and facilitating compliance. They can, in certain 
situations, even replace physicians in delivering many aspects of diabetes 
care.20-22;27;28 Guidelines are perceived as being valuable by enabling the 
safe delegation of many aspects of care to other health care professionals.29 
This study aimed to describe the present status of the way patient 
care is organized and how tasks are delegated for type 2 diabetes in the 
primary care setting, in order to find directions for future quality 
improvement strategies. 
Materials and methods 
We conducted a survey of GPs on the organization of the care of patients 
with diabetes in the Zwolle region, in the east of The Netherlands. We 
compared the organization of care and the way tasks were delegated with 
conditions described in the National GP Guidelines.9 
In April 2000, a questionnaire was distributed to all 1 92 GPs of the regional 
District's Organization of General Practitioners (DHV Zwolle/Flevoland). 
The survey contained questions on practice organization in general, methods 
of patient registration, composition of the patient population in general with 
73 
Organization of diabetes care 
a focus on the patients with diabetes, and the organization of diabetes care 
with a particular emphasis on task delegation. The three-page survey 
contained 23, mainly multiple-choice, questions with room for comments. A 
maximum of five reminders, two in writing and three by telephone, were 
used to improve the response rate . Statistical analysis was done with the 
Chi-squared test using SPSS 8.0 for Windows. 
Results 
1 92 questionnaires were mailed out. Thirteen GPs were excluded, as it 
turned out that they no longer had their own practice. Of the remaining 1 79 
questionnaires, 1 29 were returned, resulting in a response rate of 72%. 
Practice characteristics 
Most of the GPs (56%) worked in practices with more than one other GP: 
24% were in a partnership with one other GP, and 32% were in group 
practices. The average number of patients per physician was 2,360. Three 
percent of the practices worked with paper files, 89% with electronic patient 
records, and 8% with a combination of these. 45% of the GPs participated in 
diabetes projects. On average, 64 patients per GP had a diagnosis of 
diabetes, and 83% of those 64 had type 2 diabetes. This number 
corresponded with a prevalence of2.3% for type 2 diabetes. 
Practice organization 
In 70% of the practices there was some form of diabetes-specific 
registration (table 1 )  and specific diabetes clinics, varying in frequency, 
were organized by 20% of the GPs. A structural cooperation with a nurse 
specialized in diabetes (DSN) was, in one form or another, present in 38% 
of the practices. Cooperation with the DSN usually consisted of the 
opportunity to directly refer the patient to the DSN (without a referral to an 
internist in secondary care). 
Active screening to diagnose type 2 diabetes in high-risk groups, according 
to the National GP Guidelines, was performed by 4 1% of the GPs, although 
in hardly any of the cases all high-risk groups were checked structurally. 
Systematic registration of the cardiovascular risk profile was mentioned by 
78% of the GPs; the registration-rate of smoking, blood pressure, lipid 
profile abnormalities, family history and cardiovascular history varied 
between 67 and 77%. 
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Regional diabetes projects 
Practice nurse 
Referral 
On demand practice visit 
Consultation hour in practice 
Immediately schedule next follow-up visit after a consultation 
Writing repeat-prescriptions only during 3-monthly controls 
Fixed annual or 3-monthly consultation hours/days 
Telephone summons 
Telephone reminders (frequency 1 -4 (maximum 7)) 
Written reminders 
Other methods 






















The use of a specific method to improve patient attendance at regular three­
monthly consultations according to the guidelines was mentioned by 78% of 
the GPs; the most frequently used methods (or combination of methods) are 
shown in table 1 .  In 33% of the cases, checks were performed to detect non­
attendance and, if checked, 49% of GPs undertook action in order to have 
the patient still attend. 
In 95% of the cases, screening for diabetes-related eye complications 
was performed exclusively by the ophthalmologist; in the remaining cases 
screening was performed by the GP and the ophthalmologist together. 
According to the GPs, the responsibility for making follow-up appointments 
with the ophthalmologist was in the hands of the patient ( 1 7%), the 
ophthalmologist ( 1 8%), or the GP ( 12%) alone; according to 54% of GPs it 
was a shared responsibility. 
According to the guidelines, the annual check-up (table 2) was primarily 
performed by the GPs (involvement in 87% of the cases) and to a lesser 
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extent by the DSNs and/or the GP practice-assistants, who were involved in 
1 8  and 9% of the cases, respectively. Three-monthly check-ups were also 
primarily performed by the GPs (involved in 64%) but here the role of the 
practice assistants was more pronounced (52%) whereas the nurses were 
less involved (5%). 
Table 2. Regular check-ups according to the guidelines, involvement per 
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Not specified 
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Patient education (table 3) regarding diabetes in general, the use of diabetes 
related medication, foot care, and self monitoring was still handled 
primarily by the GPs (involved in 50-98%, respectively). With regard to the 
first two education topics above, the GP's assistant also had an important 
role (involved in 43% and 25%, respectively) . The DSN was the second 
most frequently mentioned caregiver involved in the education on self 
monitoring and foot care, while in the latter case podiatrists were involved 
in a minority of cases (8%). Education on diet was given mainly by 
dieticians ( 60%) but again also frequently by GPs (5 1% involved); 
education on injecting insulin was given mainly by DSNs and in a minority 
of cases by the GP or the home-care nurse. The most important methods for 
education were 'one to one' counseling (8 1 %), followed by handing out 
leaflets (77%) and group education (3%). 
Of all GPs, 81% controlled some or all patients with insulin-treated 
type 2 diabetes, and 48% initiate patients on insulin therapy themselves 
(without support from secondary care). In the latter group, 6 1% had a 
structural cooperation with a DSN; this is in contrast to the GPs who do not 
initiate insulin therapy themselves: they had a structural cooperation with a 
DSN in 1 7% of the cases (p<0.00 1 ). 
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Table 3. Diabetes education: involvement per caregiver (in percentage of 
the cases) by education subject . 
Education Type 
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Our main findings are that the conditions with respect to the organization of 
care for patients with type 2 diabetes, as described in the National 
Guidelines of the Dutch College of General Practitioners, were not yet 
sufficiently met. It appeared that several tasks were not delegated, or not to 
the most suitable caregiver. 
A limitation of the study is that the data were collected exclusively 
by a questionnaire with a response rate of only 72%. The mean response 
rate found among mail surveys published in medical journals is lower 
(60%),30 but, however small the non-response rate, a possible bias as a result 
of it must be taken into account.3 1 Another limitation, which may prevent 
the generalization of these results, lies in the higher degree of participation 
in shared-care projects (45% of participating GPs vs. a national average of 
26%).32 This was the consequence of the participation of 53 GPs (among the 
1 92 GPs invited to participate in the survey) in a large shared-care project in 
the region. Because part of the interventions in this project aimed to 
improve the organization of diabetes care, the results of the survey may 
have been influenced with respect to this subject. 
A strength of our study is that the GPs who participated in the survey 
are comparable to those in the rest of The Netherlands: the percentage of 
GPs working in 'solo practices' is the same as the national average (44%), 
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and the mean number of patients per GP is 2,360 as compared to 2, 1 98 
nationally.33 The prevalence of type 2 diabetes, as reported by the GPs is 
comparable to the prevalence found in a population-based study for the 
same period, 34 suggesting a valid registration in practice registers. 
Implementation of guidelines on practice organization and 
responsibilities 
Diabetes clinics were organized by 20% of the GPs, which is higher than 
has been reported in earlier studies (5-14%), 1 9;2 1 but a lot lower than was 
found by Pierce et al. (7 1 %) in England and Wales.35 Possible reasons for 
the lower percentage may be that different studies did not find evidence for 
the effectiveness of setting aside specific times for diabetes mini-clinics, or 
that there was insufficient assistance and/or a lack of practice facilities.20;2 1  
In various international guidelines the presence of  a balanced 
registration and call and recall system has been emphasized.7;9; 14 Our results 
show that 70% of the GPs had a specific diabetes registration, which is 
higher than has been reported in earlier studies (25%-5 1%); 19;2 1 ;36 and 78% 
had a (recall) system to stimulate attendance at scheduled regular diabetes 
check-ups, which is comparable to recent findings reported by others (7 1 %-
87%).35;37 Although this is higher than has been earlier reported ( 14%),38 
only 33% actively checked for non-attendance. 
The registration of the various cardiovascular risk factors was not 
performed systematically by 23-33% of GPs even though it is known that 
the accurate registration of these factors is associated with better treatment 
and lower mortality.394 1  This is comparable with findings from Steptoe et 
al. and can possibly be explained by the fact that in their study 10-70% of 
GPs felt that the identification of cardiovascular risk factors was not an 
important part of their work. 42 
Among GPs, views on the responsibility regarding follow-up check­
ups for retinopathy screening varied considerably: from full responsibility to 
none at all; this may indicate that in the Dutch National GP Guidelines the 
role of each team member involved in diabetes care is not defined clearly 
enough, while it should be, 14 and can be.43 Clarification may not have to 
imply a rigid role description for the different caregivers that applies to the 
entire country, but could also be the advice to discuss and describe the role 
of team members regionally, according to possibilities and limitations. 
However more clarity about this subject should be introduced. 
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(Lack of) task delegation 
Different tasks in diabetes patient care can be delegated. For example, 
screening has been mentioned as a task which practice nurses can possibly 
fulfil.44 Among the GPs surveyed, 59% stated that they do not screen for 
diabetes in high-risk groups, and that, when screening is organized, it is not 
done routinely. This is in contrast with the recommendation in various 
international guidelines.7;9; 1 5 Delegating this task may tmprove 
implementation. 
Annual and three-monthly check-ups were still mainly performed by 
the GPs themselves (involvement in 87% and 64% of the cases, 
respectively) instead of being delegated to nurses and/or GP practice­
assistants. In England and Wales GPs ran clinics on their own in only 2% of 
cases, and with nurses in 64% of cases.35 
In the treatment of patients with diabetes, initial and ongoing patient 
education plays an important role.7;9; 1 5  Moreover, without education, 
patients have a four fold higher chance of major complications.45 Education 
involves more than just the transfer of information; often a change in 
behaviour has to be effected.46;47 Already in 1 99 1 ,  GPs foresaw that patient 
education would be a major problem in establishing a diabetes service, but 
only 58% identified education as a task that could be delegated to the 
practice nurse.44 However, it has been emphasized that GPs do not have to 
be entirely responsible for the patient's education, and that this is a task 
which can and should be delegated.7;9; 1 5  Dieticians proved to be better at 
educating patients about diet than physicians, but there was little evidence 
that dieticians had better outcomes than nurses.48 However, the majori� of 
the education is still being given by the GPs, as was reported by others. In 
contrast with the recommendation in national guidelines,7;9; 14; 1 5  dieticians 
are not involved in 40% of cases of diet education, which is generally still 
better compared to other results reported in the literature (50%-96%). 1 6;49;50 
More tasks could and should be delegated in the area of patient education. 
When GPs initiate insulin therapy for their patients without external 
consultation, following the voluntary guidelines in the Dutch National GP 
Guidelines,9 a structural cooperation with a DSN is obligatory. Within this 
group of GPs, 39% mentions no such cooperation, preventing the possibility 
of delegating tasks to the DSNs. 
Implications for the future 
Why is there a lack of task delegation? This lack of teamwork with other 
health care professionals may be explained by physicians not being 
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interested in sharing the responsibility for diabetes care with other 
physicians or allied health professionals (podiatrists, nurse case managers, 
dieticians).26 Another possible reason is that GPs are not convinced of the 
effectiveness or the necessity of delegating tasks. 19 There may also be 
insufficient opportunities for task delegation within the current health care 
organization due to the insufficient availability of, or access to, specialized 
nurses and dieticians. 19;2 1  These questions need further exploration. At the 
same time, responsibilities for certain tasks need clarification. Many GPs 
seem to be searching for (support in) the optimal organization of their 
diabetes care, as is shown by their high level of participation in diabetes 
projects, therefore this could be a relevant area for future quality 
improvement strategies. 
Conclusion 
Conditions with respect to the organization of care for patients with type 2 
diabetes, as described in the National Guidelines of the Dutch College of 
General Practitioners, were not sufficiently met. Responsibilities for certain 
tasks, in particular with regard to screening for eye complications, are not 
sufficiently clear. It seems that different tasks are not delegated, or not to the 
most suitable caregiver. Barriers preventing task delegation need further 
investigation. 
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Abstract 
Background: The prevalence of type 2 diabetes mellitus (DM2) continues 
to increase worldwide. The associated cardiovascular morbidity and 
mortality are high. 
Objectives: To study daily practice in preventing cardiovascular disease 
(CVD) in an unselected primary-care patient population with DM2, and to 
study factors influencing the care delivered. 
Methods: Cross-sectional univariate and multivariate analyses of baseline 
data from a primary-care population-based sample of patients with DM2, 
participating in a shared care project in The Netherlands, in the year 
preceding the introduction of the revised guidelines of the Dutch College of 
General Practitioners. 
Results: Of 1 269 patients invited, 1 149 (9 1 %) participated. Hypertension 
was present in 78% of patients, 63% of whom were treated, 4 1% 
successfully. Lipid profile abnormalities were present in 5 1% of  patients, 
22% of whom were treated, 54% successfully. The treatment rates for lipid 
profile abnormalities were positively correlated with younger age and the 
registration of the lipid profile by the GP. For hypertension the treatment 
rates were higher for patients who were female, of an advanced age, in the 
presence of CVD, and/or whose blood pressure had been registered by the 
GP. 
Conclusions: A gap exists between recommended care and the care patients 
actually receive in the prevention of CVD in patients with DM2 in the 
primary care setting. Diagnosed CVD and the accurate registration of 
cardiovascular risk factors by GPs are associated with higher treatment 
rates. Improvement strategies could be directed at primary prevention of 




The prevalence of type 2 diabetes mellitus (DM2) is high and is increasing. 1 
People with diabetes have a two to threefold increased risk of cardiovascular 
disease (CVD), compared with the non-diabetic population.2 The treatment 
of risk factors for CVD, such as hypertension and lipid profile 
abnormalities, has been shown to be effective in reducing the overall risk for 
CVD. 3 ;4 In many countries the care for patients with DM2 is concentrated 
in the primary care setting, 5;6 and guidelines for clinical practice have been 
developed to optimise this care.6;7 The National Guidelines of the Dutch 
College of General Practitioners (short form: National GP Guidelines) for 
the assessment and treatment of DM2 were first introduced in 1 989.8 The 
revised 1 999 version has been extended to include guidelines on treatment 
of hypertension and dyslipidaemia.6 However, the implementation of 
guidelines appears troublesome; there is still a gap between recommended 
diabetes care and the care patients actually receive.9; IO Information on the 
implementation of the guidelines in daily practice, and on factors 
influencing implementation, is necessary as a basis for future 
implementation strategies. Different factors are known to influence the 
delivery of care: patient characteristics such as age1 1 , gender12, and having a 
history of CVD, 13 and other factors such as the registration of 
cardiovascular risk factors in patient records. 1 4 However, these findings 
come from selected, non-primary-care, or non-diabetic populations. 
Our study aimed to describe the status of, and factors associated 
with, the prevention of cardiovascular complications in DM2 in a 
population-based primary-care setting, in the year preceding the 
introduction of the revised National GP Guidelines, m order to find a 
direction for future implementation strategies. 
Methods 
Setting 
Baseline data were obtained from The Zwolle Outpatient Diabetes project 
Integrating Available Care (ZODIAC)-study, which investigated the effects 
of a shared-care project on patients with DM2. Patients registered with 32 
general practitioners were seen for their annual control, which was 
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performed according to the National GP Guidelines, by diabetes specialist 
nurses (DSNs). The participating GPs were each members of four GP­
working groups. GPs in GP-working groups have practices in the same 
region and collaborate mainly with respect to the delivery of medical 
services during out-of-office hours. These groups participated in the study 
as a whole, preventing the selection of GPs with a specific interest in 
diabetes. This study was approved by the Medical Ethics Committee of the 
Isala Clinics (formerly Weezenlanden Hospital). 
Patients 
20% of the 1 664 patients known to have DM2 was excluded because they 
were also being treated in secondary care; 80% (n=1326) was being treated 
exclusively in primary care. 57 of these patients ( 4%) were excluded due to 
either terminal illness or cognitive impairment, causing an incapacity to 
participate in the project, in the judgment of the GP. Of the 1 269 remaining 
patients invited to participate, 1 149 (9 1%) accepted and were enrolled in the 
study. 
Data collection 
We used two data sets, collected at the same time. Baseline data was 
collected prospectively by the DSNs. Retrospective data was collected 
manually for each individual patient from the GPs' files (electronic or paper 
medical record, including specialist correspondence) by the primary 
investigator. The latter dataset was used only to determine the degree of 
registration of variables. Data were collected for patients who entered the 
project between February 1 998 and 1999, the year preceding the 
introduction of the revised guidelines. Retrospective data collection 
concerned a period of one year for all variables except eye examinations, 
which covered two years. All laboratory measurements were performed in a 
central laboratory. Data on medication use and medical history were 
provided by the GPs and checked with the patient by the DSN. Blood 
pressure, weight, and height were measured by the nurses: blood pressure 
with a Welch Allyn Spygmomanometer in supine position after at least 5 
minutes of rest. 
Definitions 
The National GP Guidelines on the treatment of cardiovascular risk factors 
are summarized in table 1 .  As international treatment goals differ somewhat 
from the Dutch guidelines, international treatment goals have been included 
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in this table for comparison. Hypertension was defined as a blood pressure 
> 1 50/85 mm Hg or the use of antihypertensive medication. A history of 
CVD was defined as a history of myocardial infarction, coronary artery 
bypass graft, percutanous transluminal coronary angioplasty, 
cerebrovascular accident, transient ischaemic attack, bypass or percutanous 
transluminal angioplasty for peripheral artery disease, intermittent 
claudication, or angina pectoris. Glycaemic dysregulation was defined as an 
HbAl c>8.5%, and a lipid profile abnormality as one that should be treated 
according to the National GP Guidelines (table 1 ). Treatment is defined as 
successful when the goals outlined in the guidelines are met. 
Outcome measurements 
We measured the proportion of patients for whom the blood pressure, lipid 
profile, smoking status, and BMI were recorded. We studied the prevalence 
of hypertension, dyslipidaemia, and smoking; the proportion of patients 
receiving treatment; and the percentage of treatments which were 
successful. Finally, we studied the association of gender, smoking, age, 
CVD, glycaemic dysregulation, and degree of registration with the 
proportion of patients receiving treatment and the success percentages. 
Analysis 
Data were analyzed with SPSS (version 8.0 1 ). Student's T-test and the Chi­
squared test were used to analyze the statistical significance of differences 
between groups. P-values <0.05 were considered statistically significant. 
Univariate analyses for age and HbAlc  are presented in specific categories 
for clarity and readability. Multivariate analyses were performed with 
logistic regression using a model including age, gender, history of CVD, 
HbAlc, smoking, and registration of the cardiovascular risk factors in the 
medical record. In multivariate analyses patient age and HbAl c  were used 
as continuous variables. 
Results 
Population characteristics 
The demographics (age and gender) of the patients who refused to 
participate (n=120) were comparable to those of study participants (n=1 1 49, 
p>0.05). Table 2 shows the characteristics of the participating population. 
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Table 1. National and international guidelines on the treatment of 
cardiovascular risk factors 
Nationa16 Euro�e USA 
Risk factor Patients with Treatment Goal Goal Goal 
treatment indication 
HbAlc All, HbA 1 c> 7% Diet, oral <7.0% = <6.5% = <7.0% = 
blood glucose good good good 
lowering >8.5% = >7.5% = >9.0% = 
agents, insulin, poor poor poor 
or (upper combination limit of 
normal: 
6%) 
Smoking All, smoking Recornrnen- Stop Stop Stop 
dation to stop 
smoking 
Hyper- All, blood pressure Diuretic, Blood <140/90 rnrn < 130/80 
tension > 1 50/85 rnrn Hg ACE-inhibitor, pressure Hg mm Hg 
and/or beta- < 1 50/85 
blocker mm Hg 
Dys- Men aged 50-70 Dietary Total Total LDL-
lipidaemia years and women measures and cholesterol cholesterol < cholesterol < 
aged 50-75, no statin < 5  5.2* 2.6* 
CVD#, mean of two rnrnol/L 
measurements of HDL- HDL-Chol/HDLt>6 in cholesterol> cholesterol > non-smokers and 1 . 1 *  1 . 1 *  Chol/HDL>5 in 
smokers 
All patients with Dietary Total Triglycerides Triglycerides 
CVD, mean of two measures and cholesterol < 1 .7*  < 1 .7*  
measurements of statin < 5  
total cholesterol >5 mmol/L 
Patients <50 years Dietary Total 
with measures and cholesterol 
microalbuminuria, statin < 5  
total cholesterol > 5 rnrnol/L 
rnrnol/L 
# CVD: cardiovascular disease, f Choi/HDL: total cholesteroi/HDL-cholesterol ratio. * mmoi/L 
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The mean diabetes duration was 7.4 years, mean HbA1c  was 7.5% with a 
majority (70%) of patients receiving treatment with oral hypoglycaemic 
agents. The mean blood pressure was 1 55/84 mm Hg, total cholesterol 5 .7 
mmol/L, and the mean BMI was 28.9. 
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Registration in GP patient records 
Mean (St. Deviation) I % 
57.6 
68.7 ( 1 1 .5) 
7.6 (7.4) 
7.5 ( 1 .3) 
5.7 ( 1 . 1 )  
5.3 ( 1 .6) 
2.6 ( 1 .6) 
1 54 (25) 
84 ( I I )  
1 3 .5 (46.0) 
28.9 (4.8) 










The registration of variables varied from 0. 1% to 100%, and was 78% for 
blood pressure, 45% for total cholesterol, 1 1% for smoking, and 0.3% for 
BMI (table 2). 
Cardiovascular risk factors 
The prevalence of known CVD was 36%. 1 8% of the patients were 
smokers. The proportion of patients with hypertension was 78% (table 3). 
Dyslipidaemia that ought to be treated according to the National GP 
Guidelines was present in 5 1 %  of patients. 
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Treatment (success) 
Patients with hypertension received antihypertensive medication in 63% of 
cases, and 4 1% of those were treated successfully. The mean number of 
antihypertensive medications was 1 .7, with 50% of patients using one, 36% 
using two, and 14% using 3 or more. The most commonly prescribed 
medications were diuretics (45%), followed by beta-blockers (39%), ACE­
inhibitors (38%), calcium antagonists (28%) a-2 antagonists (9%), and 
combination preparations (5%). There was no difference in medication use 
between patients being treated successfully and patients being treated 
unsuccessfully. In the multivariate analysis (tables 3 and 4), the treatment of 
hypertension was positively associated with female gender, advanced age, 
having a history of CVD, and the registration of blood pressure in the 
medical record by the GP. Treatment success was associated with having a 
history of CVD. 
Patients with lipid profile abnormalities received lipid lowering 
medication in 22% of cases, and 54% of those were treated successfully. 
The treatment of lipid profile abnormalities was associated with younger 
age and the registration of the lipid profile in the medical record. Successful 
treatment was again associated with having a history of CVD. 
Discussion 
Main findings 
In this study, we found a considerable gap between the recommended and 
the actual care regarding the prevention of cardiovascular complications in 
DM2 according to the National GP Guidelines. Patient-related factors 
associated with treatment (success) of hypertension and lipid profile 
abnormalities were age, gender, and having a history of CVD. The accurate 
registration of cardiovascular risk factors by GPs was associated with better 
treatment for both hypertension and lipid profile abnormalities. 
Strengths and limitations 
These results were obtained in the period preceding the introduction of the 
revised National GP Guidelines, therefore improvements are expected as 
they are implemented. 1 5  Patient comRliance was not assessed and may have influenced treatment success rates. 6 Furthermore, the study design was 
cross-sectional: associations and not causal relations were found. 
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A strength of this study is that the selection criteria were sufficiently broad, 
ensuring a minimum of bias allowing these results to be applied to other 
primary care DM2 populations. 
Table 3. Prevalence (%), treatment (%), and treatment success (%) of 
cardiovascular risk factors by possible related variables with the results of 
the univariate and multivariate analyses. 
Gender M 73.7 0.0 1 59. 1 0.03# 53.3 <0.00 1 54.0 0.04 20.2 
F 80.5 66.2 34. 1 47.9 22.7 
Age :570 70.7 <0.00 1 # 55 <0.00 1# 40.9 0.89# 52.8 0. 1 3 *  26.0 
>70 84. 1 69.9 4 1 .5 48.3 1 7.0 
History 0rNo 73.5 <0.001 # 54.4 <0.00 1 # 35.6 <0.005# 36.0 <0.001 # 1 8.5 
CVD Yes 85 77. 1 47.6 76.5 24. 1 
HbAlc <7 76.5 0.74 67.4 0. 1 0  46.3 0. 1 0# 47.4 0. 1 4# 2 1 .0 
7-8.5 78.5 60.3 37.7 5 1 .9 2 1 . 1  
>8.5 78.4 60.5 36.9 54.7 23.3 
Smoking No 80.7 <0.001 # 64 0.33 40.2 
Yes 63.3 59.5 47.4 
0.23 47.5 <0.00 1 # 1 9.9 
65.2 27.4 
0.46 49. 1 0.30 
58.3 
0.0 1 # 53.9 0.90 
55. 1  
0. 1 0# 65.3 0.05* 
47.4 
0.87 59.6 0.36* 
56.3 
43.3 
0.06 59. 1 0. 1 0  
43.2 
Regis- No 68.9 <0.00 1 # 47.8 <0.001 # 54.5 
80.4 66.7 39.2 
0.0 1 45.6 
56.0 
0.0 1 # 1 1 .3 <0.00 1 k 39.4 0.03 
tration in Yes 
medical 
record 
Total 77.7 63.3 4 1 .3 50.7 
32. 1 60.9 
2 1 .6 54.4 
N The p-values presented are results of the univariate analyses, printed bold if significant. * I #  Differences are 
significant (* p<0.05 1 # p<O.O/) in multivariate analyses (see table 4). 
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Table 4. Presence and treatment (success) of cardiovascular risk factors by 
e.ossible related variables, with results o[the multivariate anal�ses. 
Odds ratio {Ex(!{B}} 95% CI p 
Hypertension Gender female 1 .30 0.96 - 1 .77 0.09 
Age 1 .04 1 .03 - 1 .05 <0.001 
History of CVD 1 . 7 1  1 .2 1  - 2 .4 1  0.002 
HbAl c  1 .06 0.95 - 1 .20 0.30 
Smoking 0.60 0.42 - 0.85 0.005 
Registration of blood Eressure 1 .56 1 . 1 2  - 2 . 1 7  0.01 
Treatment with Gender female 1 .64 1 .20 - 2.23 0.002 
antihypertensive Age 1 .02 1 .0 1  - 1 .04 0.001 
drugs History of CVD 2 .96 2. 14 - 4.09 <0.001 
HbA l c  0.94 0.83 - 1 .06 0.29 
Smoking 1 .08 0.7 1 - 1 .65 0.7 1 
Registration of blood Eressure 2.05 1 .44 - 2.91 <0.001 
Successful Gender female 0.75 0.54 - 1 .05 0.09 
treatment of Age 1 .02 1 .0 1  - 1 .04 0.005 
hypertension History of CVD 2.27 1 .64 - 3 . 1 3  <0.001 
HbA l c  0.80 0.70 - 0.92 0.002 
Smoking 1 .20 0.76 - 1 .87 0.43 
Registration ofblood Eressure 0.9 1 0.62 - 1 .34 0.64 
Lipid profile Gender female 1 .27 0.96 - 1 .68 0.09 
abnormality Age 0.99 0.97 - 1 .00 0.03 
History of CVD 7.34 5.42 - 9.96 <0.001 
HbAl c  1 . 1 8  1 .06 - 1 . 3 1  0.002 
Smoking 2.53 1 .76 - 3.63 <0.001 
Registration of liEid Erofile 1 .55 1 . 1 8 - 2.04 0.001 
Lipid-lowering Gender female 1 .42 0.9 1 - 2.2 1 0 . 12  
drugs Age 0.97 0.94 - 0.99 0.003 
History of CVD 2.03 1 .26 - 3 .26 0.003 
HbA l c  1 .09 0.9 1 - 1 .29 0.36 
Smoking 1 .54 0.93 - 2.56 0.09 
Registration of liEid Erofile 3 .73 2.36 - 5.89 <0.001 
Successful Gender female 0.90 0.39 - 2.05 0.80 
treatment Age 1 .02 0.98 - 1 .07 0.33 
with lipid- History of CVD 0.40 0. 1 7  - 0.99 0.05 lowering drugs 
HbAl c  0.69 0.49 - 0.97 0.03 
Smoking 0.56 0.23 - 1 .38 0.2 1 
Registration of lipid profile 2.36 0.95 - 5.87 0.07 
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Comparison with existing literature 
Our treatment (success) rates were lower than those reported in other 
settings: our patients with hypertension and dyslipidaemia received drug 
therapy in 63% and 22% of cases compared with 78% and 38% reported in 
a study conducted at an academic center. 1 3 The percentage of patients not 
reaching lipid goals was higher in our population compared to a study using 
an audit-enhanced monitoring system (46% vs. 28%). 1 7 One reason the 
defined blood pressure goals were not reached is probably due to the 
relatively low use of medication. Only 14% of patients used :2:3 
antihypertensive drugs, comparable to findings reported by others ( 1 6%), 1 8 
but lower than in the UKPDS (29%). 3 The above results support the general 
finding that improvement in the treatment of dyslipidaemia19  and 
hypertension20 is necessary. 
The absence of a history of CVD appears to be associated with lower 
treatment (success) rates, as also found by others. 13 Higher treatment 
(success) rates in the secondary prevention of CVD may be due to the 
heightened awareness of GPs. It may also be a result of initiating treatment 
during the acute phase of cardiovascular incidents, as the treatment rates 
appear higher in the secondary care setting.2 1 
Our results show a significant positive association between the 
registration of blood pressure and dyslipidaemia by GPs and the treatment 
of these cardiovascular risk factors, as was also found by Hall et al.22 Our 
data do not support the suggestion that any lack of registration is due to a 
failure in recording normal values:23 69% of our patients whose blood 
pressures had not been recorded in their medical record had hypertension. 
Comparable data were recently published by Goudswaard et al.24 
The positive bias we found towards women, concerning treatment 
rates of hypertension, is in contrast with findings reported by others. 1 2  Also 
in contrast with other studies, 25 our data do not support the presence of 
ageism taking the form of under-treatment for hypertension. For 
dyslipidaemia however, the treatment rate is lower in the elderly, 
confirming other findings_26 
Implications 
The revised National GP Guidelines, which recommend a multi-factorial 
approach, including the treatment of hypertension and dyslipidaemia, have 
widespread implications. Patients will have to be followed more intensively, 
including more control measurements and registration by physicians, and 
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more medication use by patients. Polypharmacy may be unavoidable which 
may well result in compliance issues27• 
These study findings may help to focus quality improvement 
strategies. Accurate and complete record keeping with regard to 
cardiovascular risk factors and further development of strategies for the 
primary prevention of CVD appear necessary. Successful interventions may 
include applying organizational strategies that increase structural recall, 
prompting of doctors, benchmarking, and continuing medical education, 
delegating tasks to specially trained nurses, and using electronic clinical 
information systems with decision support. 28-33 
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Abstract 
Introduction: Microalbuminuria in type 2 diabetes mellitus (DM2) is an 
independent risk factor for cardiovascular morbidity and mortality. The 
guidelines of the Dutch College of General Practitioners recommend not to 
measuring microalbuminuria in patients �50 years of age. The aim of this 
study is to present prevalence data on albuminuria in DM2 in the general 
practice setting in The Netherlands, and to evaluate whether or not the 
above recommendation is justifiable, given the arguments in 1 999. 
Methods: Data from a large primary care DM2 population were collected 
during a study into the effects of shared care between February 2000 and 
200 1 .  
Results: There were 2,094 patients with known DM2 in the practices of 32 
general practitioners, 1 ,653 (79%) of whom were being exclusively treated 
by the GP; 67 (4%) were excluded, and 144 1/1 586 (91 %) of invited patients 
participated. Microalbuminuria was present in 33% of patients, and 
macroalbuminuria in 7%, with an increase in prevalence occurring with 
increasing age. Among patients <50 years of age with microalbuminuria, 
1 8% (6/33) were treated with an ACE-inhibitor or A2-antagonist; among 
patients �50 this percentage was 33% ( 1 83/548). Among patients �50 years 
of age with microalbuminuria, 9 1% (488/539) had hypertension and/or lipid 
profile abnormalities; 82% ( 402/488) had not, or had been insufficiently 
treated for this condition. 
Conclusion: Micro- and macroalbuminuria were present in 33 and 7% of 
patients with type 2 diabetes in primary care, respectively. The treatment of 
prevalent hypertension and lipid profile abnormalities was often insufficient. 
Based on these results, the recommendation not to measure albuminuria in 




Type 2 diabetes mellitus is a chronic disease with a high co-morbidity and 
mortality. 1 The majority of patients die from cardiovascular disease. The 
treatment of hypertension and hypercholesterolemia reduces the risk of 
developing macrovascular complications.2;3 Microalbuminuria is an 
independent predictor for the development of cardiovascular morbidity and 
mortality.4 The national guidelines for type 2 diabetes mellitus from the 
Dutch College of General Practitioners which were published in 1 999 
(further referred to as the 'National GP Guidelines') advise against 
measuring microalbuminuria in patients aged 50 years and older. 5;6 The 
argument for this recommendation is that the relationship between 
microalbuminuria and renal failure in patients with type 2 diabetes mellitus 
is not clear, and it was assumed that: 'to reduce the risk of macrovascular 
complications, this group already receives optimal treatment, because lipid 
profile abnormalities are dealt with according to a strict regimen, and a 
blood pressure goal of 1 50/85 mm Hg or lower is strived for' . The 
prevalence of microalbuminuria combined with a normal blood pressure and 
a normal lipid profile in type 2 diabetes patients is unknown. 7 
The aim of this study was to present prevalence data for (micro )albuminuria 
in a Dutch primary-care type 2 diabetes population, and to evaluate if the 
arguments for the standpoint, not to measure microalbuminuria in patients 
aged over 50 years, are justified . 
Methods 
Embedding of the study 
We used data from a large primary-care population of patients with type 2 
diabetes. Data were collected during a study into the effects of shared 
diabetes care (ZODIAC-study, Zwolle Outpatient Diabetes project 
Integrating Available Care) that started in 1 998. The patient population 
consisted of patients with type 2 diabetes mellitus, treated exclusively by 
general practitioners (n=32) in the Zwolle region of The Netherlands. The 
exclusion criteria for the patients included terminal disease states or any 
cognitive disability that made education in the ZODIAC-study impossible. 
In the ZODIAC-study, the albumin concentration in a urine sample was 
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measured and the albumin to the creatinine excretion in urine was calculated 
once a year. Data were collected between 1 February 2000 and 3 1  January 
200 1 .  Patients gave consent for the use of their data. Urine and blood 
examinations, and a physical exam were performed for all patients. 
Table 1. Dutch national GP guidelines for the treatment of risk factors for 
cardiovascular disease in patients with type 2 diabetes mellitus. 
Risk factor Patients with treatment Treatment Goal 
indication 
Hypertension All, blood pressure Diuretic, ACE- Blood pressure 
>150/85 nun Hg inhibitor and/or <150/85 mm Hg 
beta-blocker 
Dys- Men aged 50-70 years and women Dietary measures Total cholesterol 
lipidaemia aged 50-75, no CVD, mean of two and statin < 5 rnmol/L 
measurements of 
Chol!HDL>6 in non-smokers and 
Chol/HDL>5 in smokers 
All patients with CVD, mean of Dietary measures Total cholesterol 
two measurements of total and statin < 5 rnmol/L 
cholesterol >5 mmol/L 
Patients <50 years with Dietary measures Total cholesterol 
microalbuminuria, total cholesterol and statin < 5 rnmol!L 
> 5 rnmol!L 
Micro- Patients <50 years 
albuminuria 
Patients >50 years 
Definitions 
ACE-inhibitor Blood pressure 
< 140/80 rnm Hg or 
maximum dose 
ACE-inhibitor 
Measuring for microalbuminuria is not 
advised. Assumption: for prevention 
of complications, this group is already 
optimally treated through treatment of 
lipid abnormalities and hypertension 
According to the guidelines,5 we defined microalbuminuria as a 
microalbumin concentration of 20-200 mg/L or an albumin to creatinine 
ratio of 2,5-25 and 3,5-35 for men and women, respectively; 
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macroalbuminuria was defined as >200 mg/L or an albumin to creatinine 
ratio >25 and >35 for men and women, respectivelr The renal clearance 
was calculated using the Cockroft and Gault formula. 
The definitions and treatment indications for microalbuminuria, 
hypertension, and lipid profile abnormalities from the National GP 
Guidelines were used and are summarized in table 1 .  A positive history of 
cardiovascular disease was defined as having a history of myocardial 
infarction, coronary artery bypass grafting (CABG), percutaneous 
transluminal coronary angioplasty (PTCA), cerebrovascular accident 
(CV A), transient ischemic attack (TIA), bypass or percutaneous 
transluminal angioplasty for peripheral vascular disease, intermittent 
claudication, or angina pectoris. 
patients with type 2 diabetes mellitus 




treated by an treated by a 
internist general practitioner 




-terminally ill invited to participate 





1 45 (9%) 144 1  (9 1%) 
Figure 1. Study population selection characteristics. 
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Results 
Figure 1 shows study population selection characteristics. 9 1% ( 144 1  I 
1 586) of all invited patients participated. Table 2 shows descriptive medical 
characteristics of the population. Micro- and macroalbuminuria were present 
in 33% and 7% of patients, respectively. Renal clearance was <50 mVmin in 
1 9% and <20 ml/min in 0.4% of patients. Hypertension and lipid profile 
abnormalities with a treatment indication were found in 75% and 50% of all 
participating patients, respectively. 
Table 2. Characteristics of 1441 patients with type 2 diabetes mellitus, 
treated within the primary care setting in the Zwolle region 2000/'01 . 
Mean Standard Deviation 
Age 68,3 1 1 ,7 
Diabetes duration 7,2 7,4 
HbA!c (%) 7,3 1 ,2 
Total cholesterol (mmol/L) 5,4 1 ,0 
Total cholesteroi!HDL ratio 4,6 1 ,2 
Systolic blood pressure (mmHg) 149 23 
Diastolic blood pressure (mmHg) 81  1 1  
Serum creatinine 93,8 22,3 
Cockcroft (mllmin) 73,0 27,6 
Microalbumin (mg/L) 65,6 234,8 
Albumin/creatinine ratio 10,0 35,8 
Bod� mass index {kg/m2} 29,2 4,9 
Number Percentage 
Women 8 1 2  56 
Smoking 262 1 8,2 
Insulin and tablets 74 5 
Insulin 1 70 1 2  
Diet 226 1 6  
Tablets 97 1 67 
Cockroft<20 6 0,4 
Cockroft 20-50 280 1 9,4 
Microalbuminuria 480 33,0 
Macroalbuminuria 102 7,0 
History of cardiovascular disease 659 45,7 
Indication for lipid lowering medication 72 1 50 
Hypertension 1083 75,2 
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1 00 patients were younger than 50 years of age, 33  of them had micro- or 
macroalbuminuria (table 3). In 1 2  patients this was known for longer than 
one year; 1 8% (6/33) of them were treated with an ACE (Angiotensine 
Converting Enzyme)-inhibitor or A2 (Angiotensine H)-antagonist. 34% of 
patients aged 50-70, and over 47% of patients aged 70 years and over, had 
micro- or macroalbuminuria. In both groups, one-third was treated with an 
ACE-inhibitor or A2-antagonist: 7 112 1 5  (33 .0%) and 1 1 2/333 (33 .6%), 
respectively. 
Table 3. Number (%) of patients with norma-, micro- and 
macroalbuminuria per age category, among 1439 patients with type 2 
diabetes mellitus, treated within the primary care setting, in the Zwolle 
region, 2000/'01 . 
Age Total 
(n= 1439) 
<50 years 50-70 years >70 years 
(n=lOO} {n=626} {n=713} 
Normoalbuminuria 67 (67%) 4 1 1 (66%) 380 (53%) 858 (60%) 
Microalbuminuria 30 (30%) 1 80 (29%) 269 (38%) 479 (33%) 
Macroalbuminuria 3 (3%) 35 (6%) 64 (9%) 1 02 (7%) 
548 patients aged 50 years and older had microalbuminuria. In 539 patients 
data on blood pressure and lipid profile were complete. The treatment of 
hypertension and lipid profile abnormalities in patients aged 50 years and 
older with microalbuminuria is summarized in table 4. In total, 9% (n=5 1 )  
of  these patients appeared to have neither hypertension nor lipid profile 
abnormalities. However, 82% ( 402/488) of patients older than 50 years of 
age with microalbuminuria, had either hypertension or lipid profile 
abnormalities that were not, or were insufficiently treated. This was 77% 
(5 1 0/661 )  in patients without microalbuminuria. 
Six percent (n=29) of patients aged 50 years and over presented with 
both hypertension and lipid profile abnormalities without having any 
medication prescribed. 
9 1 %  (n=488) of the patient population aged 50 years and over had an 
indication for antihypertensive or lipid lowering medication. 372 (76%) of 
those patients were prescribed medications; the treatment goal was not 
achieved for 286 (77%) of those patients. 
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Table 4. Treatment of hypertension and lipid profile abnormalities (n(%)) in 
548 patients with type 2 diabetes mellitus and albuminuria (complete data 
in 539), older than 50 years of age, treated within the primary care setting, 
in the Zwolle region 20001'01. 
Lipid profile abnormalities 
Hypertension No Well Insufficiently 
abnormality treated Untreated treated Total 
No hypertension 5 1  (9) 7 ( 1 )  29  (5) 5 ( l )  92 ( 1 7) 
Well treated 53 ( 10) 26 (5) 46 (9) 1 5  (3) 140 (26) 
Untreated 58 ( 1 1 )  6 ( 1 )  29  (5) 3 ( 1 )  96 ( 1 8) 
Insufficiently treated 78 ( 14) 3 1  (6) 80 ( 1 5) 22 (4) 2 1 1  (39) 
Total 240 (45) 70 ( 1 3) 1 84 (34) 45 (8) 539 ( 1 00) 
Discussion 
Main findings 
Albuminuria is highly prevalent in type 2 diabetes in the primary health care 
setting: in our study 40% of patients were found to have albuminuria (33% 
micro- and 7% macroalbuminuria). This is in line with findings from 
secondary care9; 10 and is comparable with, 1 1  or higher than rates reported in 
other studies which range from 2 1  to 33 percent. 12; 1 3 Nine percent of 
patients over 50 years of age with microalbuminuria have neither 
hypertension nor lipid profile abnormalities, and are, according to the 
National GP Guidelines not to be treated for their increased cardiovascular 
risk, which does nevertheless exist due to the microalbuminuria.4 
Additionally, 82% of patients with microalbuminuria receive no -or 
insufficient- treatment for their hypertension and/or lipid profile 
abnormalities. The presumption in the National GP Guidelines that: 'to 
reduce the risk of macrovascular complications, this group already receives 
optimal treatment, because lipid profile abnormalities are dealt with 
according to a strict regimen, and a blood pressure goal of 1 50/85 mm Hg or 
lower is strived for' '  appears not to be justified. 
In this light, it appears necessary to revise the recommendation to 
refrain from measuring microalbuminuria in patients ;;::so  years of age: on 
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the one hand because some patients with an increased cardiovascular risk 
are missed as a consequence of the absence of risk factors as mentioned in 
the National GP Guidelines and, on the other hand, because efficacious 
treatment of hypertension and lipid profile abnormalities are insufficiently 
implemented. Identifying the increased cardiovascular risk, in the form of 
demonstrated microalbuminuria, could be a strong argument for both 
caregiver and patient to start or intensify treatment. Revision of the National 
GP Guidelines with respect to this point should therefore be considered. 
Recent literature 
In patients with type 2 diabetes and microalbuminuria, treatment with ACE­
inhibitors leads, in the long term, to fewer cardiovascular complications, and 
less deterioration of renal function (table 5). Treatment with A2-antagonists 
decreases the chance of moving from micro- to macroalbuminuria. 
Combination of an ACE-inhibitor with an A2-antagonist appears to even 
further reduce blood pressure and albuminuria. 
In patients with macroalbuminuria and type 2 diabetes, the use of 
A2-antagonists appears to lead to less renal function loss and a considerably 
smaller chance of end-stage renal disease. An analysis of the study results 
which have been published more recently than the National GP Guidelines 
(see table 5) supports the contention that a revision of the standpoint in the 
National GP Guidelines should be considered. 
The annual measurement of microalbuminuria in all type 2 diabetes 
patients would also be more in keeping with other national and international 
guidelines. 14-1 6  This advice would, according to recent literature, in any case 
have to apply to patients with type 2 diabetes until the age of 70 years. 1 7 
With respect to patients with microalbuminuria in the absence of 
hypertension and lipid profile abnormalities, an ACE-inhibitor as well as an 
A2-antagonist are recommended; 1 8; 1 9 in the case of macroalbuminuria an 
A2-antagonist would be preferable. 1 7;20 
Some marginal notes 
A strong point in the ZODIAC study is that the patients with type 2 diabetes 
treated in the primary care setting were an unselected population. 
A limitation of this study is that the assessment of the microalbuminuria was 
based on a single annual measurement. The findings were comparable to 
those obtained by others however, therefore, we do not expect this to have 
erroneously affected our conclusions. 
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Our data were collected during the second year following the introduction of 
the revised National GP Guidelines, which probably explains why the 
implementation of recommendations on the treatment of microalbuminuria, 
hypertension, and lipid profile abnormalities was not yet optimal. On the 
other hand, after two years of participation in the ZODIAC-study, 
implementation may have been better than generally seen. 
Table 5. Recent literature on the treatment of albuminuria. 
J. cos = � ..... = 
= --- --- ; = "' Col .:: ._, J. Q. = ..... "' cos = "CC cos > - � I � 
• !::! = ..... � J. 
:c ,; .2! 
._, ..::: ..:c ... - � = "' = cos OJ) C2 Q, � Q, < t. 
Micro albuminuria 
IRMA 219 200 1 150 mg 1 94 30-70 2 years 39% less progression 
irbesartan* vs. vs to macroalbuminuria 
placebo 20 1 
300 mg 1 95 7 1 %.J.. macro 
irbesartan* vs. VS albuminuria;(CV 
placebo 20 1 incidents 4.5% vs. 
8.7% (NS)) 
Micro 2000 Ramiprilt on 1 140 >55 4,5 24%.J.. CV incidents 
HOPE18 top of other years 
treatment 
UKPDS21 1998 Captoprilt vs. 299 Mean 56 9 years No difference in CV 
atenolo1t incidents 
CALM22 2000 Lisinoprilt vs. 199 Mean 60 24 Less albumin 




RENAAL17 200 1 Losartan* vs. 1 5 1 3  3 1-70 3 ,4 25%.J.. SCr*2, 28%.J.. 
placebo years ESRD 
IDNT20 200 1 Irebesartan* 1 7 1 5  >20 2,6 35%.J.. SCr*2, 23%.J.. 
vs. placebo vs. 
am1odipine§ 
years ESRD 
CV= cardiovascular, ESRD= end stage renal disease, SCr*2- doubling ojse111m creatinine, * A-Il-antagonist. 




In patients with type 2 diabetes, treated in the primary care setting, the 
prevalence of albuminuria was high ( 40% ). The treatment of albuminuria 
was insufficient in patients younger than 50 years of age. The treatment of 
hypertension and lipid profile abnormalities was insufficient in 82% of 
patients �50 years of age. Based on the results of this study and on the 
results of research into the effects of treatment of albuminuria, the 
measurement of urinary albumin excretion in patients with type 2 diabetes 
aged 50 years and over, at least until the age of 70 years, appears to be a 
sound recommendation. 
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Blood pressure regulation in primary and secondary care 
Abstract 
Objective: The tight regulation of blood pressure in patients with type 2 
diabetes mellitus reduces macro- and microvascular complications. We 
studied whether the goals for adequate blood pressure control according to 
the Dutch national guidelines were met in primary and secondary care. 
Methods: Data were collected between 1999 and 2000 from patients with 
type 2 diabetes mellitus who visited the outpatient clinics of two physicians 
specialized in diabetes care. The recommended target value for blood 
pressure was ::; 1 50/85 mmHg. We compared patients whose blood pressures 
met this goal with patients whose blood pressures exceeded this value. The 
same data were collected for patients treated in primary care between 1 997 
and 1 998. At that time, the target blood pressure in primary care was 
::; 1 60/90 mmHg. 
Results: 502 patients from secondary care and 1 ,084 from primary care 
were included. The mean blood pressure in the patients from secondary care 
was 1 57/79 mmHg, vs. 1 62/87 mmHg for the patients from primary care. 
The prevalence of hypertension in the secondary care patients was 89%. 
3 7% of those patients had a satisfactory regulation of their blood pressure. 
There were no differences in the basic characteristics between the patients 
who had adequate blood pressure control and those who did not. They both 
had a mean of 2.2 prescriptions for hypertensive medications. The 
prevalence of hypertension in primary care was 69%. Adequate blood 
pressure control (� 1 60/90 mmHg) was achieved in 44%. In primary care, a 
significant difference was found between the number of anti-hypertensive 
agents prescribed in patients who met blood pressure goals compared to 
those who did not. 
Conclusion: The regulation of blood pressure does not appear to be optimal 
and needs improvement. As the mean blood pressure in secondary care is 
better than that seen in primary care, a lower blood pressure goal may lead 
to better blood pressure regulation. In primary care, patients who have 
adequate blood pressure control receive more medication, compared to 
those whose blood pressure control is unsatisfactory. Perhaps some 
advantage is to be gained from treating patients with more medication. 
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Introduction 
Type 2 diabetes mellitus is a chronic disease with a high prevalence. 
According to recent data from the Zwolle Outpatient Diabetes project 
Integrating Available Care study (ZODIAC), in the year 2000 there were 
466,000 patients with a diagnosis of type 2 diabetes mellitus. 1 Type 2 
diabetes mellitus leads to an increased mortality and morbidity from 
cardiovascular causes.2-6 This is likely due to a clustering of cardiovascular 
risk factors such as dyslipidaemia, obesity, smoking, and hypertension. The 
prevalence of hypertension ranges from 34% to 82%, depending on the 
definition used for hypertension and the population studied. 7-9 
Different studies have found that by strictly regulating blood 
pressure, the risk for developing micro-and macrovascular complications 
may be reduced. 10-23 The blood pressure goals which have been used vary: 
in time, between countries, within countries and between guidelines. In the 
national guidelines published by the Dutch College of General Practitioners 
in 1 989 the goal was ::5160/90 mmHg.24 In the revised 1 999 version the goal 
was ::5140/80 mmHg for patients aged under 50 years with 
microalbuminuria, and ::51 50/85 mmHg for all other patients?5 The blood 
pressure goals in the guidelines for secondary care, contained in the 1 998 
consensus of the CBO (National Organization for Quality Assurance in 
Hospitals) for diabetic retinopathy, diabetic nephropathy, diabetic foot, and 
cardiovascular disease for diabetes mellitus, was ::5140/90 mmHg for 
patients aged younger than 60, and ::5160/90 mmHg for patients aged over 
60.26 In the CBO-consensus on hypertension, published in 2000, a blood 
pressure ::5140/90 mmHg is recommended, independent of age.27 Data from 
primary care studies show that goals are not always achieved. 28-32 Secondary 
care studies are lacking for the Dutch population. 
The aim of this study is to describe the treatment of hypertension and 
the achievement of blood pressure goals in patients with type 2 diabetes in 
secondary care, and to compare this with primary care data within the same 
region. 
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Methods 
Patient selection in secondary care 
Between November 1 999 and May 2000 data were collected on consecutive 
patients with type 2 diabetes mellitus who visited the outpatient clinics of 
two internists with a special interest in diabetes mellitus in a large peripheral 
training hospitaL Patients were included if they had been treated for at least 
6 months by these internists. This period was chosen in order to select 
patients whose blood pressure had stabilized. Patients with secondary 
hypertension and pregnant patients were excluded. 
Data collection in secondary care 
Data on blood pressure, antihypertensive medication, age, gender, known 
duration of DM, body mass index (BMI), the use of oral blood glucose 
lowering agents and/or insulin, and the presence of micro- and 
macrovascular complications were collected during the outpatient clinic 
visit. The most recent values (within a time frame of 6 months) were 
collected for HbA1c  (%), total cholesterol (mmol/1), HDL-cholesterol 
(mmol/1), LDL-cholesterol (mmol/1), triglycerides (mmol/1), and creatinine 
(umol/1). The most recent results for proteinuria (within 1 2  months) were 
used to check for diabetic nephropathy or microalbuminuria. Nephropathy 
and microalbuminuria were defined as an albumin excretion in urine >300 
mg and >30 mg/24 hours, respectively, or an albumin/creatinine ratio in a 
urine sample >25 and >2 .5 mg/mmol for men, and >35 and >3 .5 mg/mmol 
for women. The presence of macrovascular complications was defined as 
having a history of a cardiovascular incident (myocardial infarction or 
cerebrovascular accident), an intervention (coronary angioplasty, coronary 
bypass surgery, or carotid endarteriectomy), or an artery stenosis diagnosed 
in the vascular laboratory. At the time the data were collected, the blood 
pressure goal was ::;; 1 50/85 mmHg. Hypertension was defined as a blood 
pressure above the target value and/or the use of antihypertensive 
medication. The internist measured the blood pressure with a mercury 
sphygmomanometer, during the visit at the outpatient clinic. If two 
measurements were taken, the lowest was used for the analyses. Patients 
without a documented blood pressure were excluded from the analyses. 
Patients younger than 50 years with microalbuminuria or nephropathy were 
also excluded from the analyses, because the treatment advice and blood 
pressure goal, according to the guidelines, is different for this group. 
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Data collection in primary care 
Baseline data from the ZODIAC study were used for patients from primary 
care. This is a study into the effects of different forms of shared care for 
patients with type 2 diabetes treated exclusively by their general 
practitioners. Baseline data were collected between 1 997 and 1 998. Patients 
were excluded if they were being (co-)treated in secondary care by an 
internist (n=360), if they were terminally ill, if they had been diagnosed 
with dementia (n=55), or if they had been under the care of the GP for less 
than 6 months (n=48). All other patients were invited to participate, which 
resulted in a highly unselected patient population. The data collected was 
the same as that collected for the secondary care group. The blood pressure 
was measured by a nurse specialized in diabetes with a sphygmomanometer, 
twice, with a five minute rest in between, and the lowest value was 
recorded. The blood pressure goal was :::; 1 60/90 mmHg at the time the data 
were collected. Hypertension was defined as a blood pressure above this 
target value and/or the use of antihypertensive medication. 
Statistical analyses 
The statistical analyses were performed with SPSS 10. 1 .  The Student T-test 




502 patients visited the outpatient clinic during the study period. 1 ,084 of 
the 1 ,664 patients with a diagnosis of type 2 diabetes known to 32 GPs were 
included in the study. Table 1 shows the characteristics for the patients from 
both primary and secondary care. The patients in primary care were 3 .5 
years older, on average, and had a shorter diabetes duration. Their body 
mass index (BMI) was 28.9 versus 30.9 in secondary care and the mean 
HbA1c  was 0.5% lower in primary care. The lipid profile in secondary care 
was better, and more medications were prescribed: four times as much lipid 
lowering medication and five times as much insulin. The prevalence of 
macrovascular complications was significantly higher in secondary care 
(33%) than in primary care (28%). 
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Table 1 .  Patient characteristics in primary and secondary care (mean (SD) 









Vascular disease (%) 
Microalbuminuria (%) 
Nephropathy (%) 




Lipid-lowering medication (%) 
p<0.05 
Difference (95% 
Primary care Secondary care Confidence Interval) 
1084 502 
68.7 ( 1 1 .5) 65.2 ( 1 1 .9) 
42 38  
28.9 (4,8) 30.9 (5.3) 
7.9 (7.4) 1 1 .9 (7.9) 
7.5 ( 1 .3) 8.0 ( 1 . 1 )  
1 8  90* 
96 (22) 105 (57) 
28 33*  
34 34 
8 
5.7 ( 1 . 1 )  
1 .2 (0.3) 
3 .4 ( 1 .0) 
2.6 ( 1 .6) 
1 1  
14* 
5.1  (0.9) 
1 .3 (0.4) 
3.0 (0.9) 
2.3 ( 1 .9) 
46* 
3 .5 (2.3-4.7) * 
2.0 (2.5- 1 .5) * 
4.0 (4.8-3 . 1 ) * 
0.5 (0.6-0.4) * 
9 ( 1 3-5) * 
0.6 (0.4-0.7) * 
0. 1 ( 1 .4-0.6) * 
0.5 (0.4-0.6) * 
0.3 (0. 1 -0.5) * 
Blood pressure regulation in secondary care 
Fifteen patients (3%) were younger than 50 years and had nephropathy or 
microalbuminuria. In 62 of the cases ( 12%) the blood pressure had not been 
documented during the outpatient clinic visit. Of the remaining 425 patients, 
377 (89%) had hypertension. The mean blood pressure of the hypertensive 
patients was 1 57/79 mmHg, and 140 patients (37%) achieved their blood 
pressure goal (:S1 50/85 mmHg). The blood pressure was �160/90 mmHg in 
2 1 9  patients (58%). Table 2 shows the characteristics of the patients who 
did and who did not achieve their blood pressure goal. The two groups were 
comparable with respect to age, BMI, diabetes duration, HbA1 c, creatinine, 
total cholesterol, and the prevalence of retinopathy and macrovascular 
complications. Patients with above-goal blood pressures had significantly 
more nephropathy, 2 1% vs. 9%. Both groups were prescribed an average of 
2.2 kinds of antihypertensive medications. ACE-inhibitors and diuretics 
were the most frequently prescribed antihypertensives. 
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Blood pressure regulation in primary care 
In primary care 1 7  patients younger than 50 years had diabetic nephropathy 
or microalbuminuria. Blood pressure readings were not recorded in two 
cases. Hypertension was present in 733 patients (69%), of whom 324 (44%) 
achieved the target pressure of :::; 1 60/90 mmHg. The number of prescribed 
antihypertensives was lower in patients who did not achieve the blood 
pressure goal compared to those who did: 0.8 vs. 1 .6 (p < 0.0 1 )  (table 2). 
Discussion 
The prevalence of hypertension is high in patients with type 2 diabetes 
mellitus, in primary as well as in secondary care. In the year 2000 the 
prevalence of hypertension was 89% in type two diabetic patients in 
secondary care, whereas only 37% achieved a blood pressure :::; 1 50/85 
mmHg. In primary care, in 1 998, the prevalence of hypertension was 69% 
and only 44% achieved a blood pressure :::; 1 60/90 mmHg. 
The more stringent the treatment goal, the more patients will have to 
be treated. Lowering the target blood pressure to 1 30/85 mmHg in 
secondary care, as advised by the World Health Organization, would -based 
on our data- lead to a diagnosis of hypertension for 96% of those patients. 33 
Applying these guidelines implies treating the majority of patients with type 
2 diabetes with antihypertensive medication. Is lowering the target blood 
pressure in treatment guidelines achievable? In primary care 44% of patients 
achieve a blood pressure :::; 1 60/90 mmHg; 4 years later, in secondary care, 
this goal is achieved in 58% of patients. In a recent Swedish study a 
decrease in blood pressure was found in patients with type 2 diabetes 
between 1 996 and 1 999.34 In contrast with what was found in primary care, 
there was no difference in secondary care in the number of 
antihypertensives prescribed between the group who did achieve treatment 
goals and the group who did not. Recent studies have shown that 
improvement of blood pressure regulation may be achieved by 
implementing decision trees and prescribing fixed-dose combination 
preparations, but also by treating newly diagnosed type 2 diabetes patients 
timely and with sufficient medications.35;36 Moreover, the longer a blood 
pressure remains high, the harder it is to treat.28;37 
Different studies have shown that diuretics, ACE-inhibitors, AT-II 
antagonists, beta-blockers, and calcium-antagonists are all effective m 
lowering blood pressure and preventing macrovascular endpoints. 
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Table 2. Difference between patients achieving and not-achieving blood pressure 
goals (mean (SD) unless stated otherwise) 
Secondary care Primary care 
(goal �150/85 mmHg) (goal �160/90 mmHg) 
RR RR RR RR 
Total <150/85 >150/85 Total <160/90 >160/90 
Patients (n) 377 140 (37%) 237 (63%) 733 324 (44%) 409 (56%) 
Male (%) 35 29 
Age (years) 67 ( 1 0) 67 ( 1 0) 
Untreated 20 (5%) 0 (0%) 
hypertension 
Antihypertensive 2.2 2.2 
drugs (n) 
> 2 antihypertensive 149 (40%) 5 1  (36%) 
drugs 
Systolic RR 1 57 (22) 136 ( 12) 
Diastolic RR 79 ( 1 1 )  73  (8) 
Systolic RR > goal 2 14 (57%) 
Diastolic RR> goal 90 �24%) 
ACE-inhibitor (%) 63 66 
Diuretic (%) 68 7 1  
Ca-antagonist (%) 35 33 
Beta-blocker (%) 33 3 1  
AT -II antagonist 1 7  1 8  
(%) 
Al�ha-blocker {%} 9 1 
BMI (kg/m1) 3 1 .2 (5.3) 3 1 .5 (5.4) 
Diabetes duration 1 3  (8) 12 (8) 
(years) 
HbA1c (%) 8.0 ( 1 . 1 ) 8. 1 ( 1 . 1 ) 
Creatinine (umoVI) 108 (62) 102 (29) 
Total cholesterol 5.2 (0.9) 5 . 1  (0.8) 
(mmol/l) 
Retinopathy (%) 42 38 
Vascular 37 39 
complications (%) 
Nephropathy (%) 1 6  9 
RR: blood pressure, # P<0.05 
1 22 
38 38 
67 ( 1 0) 7 1  ( 1  0) 
20 (8%/ 194 (26%) 
2.2 1 . 1  
98 (4 1%) 73 ( 1 0%) 
1 68 ( 1 6)# 162 (26) 
82 ( 12)# 87 ( 12) 
343 (47%) 




35  29 
1 6  7 
7# 0 
3 1  (5.2) 29.2 (4.8) 
13 (8) 8 (7) 
8.0 ( 1 .2) 7.6 ( 1 .3) 
1 1 2 (75) 99 (24) 
5 .2 (0.9) 5 .7 ( 1 . 1 ) 
45 1 2  
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Chapter S 
In patients with type 2 diabetes, ACE-inhibitors may be preferable, as they t 3 · t4· t S:2 1 also have a protective effect on the renal system. ' ' ' Moreover, the 
HOPE study showed that the ACE-inhibitor ramipril has a positive effect on 
the incidence of cardiovascular complications, independent of the effect on 
blood pressure.2 1  In the ALLHA T however, the ACE-inhibitor lisinopril 
showed no advantage in preventing cardiovascular endpoints compared to 
the diuretic chlortalidon.2 The preference for ACE-inhibitors and diuretics 
is clear in our primary and secondary care populations. The secondary care 
results in the present study are comparable to those from a French study in 
which 4,930 patients with type 2 diabetes mellitus were examined. 29% of 
those patients, who were treated by specialists, attained a blood pressure 
< 140/80 mmHg.38 In the United States, blood pressure regulation in the 
secondary care setting seems somewhat better: of 3 5 1  patients with type 2 
diabetes mellitus who were being treated in an academic hospital, 42% 
achieved a systolic blood pressure :::; 1 30 mmHg.39 In an earlier published 
study among American endocrinologists, 62% of 79 patients with type 2 
diabetes mellitus, who were receiving antihypertensive medication, 
achieved a blood pressure �140/90 mmHg.40 Possibly, both studies 
concerned selected populations, as, in the first study, only 73% had 
hypertension, defined as a systolic blood pressure > 1 30 mmHg, and in the 
second study, only 80% of 1 2 1  patients had a blood pressure > 130/85 
mmHg and/or used antihypertensives. In a recent American study in 
different health care systems, 27% of the patients with diabetes achieved a 
blood pressure <140/90 mmHg.4 1 
Limitations 
A limitation of our study is that we could not take into account information 
about the dosages of, or the compliance with, antihypertensive 
medication(s) and other, non-pharmacological, therapies which may have 
influenced the blood pressure regulation.42 
Conclusions 
Regulation of blood pressure in diabetic patients does not appear to be 
optimal and needs improvement. As the mean blood pressure in secondary 
care is better, a lower target blood pressure may lead to improved blood 
pressure regulation. In primary care, patients who have satisfactory blood 
pressure control receive more medication compared with patients whose 
pressures are unsatisfactory. It may be profitable to increase the number of 
prescriptions per patient. The reasons for failing to regulate blood pressure 
need further study in both the primary and secondary care settings. 
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Please let my doctor be obese 
Type 2 diabetes has a high cardiovascular morbidity and mortality, and 
obesity and smoking are important cardiovascular risk factors. 1 Physician 
characteristics, such as a�e and gender, are related to counselling practices 
for obesity and smoking. ;3 Other physician characteristics may play a role 
as well. Patients indicated that they had greater confidence in physicians 
who were not obese. It is unknown if this can be translated into increased 
success in obesity management.4 Our aim was to study associations between 
obesity and smoking patterns in general practitioners (GP) and their patients 
with type 2 diabetes. 
Research design and methods 
A postal survey was conducted among 36 GPs, participating in a shared­
care diabetes project in 2000. The survey contained questions about age, 
gender, weight, height, smoking behaviour, number of years of experience 
as a GP, size of practice population, and the GPs' opinion about the 
following statement: "I can contribute to weight reduction and/or smoking 
cessation in my patients". Patients with type 2 diabetes, participating in the 
shared-care project, were treated exclusively within the primary care health 
setting. Patients who were being (co )treated in secondary care and patients 
who were terminally ill or who had been diagnosed with dementia were 
excluded from the study. The patient population (n=1 ,44 1)  was highly 
unselected, representing 87% of the patients with type-2-diabetes being 
treated in the primary care setting. Data on the patients' age, gender, 
diabetes duration, body mass index (BMI), and smoking behaviour were 
collected by nurses specialized in diabetes, and were available in the 
database of the shared-care project. For statistical analysis we performed 
regression analyses using SPSS for Windows. 
Results 
The survey response rate was 100%. The majority of GPs were male (83%) 
and non-smoking (94%). The mean age was 5 1 . 1  (Standard deviation (SD) 
7 .0), they had 1 8 . 1  (SD 8,9) years of experience, and a mean practice size of 
2,3 1 5  patients (SD 496). The GPs had a mean BMI of 24.4 kg/m2 (SD 3 .5), 
and 72% of BMis were <25 .  17% of the GPs were convinced that they 
would be able to contribute to weight reduction ( 1 7%) and smoking 
cessation (6%) in their patients. The means for patients per GP were 68.2 
(SD 2.9) for age, 44% (SD 9%) for male gender, 7.2 (SD 1 .3) for diabetes 
1 30 
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duration, and 29.3 (SD 0.85) for BMI. We found no association between 
smoking patterns of patients and characteristics of their GPs. The results of 
the regression analyses, with the mean BMI of patients as dependent 
variable, are shown in table 1 .  The strongest correlation we found was a 
negative correlation with the BMI of the GP. The optimal model had a 
multiple correlation (R) of 0.56; removing the next variable led to a 
relatively large decrease in the multiple correlation to 0.53 .  The explained 
variance (R square) of the optimal model was 3 1% (adjusted 1 7%) and p 
was 0.07. Figure 1 shows the scatterplot of the BMI of patients per 
physician by the BMI of physicians. 
Table 1. Results of regression analysis. Dependent variable: mean BMI of 
patients per GP. 
95% Correlations 
"CC = Confidence ..... � � Interval for B .!::! = "CC = "CC "' � "' r.. ..... .!::! = = = "CC � "CC � ·o r.. ·-= = � � r.. "CC r.. "CC "; = � = ..... ..... "CC .._ "; � = � = t ..... "' � = � ;!'; = c. =  r.. = 0 = 0 ;;.. 0 0 C.. o = = ;;J u oo u  I ...,;j = ;;J =  � � � 
BMi of GP -. 1 05 -.437 .027 -. 1 97 -.0 1 3  -.398 -.360 
Opinion that GP can contribute to .996 .443 .03 1 . 1 00 1 .891 .389 .350 
weight reduction 
Opinion that GP can contribute to - 1 .625 -.445 .033 -3 . 1 1 1  -. 1 3 8  -.383 -.345 
smoking cessation 
Percentage male patients 2.042 .2 1 3  .244 - 1 .47 1 5.554 .2 1 6  . 1 83 
Mean age patients with GP -.089 -.305 .095 -. 1 94 .016 -.305 -.266 
Practice size GP -.00 1 -.3 1 1  .072 -.001 .000 -.328 -.288 
Discussion 
Our main finding was that the BMI of patients with type 2 diabetes was 
negatively correlated with the BMI of their GPs: obese doctors had lean 
patients. A limitation of our study is the cross-sectional design: associations 
were found, and not causal relations. Hash showed that patients indicated 
greater confidence in non-obese physicians.4 However, we found no 
translation into increased success in obesity management: on the contrary, 
patients of non-obese GPs had a higher BMI compared to the patients of 
obese GPs. A discemable negative impact of the patients' weight on the 
1 3 1  
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physicians' behaviour was shown earlier.5 Is it possible that non-obese GPs 
lack the motivation to treat overweight patients? And do GPs overestimate 
their capabilities? GPs reporting confidence in their ability to influence their 
patients' weight appeared less successful: they had a more obese patient 
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Figure 1. Scatterplot of the mean BMI of patients per physician (y-axis) by 
the BMI of physicians (x-axis). 
Conclusions 
The BMI of patients with type 2 diabetes was negatively correlated with the 
BMI of their GPs: obese doctors had lean patients. The GPs who felt that 
they were able to contribute to weight reduction in their patients had, in fact, 
more obese patients. We found no association between patients' smoking 
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Answers to the research questions 
The aim of this thesis was to answer three questions, using the results of the 
ZODIAC-study. The answers to these questions are presented here. 
1 .  What is, at the start of this millennium, the magnitude of 
type 2 diabetes mellitus as a health care problem in The 
Netherlands? 
Prevalence, incidence, and mortality 
The age and sex adjusted prevalence of type 2 diabetes was 2.2% in 1 998, 
and it increased by 33% to 2.9% by the year 2000. The prevalence was 
higher for women than for men: 3 . 1% and 2. 7% at follow-up, respectively. 
Patients aged >70 years accounted for almost 50% of all type 2 diabetes 
patients. An age and sex adjusted mean annual incidence per 10,000, over a 
period of three years was 22.7 overall; 23 . 1  for women and 22.2 for men. 
Though still high, the incidence decreases after the age of 70. The mortality 
rate was 4811 ,000, and the standardised mortality ratio was 1 .40. Based on 
these results, the estimated total number of subjects known with type 2 
diabetes was 466,000 for The Netherlands in the year 2000, and the number 
of patients with newly diagnosed diabetes was 36,000. With an estimated 
14,000 patients dying each year, the type 2 diabetes population grows by 
22,000 patients each year. 
(Risk factors for) complications 
80% of all type 2 diabetic patients were treated in the primary care setting. 
The prevalence of risk factors for micro- and macrovascular complications 
appeared high: glycaemic dysregulation (HbAl c>7%) was present in 56% 
of patients, hypertension and lipid profile abnormalities in 78% and 5 1%, 
and micro- and macroalbuminuria in 33% and 7% respectively. 
Complications were frequently present as well: 36% of patients had a 
history of cardiovascular disease. 
Implementation of national guidelines 
At the time of this study, the implementation of the national guidelines of 
the Dutch College of General Practitioners (shortly: National GP 
Guidelines) was not yet optimal. At baseline, 36% of patients had had a foot 
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examination during the past year and 55% had had a retinal screening 
during the preceding two years. Hypertension and lipid profile abnormalities 
had been treated in 63% and 22% of patients; successfully in 4 1% and 54% 
of these cases, respectively. Among patients <50 years of age with 
microalbuminuria, 1 8% were treated with an ACE-inhibitor or A2-
antagonist. Among those patients >50 years with microalbuminuria, and 
hypertension and/or a lipid profile abnormality, 82% were either not treated, 
or did not attain treatment goals. 
Conclusion 
We conclude that type 2 diabetes has a high prevalence, which is increasing, 
and an increased mortality compared with persons without diabetes. The 
prevalence of diabetic complications is high as is the prevalence of the 
associated risk factors. The implementation of the national guidelines is not 
yet optimal. 
2. What is the effectiveness of two different organizational 
strategies, in the form of shared care with task delegation, 
in improving quality of care for type 2 diabetes? 
In a prospective non-randomized design, we studied two interventions and 
standard care. The interventions were complex with extensive (A: annual 
control by DSNs) or limited (B: on demand consultation with DSNs only) 
task delegation from general practitioners to hospital-liaised nurses 
specialized in diabetes. These interventions included a diabetes register, 
structured recall, facilitated communication between the general practitioner 
and the specialist, audit and feedback, patient-specific reminders, and an 
emphasis on patient education. The population consisted of patients with 
type 2 diabetes treated within the primary health-care setting, excluding 
patients who were terminally ill or who had been diagnosed with dementia 
(5% of the patient population). Patient participation was high (90%) and 
stable during all three years of the project. The participating population was 
highly unselected and represented 65-70% of all patients with type 2 
diabetes, and 85-90% of all patients with type 2 diabetes treated within the 
primary health-care setting. None of the GPs discontinued their participation 
in the study. 
Longitudinal analyses showed significant improvements in quality 
indicators in both intervention groups: in both process parameters and 
outcomes (achieved target values on the individual patient level); in 
standard care, performance remained stable or deteriorated. Both patients 
and caregivers appeared satisfied with the project. The highest performance 
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was found for intervention group A, where DSNs performed all annual 
check-ups. 
Conclusion 
Structured shared care with tasks delegated to specialized nurses, targeted at 
a large unselected type 2 diabetes population in a general practice, is 
feasible and can positively influence the quality of care (process and 
outcome). 
3. What should be the aim of future improvement 
strategies? 
Organisation and task delegation 
The results of our survey indicate that tasks that are suitable for delegation, 
such as organizing active screening for type 2 diabetes in high-risk groups, 
education, and regular check-ups, all tasks inherent to caring for patients 
with type 2 diabetes in the primary health care setting, are scarcely 
delegated. Future improvement strategies should, therefore, be directed at 
improving and/or expanding task delegation. As individual opinions varied 
regarding responsibility for follow up appointments for retinal screening, 
the responsibility for these follow-up screenings needs to be clarified for the 
caregivers involved. Further exploration of the barriers preventing efficient 
task delegation are required. 
Advice given within shared care 
We examined the responsiveness of GPs to advice given within a shared­
care setting in a longitudinal analysis. The GPs complied with less than 50% 
of the recommendations received in shared diabetes care. Follow-up of 
recommendations may depend on the format of the recommendation. 
Recommendations concerning the dysregulation of glucose metabolism, as 
assessed through HbAlc, led to more treatment changes than the 
dysregulation of blood pressure or lipids. 
Therefore, if advice is given in a shared-care setting in the future, 
attention should be paid to the implementation rate of the recommendations 
and to the format in which they are given. The cardiovascular risk profile 




Treating cardiovascular risk factors 
In a cross-sectional analysis of the baseline data we found unsatisfactory 
treatment and success rates for hypertension and lipid profile abnormalities. 
The presence of cardiovascular disease in patients and the accurate 
registration of cardiovascular risk factors by GPs were associated with 
higher treatment rates. Therefore, future implementation strategies could be 
directed at primary versus secondary prevention of cardiovascular disease 
and at improving the registration of cardiovascular risk factors by GPs. 
Measurement of microalbuminuria 
We studied the prevalence of micro- and macroalbuminuria in type 2 
diabetes in the primary health-care setting in the year 2000/'0 1 in a cross­
sectional analysis. We also evaluated whether the recommendation in the 
Dutch Guidelines, not to measure microalbuminuria in patients aged 50 
years and over, based on the argument that these patients are already being 
optimally treated for their hypertension and lipid profile abnormalities, was 
justifiable. The prevalence of micro- en macroalbuminuria appeared high, 
33% and 7% respectively, and micro- and macroalbuminuria was treated in 
1 8% of patients aged < 50 years. The treatment of hypertension and lipid 
profile abnormalities in patients aged 50 years and over with 
microalbuminuria was insufficient in 82% of the cases. Moreover, in 9% of 
the cases micro- and macroalbuminuria were present in the absence of 
hypertension and lipid profile abnormalities. Our findings, in combination 
with findings from other recent studies, supply strong arguments supporting 
the measurement of albumin excretion and making necessary treatment 
decisions, at least until the age of 70 years. 
Blood pressure treatment and goals 
We compared blood pressure regulation between primary and secondary 
care. In primary care, patients who attained their blood pressure goals 
received a significantly higher number of anti-hypertensive agents, 
compared to those who did not. The target blood pressure in secondary care 
was lower than that strived for in primary care. The mean blood pressure in 
secondary care (with a guideline with a lower blood pressure goal compared 
to primary care) was lower than the mean measured in the primary care 
setting. In the future, therefore, profit may be gained by treating patients 
with more medications, and by lowering the target values for blood 
pressure. However, reaching lowered treatment goals will be a daunting 




Although it has been shown that patients indicate greater confidence in non­
obese physicians, we found no translation into increased success in obesity 
management On the contrary, patients of non-obese GPs had a higher BMI 
compared to patients of obese GPs. A discernable negative impact of 
patients' weight on physician behaviour has been shown earlier. Could it be 
that non-obese GPs lack the motivation to treat overweight patients? With 
respect to the treatment of obesity, could it be time for us, as GPs, to search 
our own hearts? 
Limitations 
Certain limitations need to be discussed with respect to the findings 
presented here. One limitation of the epidemiological study is related to the 
comprehensiveness of the data. Although we had complete data on the 
patients with a known diagnosis of type 2 diabetes mellitus, we had no data 
about undiagnosed cases; a number of which may be as high as 50%. 1 ;2 
However, due to the increased attention of health-care providers regarding 
the detection of diabetes and the screening of high-risk populations, the 
percentage of undiagnosed diabetes may have decreased in The Netherlands 
during past years, as has also been found in the US.3;4 
The interpretation of the results from the prospective study into the 
effects of shared-care interventions with task delegation was limited by the 
non-randomized design. For pragmatic reasons, we chose to allocate the 
interventions according to the preference of the GP-working groups, 
although randomisation was seriously discussed. Extending the co-operation 
between primary and secondary care had proven not to be straightforward in 
the initial phase of the project. Therefore, a higher priority was given to 
further extension of the regional co-operation than to the randomisation for 
the benefit of the study. To study how evidence and guidelines may be 
translated into daily practice, flexibility is necessary to deal with pragmatic 
issues; rigorous nonrandomized study designs including quasi-experimental, 
time-series, and observational studies are sometimes more appropriate.5 
Thinking about randomisation, one could ask oneself at what level this 
should have been done. The different levels all have possible disadvantages. 
Randomisation of the patient or the individual GP could cause disruption of 
existing patient-provider relationships and intraprovider contamination 
(accompanying randomisation at the patient level), or the disruption and 
contamination that would occur with randomisation of providers due to 
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cross-coverage arrangements6. Randomisation of a small number of GP 
working-groups does not guarantee comparability of groups with regard to 
potentially confounding factors. Moreover, for interventions to work, 
methods must be acceptable to the target groups7, as physicians, like all 
people, will only change their behaviour if they are motivated. However, as 
a consequence of the non-randomised design, the effects of the interventions 
may have been overestimated, 8 and the baseline values for the three groups 
which were analyzed could not be compared with one another in a 
meaningful way. We therefore decided to limit our analysis to independent 
descriptions of the three groups, and focused on quality indicators at the 
patient level instead of at the group level as means. Another possible reason 
for overestimation of the improvements found in the different study groups 
is the "Hawthorne effect" .9 This effect is often mentioned as a possible 
explanation for positive results in intervention studies. It is used to cover 
many phenomena, like behavioral change due to an awareness of being 
observed, active compliance with the supposed wishes of researchers 
because of special attention received, or positive response to the stimulus 
being introduced. However, this will be the case in all three study groups 
and the effect may possibly be smaller in studies with large target 
populations with longer follow-up, and therefore we do not expect this 
effect to influence our conclusions. A limitation possibly leading to the 
opposite, underestimation of the effect, is the relatively short follow-up of 2 
years. There may also be an information bias as the collection of outcome 
data was performed differently in intervention group A compared to group 
B and the control group. In group A measurements were performed and 
registered by the DSNs. In the other groups this was done by the GPs and 
these data were retrieved from the patient records by the investigator of the 
study. There was also a difference in the amount of available data: in group 
A the DSNs collected data which was nearly complete from patients during 
consultations. In groups B and C, however, the data were collected from the 
GPs' patient records, and the comprehensiveness of data was not always 
optimal. Obtaining data provided from medical records can lead to 
underreporting of care delivered. 1 0  However, although the same lack of 
documentation has been found by others, 1 1 ; 1 2 and the intermediate outcomes 
may not be different for the patients concerned, 1 1  the delinquent recording 
of risk factors reflects suboptimal care, because opportunities to detect 
increased risk and therefore to start treatment are missed. Moreover, the 
quality of care delivered lacks transparency. Our findings regarding the 
satisfaction of patients with the shared care project are limited by the fact 
that patients were not asked directly for their opinion. We asked what GPs 
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thought about their patients' perceptions about the project. Unfortunately we 
have not been able to include a cost-effectiveness analysis. We can only 
roughly estimate what would be necessary for a wider implementation of the 
structured shared care. The project has been conducted with a limited 
budget. The care was delivered with only 1 .6 fte DSNs. Extrapolating this 
for the Netherlands, approximately 3 1 5  DSNs would be necessary to 
delegate the annual check-up, performed according to the national 
guidelines. This estimate is based on 466.000 patients known with DM2, 
approximately 375 .000 (80%), being treated in primary care, with nurses 
performing a mean of 6 annual screenings per day, 200 working days a year. 
Our data about the organization of diabetes care in the primary 
health-care setting was collected solely by means of a questionnaire, with a 
response rate of 72%. The mean response rate found among mail surveys, as 
reported in one study, is lower, at 60%, 13 but, however small the group of 
non-responders, the possible resulting bias must be taken into account. 14 
A limitation of our study into the prevalence of micro- and 
macroalbuminuria, is that we measured albuminuria only once each year. 
Factors such as urinary tract infections and heart failure were not ruled 
out. 1 5;1 6  These factors may have influenced the measurement resulting in the 
prevalence being overestimated. Our results were, however, comparable to 
those reported by others, and we therefore expect our conclusions to be 
valid. Another point in this analysis was that, to calculate the percentage of 
patients with an indication to receive treatment for lipid profile 
abnormalities for primary prevention of CVD, we used the rough translation 
of the risk table as described in the National GP Guidelines. It would have 
been more correct to use the original rule: to limit treatment of lipid profile 
abnormalities, in the case of primary prevention of CVD, to patients with a 
life expectancy of at least 5 years, and a risk for coronary heart disease of at 
least 25% in 10  years. This led to an underestimation of the treatment and 
success rates; moreover, it needs to be emphasised that following the 
original rule of the guideline, the percentage of patients with dyslipidaemia 
that should receive lipid lowering medication would never be 100%. 
General limitations, applicable to various chapters, should also be 
mentioned. Some results were obtained in the period preceding, or shortly 
following the introduction of the revised National GP Guidelines. Therefore 
implementation could not be expected to be optimal and improvements may 
reasonably be expected; 1 7  a learning curve has probably been present during 
this phase. Patient compliance was not assessed and may have influenced 
treatment rates and treatment success. 1 8 The GPs were not asked to give 
reasons for their policies, and they may have had valid reasons to deviate 
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from the recommendations in the National GP Guidelines for specific 
patients. Furthermore, the design of the majority of the analyses was cross­
sectional : associations cannot be interpreted as causal relations. Finally, the 
study was performed in one region. Our region may be different compared 
to other regions with respect to organization or attention for diabetes care. 
However, there a no data available regarding differences between Dutch 
regions with respect to the organisation of diabetes care. What is known, is 
that shared care projects can be found all over The Netherlands; more than 
70 projects have been described. In this light, the Zwolle region is no 
exception compared to other regions. Still, generalisability of our findings to 
other regions will have to be judged in light of possible regional differences. 
Strengths 
A strong point of this study is that most of the results may be applied to 
other patient populations which have similar characteristics, because we 
used broad selection criteria, unlike many of the previous trials in this area. 
The study population represented 65-70% of all type-2-diabetes patients in 
the registration area, and 85-90% of the patients being treated in the 
primary-care setting. The only patients excluded from the study were those 
who were terminally ill and those who had been diagnosed with dementia 
(5% of patients). Excluding such patients seems realistic from a clinical 
point of view: intensive therapy is either not useful for prevention of long­
term complications or not possible. 19 All other patients could participate. 
The generalized applicability of these results is also supported by the 
fact that the GPs who participated in the survey are representative of the 
average GP working in The Netherlands: the percentage of GPs in the study 
working in 'solo practices' is 44%, which is the same as the national 
average, and the mean number of patients per GP is 2,360 as compared to 
2, 1 98 nationally.20 The prevalence of type 2 diabetes, as reported by the GPs 
in the survey, is comparable to the prevalence found in our epidemiology 
study for the same period,2 1  suggesting a valid registration in practice 
registers. 
Another strong point was the continued high participation rate by 
both the patients (90%) and the GPs ( 100%) in the study, indicating the high 




The magnitude of type 2 diabetes as a health care problem; 
how to interpret the findings? 
Prevalence and incidence of type 2 diabetes 
According to media and internet sources, there are currently 850,000 
patients with diabetes in The Netherlands.22 A recent epidemiological study 
presented a number of 65,000 newly diagnosed patients each year.23 The 
estimates generated with the present study are considerably lower: we 
estimated the national prevalence to be 466,000 for 2000, with an incidence 
of 36,000 per year. At the time our epidemiology data were published, data 
from other studies were presented by the RIVM (the National Institute for 
Public Health and the Environment), originating from epidemiological 
studies as well as from general-practice registrations.24 The RIVM presented 
an estimate of the national prevalence and incidence based on the combined 
data from these studies. According to this report, published in 2004, the 
prevalence of type 2 diabetes is between 4 10,000 and 443,000, and the 
incidence is between 58,000 (type 1 and 2 diabetes combined, data obtained 
from general practice registrations) and 66,000 patients per year (the above 
mentioned epidemiological study based on population screening). 
The range in the prevalence estimate may be accounted for by a 
unknown percentage of undiagnosed diabetic patients. As mentioned earlier, 
the number of undiagnosed patients may be as high as 50%. I ;Z The 
percentage of undiagnosed diabetes has decreased in The Netherlands 
during recent years due to the increased attention being paid by all health 
care providers to the early detection of diabetes and the screening of high­
risk populations. A similar trend has been reported in the United States. 3:4 
We are, therefore, convinced that the prevalence figure of 850,000 is an 
overestimate, and this number should therefore not be used for health care 
planning. 
We discussed the difference between our low (36,000) incidence rate 
and the hi�h (66,000) rate reported in the Room study with the authors of 
that study. 5 Much of this difference is explained by their age criteria (50-74 
years), which differed from those used in the present study, and the fact that 
their incidence calculation included patients who were diagnosed during the 
study by screening. 
Although knowledge about undiagnosed patients is important for 
discussions about diabetes screening programs, because there IS 
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considerable uncertainty about the exact percentage of undiagnosed patients 
it is probably best to work with (pooled) data on diagnosed patients only, 
particularly when these data are to be used for short-term health care 
planning. 
More importantly, there is no doubt about the fact that the 
prevalence is high and increasing. Projections from the nineties predicting 
the increase in the next 1 5-20 years, varied between 20% and 40%.26;27 We 
found an increase of 33% over a period of 2 years. Factors which are 
probably playing a role in this increase include population factors such as 
increasing obesity, decreasing physical activity, changing nutrition, but also 
health care factors such as the active case-finding by GPs, especially 
following the introduction of the revised guidelines in 1 999.28 Because of 
this high and rising prevalence of type 2 diabetes, and because of the high 
prevalence of cardiovascular risk factors and complications, it is important 
to invest in diabetes prevention. Preventive measures have been reported to 
be effective according to recent trials.Z9;3° Funding is also necessary to 
improve the quality of care for patients with diabetes, to prevent 
complications and improve quality of life. 
Insufficient implementation: yes . . .  or no? 
Looking at the quality of diabetes care delivered in the primary health-care 
setting, we found a suboptimal performance with respect to process 
parameters and patient outcomes according to the guidelines. Therefore, in 
this light, implementation is insufficient and the quality needs improvement. 
But how, and when is the quality good enough? A 100% implementation 
rate is not achievable, as co-morbidity and patient compliance are also 
important factors influencing this rate. We need realistic targets.3 1 
Comparing performance with other national practices or studies is often not 
useful: the patients involved may be too diverse a group, and methods of 
data collection vary. Comparison with international data is also not useful 
for the above mentioned reasons, and because guidelines differ in many 
respects from the Dutch guidelines: for example, differences in control 
frequencies and treatment goals. A solution to this problem could be using 
quality indicators, with benchmarks, that fit in with national guidelines. 
Examples of this method include the score on quality indicators from the 
DQIP (Diabetes Quality Improvement Project)32 and the quality indicators 
that have already been proposed for diabetes in The Netherlands.33;34 
Quality indicators for process and outcome parameters can be combined, 
and used to make the delivered quality of care transparent. Comparing our 
findings to the proposed secondary care benchmarks, for example for the 
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percentage of patients that should have a total cholesterol <5 mmol/L 
(benchmark 42%)/4 would show that the control group needs to improve 
considerably (26% with a cholesterol<5), but that intervention group A 
almost achieves the benchmark ( 40% ), and that group B does indeed 
achieve it (49%). So, implementation would not be insufficient in all 
aspects. Comparing local or regional data with achievable benchmarks leads 
to realistic targets, maintaining the motivation of health care providers . Our 
cups would not always be half empty, but would instead be half full. 
Benchmarking of data on process parameters and outcome measures 
proved feasible in the shared-care project. Physicians were enthusiastic 
about the eye-openers that were provided in this system of receiving 
feedback and discussing the results with their colleagues. However, we 
should be very careful not to confuse performance indicators and health 
outcomes: performance indicators should relate to those aspects of care 
which can be altered by the staff whose performance is being measured. 35 
Therefore, we would plead for the introduction of a set of carefully 
chosen quality indicators with achievable benchmarks for type 2 diabetes in 
the primary health-care setting. Health care providers should participate in a 
system in which feedback on their performance is provided and discussed, 
in order to find directions to further improve their quality of care. 
Table 1. Proposal for what could be part of a quality indicator set for 
primary care 
Process control Achievable Outcome control Achievable 
benchmark benchmark 
(%)* (%)* 
Foot exam 74 
Eye exam 7 1  
HbAlc 75 HbAlc :5 7.0 % 36 
Blood pressure 75 Blood pressure :5 150/85 mm Hg 43 
Total Cholesterol 75 Total Cholesterol :5 5 mmol/L 34 
Creatinine 75 
Body Mass Index 75 BMI < 30 53 
Smoking status 76 No smoking 7 1  
known 
*We corrected the achieved benchmark for the population that did not participate and the excluded population 
(10-1 5% of the diabetes population) by dividing the achieved results in intervention A by 1. 18. 
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Based on the outcomes of intervention group A we can do an initial 
proposal (table 1 )  for what could be part of a quality indicator set for 
primary care. The set we chose consists of performance indicators that relate 
to those aspects of care which can be altered by the staff whose performance 
is being measured, and includes achievable benchmarks. However, as 
written in the proposal of the Dutch Diabetes Federation, a good quality 
indicator set should include more indicators, for example with respect to 
education, self control, or patient satisfaction. 
Structural shared care: to be continued? (and consequently 
financed?) 
Structural shared care: to be continued? 
There are many shared-care projects in The Netherlands. But only a few 
have integrated a study into the effects of the intervention. 36 This has not 
been without reason: it is difficult to obtain project financing, and the 
evaluation is always the closing entry. Moreover, projects that are initiated 
to improve care frequently do not have the design that is necessary for a 
methodologically good analysis. The best evidence is provided by 
randomized controlled trials, which are not easy to perform. Consequently, 
these trials usually include selected populations, frequently excluding 
elderly patients and those with co-morbidity (more than 50% of the primary­
care-treated type-2-diabetes population). 
The main aim of our shared-care project was to improve the care for 
the total population of patients with type 2 diabetes in primary care for a 
large group of GPs: improving care for a large and relatively unselected 
population. But as we strived to find a satisfactory balance between costs 
and outcome, we studied two interventions, one with extensive and one with 
limited task delegation, in order to determine which form would be the most 
efficient. We also followed a standard-care group, in order to know what 
would have happened without the interventions. 
However, for pragmatic reasons, we decided to perform a non­
randomized trial. An important question is what the impact of this decision 
has been on our results? We found more (clinically relevant) improvements 
in process and outcomes in the intervention groups compared with the 
standard-care group. The best improvements were, especially for process 
parameters, found in intervention group A (annual control by DSNs), but the 
patient outcomes in intervention group B also improved (on-demand 
consultation with DSNs only). Less data were available for intervention 
group B and the standard-care group compared to intervention group A, 
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making interpretation of the results difficult. Moreover, we may have 
overestimated the effect of the interventions due to having allocated 
according to preference instead of randomization. 8 On the other hand, this 
effect may be maintained if both forms of shared care remain available for 
participating GPs, as no single best practice is appropriate for all clinicians 
or in all settings.37 
In light of the above limitations, one could question the value of our 
results. However, to study the difficulties inherent to translating research 
evidence and guidelines into daily practice, pragmatic issues such as patient 
diversity, provider time constraints, reimbursement limitations, and the 
history and politics of an organization must be taken into account. Rigorous 
nonrandomized study designs including quasi-experimental, time-series, and 
observational studies may sometimes be more appropriate. "The 
examination of natural experiments in clinical care can help identify best 
practices and innovative programs worthy of translation."5 We present, in 
our opinion, the first Dutch study of an unselected, non-academic, type-2-
diabetes patient population in a primary care setting, which is large enough 
and unselected enough to allow conclusions to be drawn regarding the 
(in)ability (to study the results) of translating evidence and guideline 
recommendations translating evidence and guidelines into daily practice; 
not only for glycaemic regulation, but also for cardiovascular risk factors. 
Important strengths of this study are that the population of type 2 diabetes 
patients was largely unselected; patients were not excluded on the basis of 
age or co morbidity, and we did not restrict our effect evaluation to 
glycaemic regulation, but also included cardiovascular risk factors, process 
parameters (and quality of life (not this thesis)). The follow-up period may 
have even been too short to show all the potential positive effects, since GPs 
started to make more use of on-demand consultations only after two years. 
Ultimate proof of the effectiveness of these interventions and the 
differences between them can only be seen and evaluated after analysing the 
development of complications, as was done recently by Gaede et al. 38 We 
are currently following the initial study population, and intend to conduct a 
follow-up study of the ZODIAC-patient population at 10  years to assess the 
long-term effects of the implemented interventions and to determine if the 
interventions and their effects can be sustained once the intensity and the 
excitement of the study are over.5 We expect that the difference in the 
quality of care between the intervention groups and the control group will 
increase. Thus, in our opinion, the structured shared-care that we studied 
should be continued. However, as there are many more shared care projects 
in The Netherlands, and other interventions may also be effective (or have 
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been proven effective) in improving quality of care, other interventions 
should also be considered for implementation3942 42;43 . 
Structural shared care: financial issues 
To be able to continue structured shared care, after proving its effectiveness, 
finances should be available. Many shared-care projects have been 
discontinued because of the lack of an effect evaluation, and, consequently, 
arguments for continued funding were unsuccessful. Successful projects 
have also been discontinued, due to lack of funding. Money still does not 
follow care. In 2000, only one-third of the shared-care diabetes projects was 
independent of periodical financing.36 Most motivated project leaders are 
able to find funding for the short term, but renewal of funding frequently 
depends on the cooperation shown by insurance companies. This was also 
the case for our project, although we did not include a cost-effectiveness 
analysis in our study, which reduced the transparency of the shared-care 
project and hampered our negotiations with insurers and other financing 
parties. However, in our opinion, even the best projects/interventions will 
ultimately not survive, as long as there is no regular financing structure for 
shared care. 
The lack of sufficient funding does not only lead to problems in 
keeping the projects going; for a project to be successful, the GP 
participation rate must also be kept up. Currently, they participate because 
of their intrinsic motivation to improve their quality of care. In the current 
national financing system, the GPs receive no financial remuneration for 
participating in studies and assuming the associated workload. This situation 
will not continue indefinitely, regardless of the value of the intrinsic 
motivators, and GP participation in studies will inevitably decrease. The 
current financial system, based on fees for subscription, thus hampers any 
attempts at improving the quality of diabetes care. 
Considering the above arguments, we propose the following criteria 
which must be met by proposed quality improvement projects for them to 
receive funding: ( 1 )  evidence for the effectiveness of the intended 
intervention must either exist, or (2) a (methodologically acceptable) effect 
evaluation and a cost-effectiveness analysis must be included at the start of 
the project. Furthermore, when a new intervention proves to be successful, 
the financial resources for integrating it into standard care should be 
automatically available: through the regular financial system. This way, 
health care money will be used efficiently instead of being wasted before 
the quality improvement project has even started or when improvements 
achieved stall or disappear through lack of use or lack of application. 
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"Developing financial supports and grant mechanisms for sustaining gains 
at the program level is a ripe area for real-world translational research."5 
Directions for future quality improvement 
From the studies described in this thesis we found several possible 
directions for future quality improvement. 
Task delegation should receive more attention. GPs do not delegate 
tasks that they could, and perhaps should, delegate. Screening has been 
mentioned as a possible task for general practice nurses,44 and it has been 
emphasized that GPs are not responsible for educating the patients on their 
own.Z8;45 :46 Dieticians proved to be better at diet education than physicians,47 
and nurses can achieve health outcomes that are as good as those achieved 
by the GPs.48;49 Why then are the tasks not being delegated? Perhaps there is 
a lack of teamwork because the physicians are not interested in sharing the 
responsibility for diabetes care with other physicians and/or other allied 
health professionals {podiatrists, nurse case managers, dieticians). 50 Another 
possible reason is that GPs are not convinced of the effectiveness or the 
necessity of delegating tasks.5 1  Maybe there are not enough delegation 
opportunities, considering the way health care is currently organized with an 
insufficient availability of DSNs and dieticians; and legal bottlenecks which 
may also play a role.5 1 -53 These questions need further exploration. The 
introduction of nurse practitioners in The Netherlands since 1 999 may 
facilitate task delegation, as they can undertake much of the health 
promotion work which is part of a general practice and they can play a ke� 
role in the routine management of chronic diseases such as diabetes. 4 
Although there is insufficient evidence as yet, they seem to be having a 
positive effect on the quality of care. However, we should be careful with 
over-generalizing: a large difference exists between nurse practitioners and 
DSNs, and nurse practitioners also differ with respect to training and 
education. It remains to be seen if general practice nurses can accomplish 
the same things in diabetes care as DSNs. For nurses to deliver good 
diabetes care a thorough training program is necessary. Moreover, the 
presence of nurse practitioners will not automatically lead to a reduction in 
the GPs' workload. 55 Another point to consider in task delegation is the 
enabling of the DSNs to refer patients directly to dieticians, podiatrists, and 
chiropodists, as less than half of GPs followed the DSNs' referral 
recommendations. Moreover, nurses could also prescribe certain 
medications, according to strict protocols. 53 
A second direction for future quality improvement is that more 
attention should be paid to treating cardiovascular risk factors, especially in 
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the case of primary prevention, where treatment appeared worse compared 
to secondary prevention. Hypertension should be treated earlier/8;5 and 
more aggressively, as shown by the findings in the present study. Weight 
management needs extra attention, maybe especially from non-obese GPs. 
Treatment and success rates of treatment may be improved by investing 
time in a very basal task: the better (measurement and) registration of 
cardiovascular risk factors. This step may sound too simple to be taken 
seriously. Still, without accurate measurements, values exceeding targets 
will not be detected, and the triggers for initiating or intensifying treatment 
will be missed. However, rigorous measuring of agreed upon end points and 
their proper registration are not easy tasks. One solution could be to assign 
this task to nurses, as we found that they are better at following protocols 
than most GPs. Alternatively, better use may be made of information and 
communication technology resources. 57 Treating the cardiovascular risk 
factors of those patients most at risk may be stimulated by changing the 
national guidelines with respect to the measurement of microalbuminuria. 
The presence of one extra cardiovascular risk factor may just be what 
convinces the physician and/or the patient to initiate or intensify treatment. 
Finally, the quality of care would benefit if the national and 
international guidelines were standardized. This would improve clarity, 
possibilities for comparison, and benchmarking, and prevent situations 
where benefits gained with intensive treatment in one setting were lost in 
another setting due to less stringent standards. The treatment goals for blood 
pressure in primary and secondary care have recently been made the same 
with the introduction of the revised guidelines of the Dutch College of 
General Practitioners for hypertension.58 However, among GPs, the views 
on the responsibility regarding follow-up visits for retinopathy screening 
varied considerably; which may indicate that the role of each team member 
involved in diabetes care is not defined clearly enough in the guidelines, 
while it should be,59 and while it is in other settings.60 This may not have to 
be a rigid role description for the different caregivers that applies to the 
entire country, but could also be the recommendation to discuss and 
describe the role of team members regionally, according to possibilities and 
limitations. However more clarity about this subject should be introduced. 
Measurement of microalbuminuria should not be restricted to patients 
younger than 50 years of age, 28 but could be measured regardless of age, as 
discussed earlier by others,6 1 , or at least until the age of 70. This would also 
in line with the guidelines for secondary care62 . We provided arguments to 
reconsider this, based on our study and recent literature. 
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Recommendations 
1 .  Funding is necessary for the prevention and treatment of type 2 
diabetes: the combination of a high, increasing prevalence, a raised 
mortality ratio compared with persons without diabetes, a high 
prevalence of (risk factors for) complications, and insufficient 
implementation of the national guidelines leads to a negative impact 
on quality of life and rising demands on health care. 
2. The effects of structured shared care with task delegation to nurses, 
should be followed for a longer time period to allow the analysis of 
the effects on important end points such as disease complications and 
mortality, and to see if the effects of the interventions, and the 
interventions themselves, can be sustained. 
3 .  Further study is necessary into the barriers preventing task delegation, 
into (reasons for lack of) follow-up of recommendations given within 
shared-care, and the optimal format of such recommendations. 
4. The quality of diabetes care would benefit if more attention were 
given (by prescribing more medication) to the cardiovascular risk 
profile in addition to glycaemic regulation, accurate registration of 
cardiovascular risk factors, and more focus on primary versus the 
secondary prevention of cardiovascular disease. 
5 .  The introduction of a set of carefully chosen quality indicators with 
achievable benchmarks for diabetes in the primary health-care setting 
could improve transparency and stimulate quality improvement. The 
effects of health care providers participating in a system which 
provides feedback and the opportunity for discussion about their 
performance should be studied, so they can find direction and 
motivation to further improve their quality of care. 
6. New quality improvement projects should only be financed if : ( 1 )  
evidence for the intended intervention exists, or (2) if a 
(methodologically acceptable) effect evaluation is included at the start 
of the project together with a cost-effectiveness analysis. 
Furthermore, if new interventions prove successful, the integration of 
them interventions into regular care must be automatically financed 
through a regular financing system for shared care. 
7 .  The quality of care would benefit if the national guidelines of the 
Dutch College of General Practitioners were improved: national and 
international guidelines should be standardized, the responsibility 
issue for retinal screening must be clarified, and the recommendations 
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The aim of this thesis was to study the current magnitude of type 2 diabetes 
mellitus as a health care problem, and to study the effectiveness of different 
organizational strategies to improve quality of care for type 2 diabetes in the 
primary health care setting, now and in the future. 
Chapter 1 describes the background leading to the three research questions 
that are addressed in this thesis, it describes the outline of the thesis, and 
gives a detailed description of the ZODIAC-study (Zwolle Outpatient 
Diabetes project Integrating Available Care) that was performed to answer 
the research questions. 
Because of recent developments, type 2 diabetes is becoming a worldwide 
epidemic with enormous consequences for morbidity, mortality, quality of 
life, and demands on health care. Type 2 diabetes is no longer an isolated 
disorder of glucose metabolism, but a risk factor for cardiovascular disease. 
As in other countries, in The Netherlands there has been an ongoing shift 
from secondary to primary care. To improve the quality of care for patients 
with diabetes, clinical guidelines have been developed. Merely 
implementing the guidelines is insufficient, however. 
This background led to the following research questions: 
1 .  What is the magnitude of type 2 diabetes as a health care problem in The 
Netherlands? 
2 .  What is  the effectiveness of two different organizational strategies, in 
the form of shared care with task delegation, in improving quality of 
care for type 2 diabetes? 
3 .  What should be the aim of future improvement strategies? 
The ZODIAC-study 
The ZODIAC-study investigates the effects of structured shared care for 
type 2 diabetes within the MCC-Klik shared-care project, between 1 998 and 
200 1 ,  in order to further improve diabetes care in the region. Eight GP­
working groups were invited to participate. Allocation to intervention A, B, 
or standard care was done according to the preference of the GP-working 
groups. In intervention A -annual check-up by DSNs and on demand 
consultations- 32 GPs received extensive support from diabetes specialist 
nurses (DSNs) who were hospital-based, but worked for the project within 
the primary health care setting. In intervention B -on demand consultation 
with DSNs only-, 2 1  GPs received limited support from DSNs, and in the 
standard-care group, 8 GPs delivered standard care receiving no extra 
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support at all. The target population consisted of patients diagnosed with 
type 2 diabetes who were being treated within the primary health-care 
setting (n=2660). 
Chapter 2 describes the epidemiology of type 2 diabetes in the Zwolle 
region during 1 998-2000, in the eastern part of The Netherlands. We found 
that the age and sex adjusted prevalence of type 2 diabetes increased by 
33% from 2.2% in 1 998 to 2.9% in 2000. The prevalence was higher for 
women compared to men. Patients older than 70 years accounted for almost 
50% of all type 2 diabetes patients. The age and sex adjusted mean annual 
incidence per 10,000 was 22.7. The incidence -though still high- decreased 
after the age of 70. The mortality rate was 48/1 ,000 and the standardized 
mortality ratio was 1 .40. Based on these results, the estimated total number 
of patients known with type 2 diabetes extrapolated to the Dutch population 
was 466,000 in 2000; the number of patients with newly diagnosed diabetes 
was 36,000. With an estimated 14,000 patients dying each year, the type 2 
diabetes population grows with 22,000 patients per year. 
Chapter 3 In a prospective non-randomized design, we studied the effects 
of two structured shared care interventions and compared them with 
standard care as described in the above ZODIAC-study. Patients who were 
terminally ill or who had been diagnosed with dementia were excluded 
(5%). The participating population was highly unselected and represented 
65-70% of all patients with type 2 diabetes, and 85-90% of all patients with 
type 2 diabetes being treated within the primary health-care setting. None of 
the GPs discontinued their participation in the study. Patient participation 
was high (90%) and remained stable during the project. Longitudinal 
analyses showed significant improvements in quality indicators in both 
intervention groups: in both process parameters and outcomes (achieved 
target values at the individual patient level). Intervention group A achieved 
the best results with DSNs performing all annual check-ups. In the standard 
care group the results remained stable or deteriorated. Both patients and 
caregivers appeared satisfied with the project. We conclude that structured 
shared care with task delegation to nurses, targeted at a large unselected 
patient population with type 2 diabetes in the primary care setting, is 
feasible and can positively influence the quality of care (process and 
outcome). 
Chapter 4 describes the study into the responsiveness of general 
practitioners to recommendations concerning individual patients, gtven 
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within the first year of the shared-care project in intervention group A. 
Recommendations studied were in either a direct format (in writing) from 
nurses specialized in diabetes concerning referrals to dieticians, 
chiropodists, or podiatrists, or in an indirect format (checkbox) judging 
glycaemic regulation, the regulation of blood pressure, and lipid profile. In a 
one-year longitudinal analysis we found that less than 50% of the 
recommendations were being followed. Follow-up of recommendations may 
depend on the format of the recommendation. The dysregulation of glucose 
metabolism, as assessed through HbAl c  led more frequently to treatment 
changes than the dysregulation of blood pressure or lipids. Patient refusal of 
referral appeared non-modifiable. Therefore, when recommendations are 
given in future shared-care situations, attention should be given to the 
implementation rate, and to the format in which they are given. From these 
results, GPs need to pay more attention to the cardiovascular risk profile in 
addition to glycaemic regulation. 
Chapter 5 describes a survey about the organization of diabetes care in the 
primary health-care setting, with an emphasis on task delegation. The 
questionnaire was mailed to 1 92 general practitioners, 72% of whom 
responded. Our main finding was that delegation of tasks, such as 
organizing active screening to diagnose type 2 diabetes in high-risk groups, 
education, and regular check-ups, scarcely occurred. Opinions varied about 
the responsibility for follow-up appointments for retinal screening. In the 
future, improving and expanding task delegation should receive more 
attention. 
Chapter 6 describes a cross-sectional analysis of the prevalence, treatment, 
and treatment success of cardiovascular risk factors. We found that, in the 
population that participated in intervention group A of the ZODIAC-study, 
hypertension and lipid profile abnormalities were present in 78% and 5 1%, 
were treated in 63% and 22%, and treated with success in 4 1% and 54% of 
cases, respectively. The presence of cardiovascular disease in patients, and 
the accurate registration of cardiovascular risk factors in the patient record 
by general practitioners, were associated with higher treatment rates. 
Therefore, future implementation strategies could be directed at the primary 
versus the secondary prevention of cardiovascular disease, and at improving 
the registration of cardiovascular risk factors. 
Chapter 7 describes a cross-sectional analysis into the prevalence of micro­
and macroalbuminuria in patients with type 2 diabetes in the primary health-
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care setting. We also evaluated whether the recommendation in the 
guidelines of the Dutch College of General Practitioners, not to measure 
microalbuminuria in patients aged 50 years and over, based on the argument 
that these patients are already being optimally treated for their hypertension 
and lipid profile abnormalities, was justifiable. The prevalence of micro- en 
macroalbuminuria appeared high, 33% and 7% respectively, with an 
increase in prevalence occurring with age. Eighteen percent of patients <50 
years of age with microalbuminuria was being treated with an ACE­
inhibitor or an A2-antagonist, as well as 33% of patients �50 years. 82% of 
patients �50 years with microalbuminuria known to have hypertension 
and/or lipid profile abnormalities was not being, or was being insufficiently, 
treated for this condition. Moreover, in 9% of cases micro- and 
macroalbuminuria were present in the absence of hypertension and lipid 
profile abnormalities. Our findings, in combination with other recent 
findings in the literature, supply strong arguments for measuring 
albuminuria, and treating abnormal values, in patients at least until the age 
of 70. 
Chapter 8 describes a study comparing the prevalence and the treatment of 
hypertension in primary and secondary care. In 1 999/2000 data were 
collected from consecutive patients with type 2 diabetes mellitus who 
visited the out-patient clinic of two physicians specialized in diabetes care. 
At that time, the blood pressure goal in secondary care was :::::; 1 50/85 mmHg. 
The same data were collected for patients who were treated in primary care 
in 1 9971 1998 (blood pressure goal :::::; 1 60/90 mmHg). The mean blood 
pressure was 1 57/79 mmHg in secondary care, versus 1 62/87 mmHg in 
primary care. The prevalence of hypertension in secondary care was 89%, 
with 37% having an adequate regulation (:::::; 1 50/85 mmHg) of their blood 
pressure. The prevalence of hypertension in primary care was 69%; 
adequate blood pressure control (� 1 60/90 mmHg) was achieved in 44% of 
patients. In primary care, a significantly higher number of anti-hypertensive 
agents was prescribed for patients who met blood pressure goals compared 
to those who did not. Therefore, in the future, profit may be gained by 
treating patients with more medication, and by lowering blood pressure 
target goals recommended in the guidelines. 
Chapter 9 describes an analysis into the associations of body mass index 
and smoking habits between patients and their physicians, and the role of 
other physician characteristics and attitudes. Data were collected by postal 
survey (response rate 100%). Regression analyses, with the mean BMI of 
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patients as the dependent variable, showed the strongest correlation with the 
BMI of GPs: -0.40 (partial correlation); the explained variance was 3 1 %  
(adjusted 1 7%). Although patients indicated greater confidence in non-obese 
physicians, we found no translation into increased success in obesity 
management. On the contrary, the patients of non-obese GPs had a higher 
BMI compared to the patients of obese GPs. A discemable negative impact 
of the patients' weight on physician behaviour had been shown earlier. 
Could it be that non-obese GPs lack the motivation to treat overweight 
patients? 
Chapter 10 answers the research questions and discusses the limitations, 
strengths, and results critically. The difficulties of (studying) the translation 
of evidence and guidelines to the real world are discussed. An initial 
proposal for what could be part of a quality indicator set for primary care is 
described. Financial issues are addressed as well. This chapter concludes 
with the following recommendations: 
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1 .  Investments are necessary for the prevention and treatment of the 
growing epidemic of type 2 diabetes, because of the large negative 
impact on quality of life and the rising demands on health care. 
2 .  The effects of structured shared care with task delegation to nurses, 
should be followed for a longer time period to allow an analysis of 
the effects on important end points such as disease complications and 
mortality, and to see if the effects of interventions, and the 
interventions themselves, can be sustained. 
3 .  Further study is necessary into the barriers preventing task 
delegation, into (the reasons for the lack of) adherence to 
recommendations given within shared-care, and the optimal format 
such recommendations should take. 
4. More attention from GPs is necessary for the cardiovascular risk 
profile (in addition to glycaemic regulation), the accurate registration 
of cardiovascular risk factors, and more focus on primary versus the 
secondary prevention of cardiovascular disease. 
5. Introducing carefully chosen quality indicators with achievable 
benchmarks for diabetes in primary care could improve transparency 
and the quality of care. The effects of participation of health care 
providers in a benchmark system should be studied. 
6. New quality improvement projects should only be financed if: ( 1 )  
evidence for the intended intervention exists, or (2) if a 
(methodologically acceptable) rigorous effect evaluation is included, 
Summwy 
together with a cost-effectiveness analysis. Integration of any 
successful interventions in regular care should be automatically 
financed through a regular financing system for shared care. 
7. The quality of care would benefit from improvements in the national 
guidelines of the Dutch College of General Practitioners: from 
standardizing national and international guidelines, clarifying the 
subject of responsibility for retinal screening, and from revising the 
recommendation concerning the measurement of microalbuminuria. 
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Sam en vatting 
Samenvatting 
Het doel van dit proefschrift was het bestuderen van de omvang van 
Diabetes Mellitus Type 2 als gezondheidszorgprobleem en de effectiviteit 
van verschillende strategieen om de kwaliteit van zorg voor Diabetes 
Mellitus Type 2 in de eerste lijn te verbeteren, nu en in de toekomst. 
Hoofdstuk 1 beschrijft de achtergronden die hebben geleid tot de drie 
onderzoeksvragen die in dit proefschrift worden uitgewerkt en de ZODIAC­
studie (Zwolle Outpatient Diabetes project Integrating Available Care), die 
werd uitgevoerd om de onderzoeksvragen te beantwoorden, wordt in detail 
beschreven. 
Diabetes type 2 verandert in een wereldwijde epidemie met enorme 
consequenties voor mortaliteit, morbiditeit, kwaliteit van leven en 
zorggebruik. Type 2 diabetes is niet langer een gei'soleerde stoomis van het 
glucosemetabolisme, maar een cardiovasculaire risicofactor. En, zoals ook 
in andere landen, is er in Nederland een verschuiving van de diabeteszorg 
van de tweede naar de eerste lijn; van het ziekenhuis naar de 
huisartspraktijk. Om de kwaliteit van de diabeteszorg te verbeteren zijn 
landelijke richtlijnen ontwikkeld. Echter, de implementatie van deze 
richtlijnen is nog onvoldoende. Vanuit deze achtergrond zijn wij tot drie 
onderzoeksvragen gekomen: 
1 .  Wat is de huidige omvang van diabetes mellitus type 2 als 
gezondheidszorg probleem? 
2. Wat is de effectiviteit van verschillende strategieen, in de vorm van 
transmurale zorg met taakdelegatie, om de kwaliteit van zorg voor 
Diabetes Mellitus Type 2 in de eerste lijn te verbeteren? 
3 .  Waar zouden toekomstige verbeteringsstrategieen op gericht kunnen 
worden? 
De ZODIAC-studie 
De Zwolle Outpatient Diabetes project Integrating Available Care 
(ZODIAC)-studie onderzoekt de effecten van gestructureerde transmurale 
zorg voor type 2 diabetes binnen het MCC-Klik transmurale diabetes 
project. De deelnemende huisartsen werden naar eigen keus verdeeld over 
drie onderzoeksgroepen: de eerste groep (interventie A -jaarlijkse controle 
door diabetesverpleegkundigen en consultatie op verzoek-, 32 huisartsen) 
ontving uitgebreide ondersteuning door een diabetesverpleegkundige. Deze 
diabetesverpleegkundigen waren verbonden aan het ziekenhuis, maar 
werkten binnen de eerste lijn. De tweede groep (interventie B -uitsluitend 
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consultatie van diabetesverpleegkundigen op verzoek-, 2 1  huisartsen) 
ontving beperkte ondersteuning van deze diabetesverpleegkundigen en de 
derde groep ('standaardzorg' ,  8 huisartsen), leverde de gewoonlijke zorg 
zonder enige vorm van extra ondersteuning 
Hoofdstuk 2 beschrijft de epidemiologie van type 2 diabetes in de regio 
Zwolle in 1 998-2000. We vonden een voor leeftijd en geslacht 
gecorrigeerde prevalentie van type 2 diabetes die toenam met 33% van 2,3% 
in 1 998 tot 2,9% in 2000. De prevalentie was hoger voor vrouwen in 
vergelijking met mannen. Bijna 50% van alle patienten met type 2 diabetes 
was ouder dan 70 jaar. De voor leeftijd en geslacht gecorrigeerde 
gemiddelde jaarlijkse incidentie per 1 0.000 was 22,7. De incidentie -hoewel 
nog steeds hoog- daalde na de leeftijd van 70 jaar. De mortaliteitsratio was 
48/1 .000 en de gestandaardiseerde mortaliteitsratio 1 ,40. Gebaseerd op deze 
resultaten was het geschatte totale aantal mensen bekend met type 2 
diabetes, geextrapoleerd naar de Nederlandse bevolking, 466.000 in 2000; 
het aantal nieuw gediagnosticeerde patienten 36.000. Met een geschat aantal 
van 14.000 patienten met type 2 diabetes die jaarlijks overlijden, zou de 
type 2 diabetes populatie groeien met 22.000 per jaar. 
Hoofdstuk 3 Binnen een prospectieve niet-gerandomiseerde 
onderzoeksopzet onderzochten we de effecten van twee interventies en 
'standaardzorg' in de hierboven beschreven ZODIAC studie. De 
deelnemende populatie was ongeselecteerd en bestond uit 65-70% van alle 
patienten met type 2 diabetes, en 85-90% van alle patienten met type 2 
diabetes die werden behandeld binnen de eerstelijns gezondheidszorg. Het 
percentage patienten dat deelnam was hoog (90%) en stabiel in de drie 
projectjaren. Geen van de huisartsen stopte de deelname tijdens het project. 
Longitudinale analyses toonden significante verbeteringen in 
kwaliteitsindicatoren in beide interventiegroepen: in procesparameters en in 
uitkomsten (bereikte streefwaarden op het individuele patientenniveau). De 
beste resultaten werden gevonden voor interventiegroep A, waar de 
diabetesverpleegkundigen alle jaarlijkse controles uitvoerden. In de 
' standaardzorg' bleef de geleverde zorg meestal stabiel en verslechterde in 
een enkel geval. Zowel patienten als zorgverleners bleken tevreden met het 
project. We concluderen dat gestructureerde transmurale zorg met 
taakdelegatie naar diabetesverpleegkundigen, gericht op een grote 
ongeselecteerde type 2 diabetespopulatie in de huisartspraktijk, haalbaar is 
en de kwaliteit van zorg positiefkan bei"nvloeden. 
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Hoofdstuk 4 beschrijft de studie naar de reactie van huisartsen op adviezen 
betreffende individuele patienten in interventiegroep A. De adviezen 
kwamen van diabetesverpleegkundigen betreffende verwijzingen naar 
dietisten, pedicures en podotherapeuten, en indirecte adviezen. Deze 
indirecte adviezen betroffen een oordeel over de glycaemische regulatie en 
de regulatie van bloeddruk en het lipidenprofiel volgens de landelijk 
richtlijnen. In een 1 -jaars longitudinale analyse vonden we een follow-up 
percentage van <50% voor deze adviezen die werden gegeven binnen het 
transmurale diabetesproject aan huisartsen. Follow-up zou athankelijk 
kunnen zijn van de vorm waarin het advies werd gegeven. Glycaemische 
disregulatie, beoordeeld aan de hand van het HbA 1 c, leidde vaker tot 
aanpassing van de behandeling dan disregulatie van bloeddruk of lipiden. 
We concluderen dat, als er in de toekomst advies wordt gegeven binnen 
transmurale zorg, er aandacht nodig is voor de implementatie van gegeven 
adviezen en voor de vorm waarin de advisering wordt aangeboden. Extra 
aandacht van huisartsen lijkt nodig voor het cardiovasculaire risicoprofiel 
naast de aandacht voor de glycaemische regulatie. 
Hoofdstuk 5 beschrijft een enquete naar de organisatie van de diabeteszorg 
in de eerste lijn, met nadruk op taakdelegatie. De enquete werd uitgevoerd 
onder 1 92 huisartsen (respons 72%). Taken, zoals het organiseren van 
actieve screening in hoogrisico groepen, educatie, en reguliere controles, 
werden slechts beperkt gedelegeerd. Meningen over de 
verantwoordelijkheid voor vervolgafspraken voor oogonderzoek varieerden 
onder huisartsen. In de toekomst is meer aandacht nodig voor het verbeteren 
en uitbreiden van de taakdelegatie. 
Hoofdstuk 6 beschrijft het onderzoek naar de prevalentie en behandeling 
van cardiovasculaire risicofactoren. In de populatie die deelnam in 
interventiegroep A van de ZODIAC-studie, waren hypertensie en 
vetspectrumstoomissen aanwezig bij respectievelijk 78% en 5 1%. Ze 
werden behandeld in 63% en 22% van de gevallen en met succes bij 
respectievelijk 4 1% en 54% van de patienten. Een positieve 
cardiovasculaire voorgeschiedenis bij patienten, en accurate registratie van 
cardiovasculaire risicofactoren door huisartsen, waren geassocieerd met 
hogere behandelpercentages. Toekomstige implementatie strategieen 
zouden meer aandacht moeten besteden aan primaire versus secundaire 
preventie van cardiovasculaire aandoeningen en op het verbeteren van de 
registratie van cardiovasculaire risicofactoren door huisartsen. 
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Hoofdstuk 7 beschrijft een cross-sectionele analyse naar de prevalentie van 
micro- en macroalbuminurie bij type 2 diabetes in de huisartspraktijk. We 
evalueerden ook of het argument voor advies in de NHG-standaard om 
microalbuminurie niet te meten bij patienten ouder dan 50 jaar, namelijk dat 
deze patienten reeds optimaal worden behandeld voor hun hypertensie en 
vetspectrumstoornissen, terecht was. Prevalentie van micro- en 
macroalbuminurie bleken hoog, respectievelijk 33% en 7%, met een 
oplopende prevalentie met de leeftijd. Van de patienten jonger dan 50 jaar 
met microalbuminurie werd 1 8% behandeld met een ACE-remmer of A2-
antagonist en van de patienten �50 jaar 33%. Van de patienten �50 jaar met 
microalbuminurie, werd 82% van de patienten met hypertensie en/of 
vetspectrumstoornissen niet, of onvoldoende behandeld hiervoor. Negen 
procent van de patienten met micro- en/of macroalbuminurie had 
hypertensie noch vetspectrumstoornissen. Op basis van onze bevindingen, 
in combinatie met resultaten van recent onderzoek, lijkt het aan te bevelen 
om microalbuminurie te meten en te behandelen, ten minste tot de leeftijd 
van 70 jaar en de NHG-standaard in die zin te wijzigen. 
In hoofdstuk 8 wordt de prevalentie en behandeling van hypertensie in de 
eerste en tweede lijn vergeleken. Tussen 1 999 en 2000 werden gegevens 
verzameld van alle achtereenvolgende patienten met type 2 diabetes onder 
behandeling van twee internisten met als aandachtsgebied diabetes mellitus. 
De streefwaarde in de tweede lijn voor de bloeddruk was op dat moment 
:::; 1 50/85 mm Hg. Dezelfde gegevens werden verzameld bij eerstelijns 
patienten tussen 1 997 en 1 998 (streefwaarde :::; 1 60/90 mm Hg). De 
gemiddelde bloeddruk in de tweede lijn was lager (bij een richtlijn met een 
lagere streefwaarde ten opzichte van de eerste lijn): 1 57/79 mm Hg versus 
1 62/87 mm Hg in de eerste lijn. De prevalentie van hypertensie in de tweede 
lijn was 89%. Hiervan had 37% een adequate bloeddrukregulatie (:::; 1 50/85 
mm Hg). De prevalentie van hypertensie in de eerste lijn was 69%. 
Adequate bloeddrukcontrole (:S 1 60/90 mm Hg) werd bereikt bij 44%. In de 
eerste lijn werd een significant boger aantal antihypertensiva 
voorgeschreven bij patienten die wel, versus degenen die niet hun 
bloeddrukstreefwaarde haalden. We concluderen dat in de toekomst winst 
zou kunnen worden behaald door patienten te behandelen met meer 
medicatie en mogelijk met het verlagen van de streefwaarden voor de 
bloeddruk. 
Hoofdstuk 9 beschrijft de samenhang van de Body Mass Index (BMI) en 
het rookpatroon van diabetespatienten en hun huisartsen, naast de rol van 
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andere kenmerken en opvattingen van huisartsen. Met behulp van een 
enquete (respons 1 00%) werden gegevens van huisartsen verkregen. De 
sterkste correlatie bleek die tussen de BMI van patienten en die van de 
huisartsen: -0.40 (partiele correlatie). Hoewel in de Iiteratuur is beschreven 
dat patienten meer vertrouwen stelden in niet-obese dokters, vonden we hier 
dat patienten van niet-obese huisartsen een hogere BMI hadden in 
vergelijking met patienten van obese huisartsen. Een negatieve impact van 
het overgewicht van patienten op het gedrag van dokters werd eerder 
aangetoond. Zou het zo kunnen zijn dat niet-obese huisartsen onvoldoende 
motivatie hebben om patienten met overgewicht te behandelen . . . .  ? 
Hoofdstuk 10 vat de antwoorden op de onderzoeksvragen samen. 
Vervolgens worden de beperkingen, sterke punten en resultaten kritisch 
besproken. De problemen bij het bestuderen van het vertalen van evidence 
en richtlijnen vanuit de onderzoeksomgeving naar de 'echte wereld', de 
dagelijkse praktijk, worden belicht. Ook aan financiele aspecten wordt 
aandacht besteed. Kwaliteitsindicatoren voor de eerste lijn worden 
besproken en een praktisch voorstel wordt naar voren gebracht. Het 
hoofdstuk eindigt met de volgende aanbevelingen: 
1 .  Investeringen zijn noodzakelijk in preventie en behandeling van de 
type 2 diabetes epidemie vanwege de grote negatieve maatschap­
pelijk en economische impact hiervan: een negatief effect op de 
kwaliteit van Ieven en een sterk toenemende zorgvraag. 
2. Effecten van gestructureerde transmurale zorg met taakdelegatie naar 
verpleegkundigen moet gedurende langere tijd worden gevolgd om 
ook eindpunten zoals complicaties en mortaliteit te kunnen 
analyseren en om te beoordelen of de bereikte effecten van de 
interventies kunnen worden gehandhaafd. 
3 .  Meer onderzoek is nodig naar barrieres in taakdelegatie, naar 
(redenen voor gebrek aan) follow-up van advies dat wordt gegeven 
binnen transmurale zorg en naar de optimale vorm voor advisering 
binnen transmurale zorg. 
4. Meer aandacht is nodig van huisartsen voor het cardiovasculaire 
risicoprofiel (naast de aandacht voor glycaemische regula tie) in de 
vorm van meer medicatie, voor accurate registratie van 
cardiovasculaire risicofactoren, en meer focus op primaire versus 
secundaire preventie van cardiovasculaire aandoeningen. 
5 .  Introductie van een set zorgvuldig gekozen kwaliteitsindicatoren, 
met haalbare benchmarks voor diabetes in de eerste lijn, zou de 
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transparantie en de kwaliteit van de zorg kunnen verbeteren. Effecten 
van deelname van zorgverleners in een benchrnarksysteem moeten 
verder worden onderzocht. 
6. Nieuwe kwaliteitsverbeteringprojecten zouden uitsluitend nog 
moeten worden gefinancierd op voorwaarde dat: ( 1 )  bewijs voor de 
effectiviteit van de toe te passen interventie bestaat, of (2) dat een 
(methodologisch acceptabele) gedegen effectevaluatie wordt 
geincludeerd, met een kosteneffectiviteitanalyse. Daartegenover 
moet in de voorwaarde worden voorzien dat de bewezen succesvolle 
interventies in de reguliere zorg worden gerntegreerd, waarbij er 
automatisch een reguliere vergoeding beschikbaar is via een 
financieringssysteem voor transmurale zorg. 
7. De kwaliteit van zorg zou kunnen profiteren van het verbeteren van 
onze nationale huisartsenrichtlijnen: van het afstemmen van 
richtlijnen nationaal en intemationaal, mogelijk het verlagen van 
streefwaarden, verduidelijking ten aanzien van de 
verantwoordelijkheid voor vervolgonderzoek voor het screenen op 
diabetische retinopathie en van het veranderen van het advies over de 





Bij de totstandkoming van dit proefschrift hebben veel mensen een 
belangrijke rol gespeeld. Hoe Ianger ik er over nadenk, hoe Ianger de lijst 
wordt. Ik zou graag iedereen willen bedanken die iets heeft bijgedragen, 
maar bet lijkt haast onvermijdelijk dat ik, zodra bet proefschrift gedrukt is, 
toch nog mensen vergeten zal zijn te noemen. Dit betekent niet dat deze 
mensen geen bedankje verdienen! 
Henk Bilo is degene die mij in 1997 vroeg of ik onderzoek wilde doen en 
wilde promoveren. Onwetend wat mij te wachten stond ging ik akkoord. 
Henk, jij was de initiator en de grote motor achter bet diabetesproject. Ik 
heb een enorme bewondering voor je niet aflatende energie, werklust, en 
vakkennis en je alomvattende overzicht over de diabeteszorg, zowel op 
inhoudelijk als op beleidsniveau. Hier zou veel meer gebruik van gemaakt 
moeten worden. Ik ben er nog steeds trots op dat je me hebt gevraagd om 
bet onderzoek te gaan doen en wil je bedanken voor alles wat ik van je 
geleerd heb, voor de mogelijkheden die je me hebt geboden (niet te vergeten 
de vele intemationale congresbezoeken), maar vooral ook voor je 
betrokkenheid en de geweldige samenwerking. Deze samenwerking zal 
zeker niet stoppen bij bet afronden van deze promotie. 
Betty Meyboom, mijn promotor, kende ik voorafgaand aan dit 
promotietraject uitsluitend van het college over seksualiteit bij bejaarden. 
Dit bleek een zeer eenzijdig beeld. Betty, ik heb erg veel respect voor je. Je 
bent een groots organisator, die ondanks bet vele werk dat je verzet steeds 
het overzicht houdt. Je structureerde de projectvergaderingen, en bewaakte 
de grote lijnen in het project en in de manuscripten. Je reacties op vragen en 
correcties van artikelen waren altijd snel, opbouwend en kritisch. Je bent 
consequent, duidelijk en houdt niet van gezeur. Tegelijkertijd toon je ook 
een warme persoonlijkheid met interesse voor de prive-situatie van de 
mensen om je been. lk heb heel veel van je geleerd. Voor mij , als 
vrouwelijke (bijna) huisarts en onderzoeker een rolmodel. 
Zonder diabetesproject geen onderzoek. En zonder huisartsen en patienten 
geen project. Ik wil zowel alle deelnemende huisartsen als hun patienten 
bedanken voor hun deelname en bet beschikbaar stellen van hun gegevens. 
Ook de assistentes van de huisartsen wil ik noemen; zij waren onmisbaar bij 
het verzamelen van de gegevens. 
Het MCC Klik diabetesproject, nu reguliere diabeteszorg, werd bet succes 
dat het nu is mede dank zij een aantal zeer betrokken mensen die ik wil 
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bedanken voor de samenwerking waar ik van heb genoten. Gerard 
Hoogvliet, als directeur van MCC Klik met zijn scherpe oog voor 
beleidslijnen; Jan Evert Heeg, altijd net iets te laat op de vergaderingen, 
maar met veel realiteitszin en een groot strategisch vermogen. Gerda 
Timmerman en Anne Marijke Sebel, twee geweldige vrouwen, en 
diabetesverpleegkundigen van het eerste uur. Jullie hebben heel veel in het 
project opgebouwd, met vele hindemissen. Ik denk nog regelmatig terug 
(met plezier) aan de drukte die we hebben gemaakt over het maken van 
retinafoto's  . . .  En niet te vergeten, Yolande Toller, en Claire Blom, de 
secretaresses van MCC Klik en het project, allebei onmisbaar voor de 
gezelligheid en het functioneren van bovengenoemde mensen. 
Het Diabetes Electronic Management System (DEMS) met daarin de 
database van het project werd beheerd door Gert Broekhaar, van de afdeling 
ICT. Gert, we hebben een flinke periode intensief samengewerkt en een 
aantal mooie producten gecreeerd. lk heb erg van de samenwerking 
genoten, zeker ook wanneer de toneelspeler in jou naar hoven kwam. Dank 
voor je hulp met mijn databasefrustraties en de gezelligheid. Ik kom graag 
nog eens naar een van je toneelvoorstellingen. 
De database van het project werd gevuld door vele invoerders, die kwamen 
en gingen. Het coordineren hiervan was een leuke klus. Vele totaal 
verschillende jonge mensen leverden hun bijdrage. In willekeurige 
volgorde: Pieter Zeeman, Roel Hoogendoom, Djoeke Dammers, Marlies 
Hoogvliet, Dyonne Hartong, Hester Starn, Anneleen Knook, Eefje 
Hamminga, Jenneke Homan, Roeland de Wilde, Lisette Pels, Liesbeth van 
de Ziel, Margje Hamminga, Carlijn Zuure, Marcel Broekhaar, Silvia Pels, 
Marieke Kienhuis, Hannelieke Zevenhuijzen, Mascha Wolters, Esther van 
den Brink, Albert Christerus, Krista de Ruwe, Karin Bilo, Margreet van 
Litsenburg, Maartje Poelman, Marijn Poelman, Esther Vollaard, mijn 
moeder Gerda Veltmaat, Tessa Hoogvliet, Andrea de Jong, Alain de Jong, 
Diane Dikkeschei, Cindy den Herder, en mijn zusje Heidi Veltmaat. 
Speciaal wil ik Sandra Offenberg en Laura Prins noemen, die de hoogste 
productie haalden van allemaal, en als laatste Robert Jan Rischen, mijn 
meest favoriete invoerder, die helaas niet meer bij ons is. 
Marleen Peek deed haar wetenschappelijke onderzoeksstage in het 
diabetesproject en ons gezamenlijk eindresultaat is beschreven in hoofdstuk 
4. Marleen, het halve jaar dat wij samenwerkten was een heel gezellige tijd. 
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Het woord 'verzorgpony' (zoals j ij jezelf noemde) is definitief aan mijn 
persoonlijk woordenboek toegevoegd . . .  
Sabine Diepeveen, Kees de Visser, Bas Houweling, Nanno Kleefstra, Helen 
Lutgers, Iwan van der Horst, Anouk van der Horst-Schrivers, mijn 
medeonderzoekers in Zwolle. Met jullie allemaal heb ik in meer of minder 
mate samengewerkt: kennis, auteurschap, frustraties, jubelmomenten en 
veel gezelligheid gedeeld. Bas, speciaal mijn dank aan jou voor je hulp met 
de lay-out van het proefschrift. Ik hoop dat we nog lang blijven 
samenwerken. 
Klaas Groenier was er voor de statistiek van mijn onderzoek. Maar Klaas, je 
deed meer. Je liet me kritisch nadenken over wat ik nu eigenlijk wilde 
bewijzen en probeerde me ook wat statistiek bij te brengen. Vaak vroeg ik 
me af of j ij nu zo slim was, of ik zo dom, omdat ik het soms gewoon niet 
kon snappen. Ik hou het bij het eerste, en heb als oplossing voor mezelf al 
jouw uitleg per e-mail goed bewaard zodat ik het nog eens kan nalezen. 
Dank voor je altijd optimistische ondersteuning. 
Secretaresses van mijn 'hazen' speelden een belangrijke rol in de afgelopen 
jaren. lneke Brink, de spil van de afdeling huisartsgeneeskunde in 
Groningen, en Greetje Kroes, met dezelfde functie op de diabetespoli in 
Zwolle. Dank voor jullie ondersteuning, die ik altijd kreeg, ook bij 
schijnbaar onmogelijke verzoeken, en vooral ook dank voor jullie 
luisterende oren. Jullie waren onmisbaar. 
Veel mensen van de diabetespoli, het laboratorium, en de afdeling ICT 
waren in meer of mindere mate betrokken bij het diabetesproject of het 
onderzoek. lk kan helaas niet iedereen bij naam noemen, maar weet dat mijn 
dank ook jullie betreft! 
Thea Schenk corrigeerde het engels in de eerste versies van een aantal 
manuscripten, Anne Starreveld corrected the final version of this thesis. 
Thank you both for your help, which was to the point and very adequate, 
and also for the pleasant cooperation. 
De leescommissie, bestaande uit Prof. Assendelft, Prof. Rutten, Prof. 
Wolffenbuttel en Steve Smith wil ik bedanken voor hun kritische oordeel 
over en hun bijdragen aan de verbetering van het proefschrift. 
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Steve, a special thanks to you, and the other members of the Mayo team, for 
our pleasant cooperation in the past years; with respect to DEMS and with 
respect to sharing our thoughts about the research we both conduct. I am 
honored that you were willing to be part of my manuscript committee. 
Roel Rischen, huisartscoordinator van het diabetesproject, huisartsopleider, 
medeauteur, paranimf, toekomstig collega . . .  Roel, we werken al 7 jaar 
samen. Als ik nadenk over wat mijn onderzoeksperiode me heeft 
opgeleverd, sta j ij hoog op het lijstje. Je hebt me vaak met mijn twee 
onderzoekersbenen op de huisartsengrond gezet, we hebben samen de 
benchmarking opgezet, intemationale congress en bezocht, veel nuttig 'ge­
netwerkt' ,  en we zijn het maar een keer echt oneens geweest. We hebben 
veel lol, maar ook verdriet gedeeld. Als huisartsopleider heb j ij me aile 
ruimte gegeven om het proefschrift af te kunnen ronden. Dit heeft voor een 
belangrijk deel meebepaald dat het nu zover is. Jij noemde ons ooit 'maatjes 
in mellitus madness' . . .  ik hoop dat we lang maatjes zullen blijven! 
Joop en Wim Ubink, mijn schoonouders, dank voor jullie ondersteuning van 
en interesse voor mijn proefschrift, en zeker ook voor de flexibiliteit bij het 
oppassen op Anna Rosa. Het diabeteskruidendoosje dat ik van jullie kreeg 
vond ik zo speciaal dat het nu op de omslag van het proefschrift staat. Ineke 
Bobbink-Ubink, ook jou wil ik graag bedanken voor je bijdrage aan het 
verhaal bij het diabeteskruidendoosje. 
Heidi Veltmaat, mijn 'kleine' zusje, nu een aanstaande moeder. Je hebt veel 
onderzoeksgegevens in verschillende databases ingevoerd en geholpen met 
correcties, maar buiten dat heb je niet zo heel veel met mijn 
promotieonderzoek. Toch ben je niet voor niets mijn paranimf. Je bent er 
voor me als het nodig is: ik ben blij met zo'n geweldige zus als j ij .  
Gerda en Marinus Veltmaat, lieve mam en pap. Zonder jullie zou ik nu niet 
promoveren. Jullie hebben gezorgd voor de basis die nodig was om dit te 
bereiken. Jullie stimuleerden het volgen van een goede opleiding, zorgden 
dat ik zonder financiele zorgen kon afstuderen, en leerden me wat 
discipline, hard werken en doorzetten is. lk kreeg aile ruimte om me te 
ontwikkelen en jullie staan altijd achter me. lk hoop dat ik voor Anna Rosa 




Aldred Ubink, mijn echtgenoot en vader van ons mooie meisje Anna Rosa. 
Niet zo lang geleden zuchte je opgelucht toen je las dat er meer echtgenoten 
zijn die niets van de inhoud van het proefschrift van hun partner begrijpen. 
Je vindt bovendien een dankwoord maar onzin, in het algemeen, maar 
vooral ook voor jezelf. Immers, je hebt er toch niets aan gedaan . . .  Lieve, 
lieve Aldred, je hebt juist heel veel bijgedragen, inderdaad soms door 
dingen niet te doen. Geen gezeur over vele avonden alleen voor de buis, 
geen geklaag als ik op reis was of als jij de was weer eens stond te doen 
omdat ik achter die eeuwige laptop zat. Geen gemopper wanneer ik mijn 
frustraties over geweigerde artikelen of andere tegenvallers op jou 
afreageerde. Jij hebt gezorgd voor de belangrijkste voorwaarde om dit 
promotietraject af te ronden: jouw lach. Ik zeg het niet vaak genoeg, maar 
meen het des te meer: ik kan alles aan, als jij maar naar me lacht. . . .  
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Report 
MCC KLIK Diabetes proj ect 
Report MCC KLIK Diabetes project 
General Practitioner: 
Date consultation: 
Home visit: Y IN 
Performed by: 
Baseline data: Tablets :(diabetes) 
Diabetes since Newly diagnosed Y I N 
Therapy: tablets : N I Y 
Insulin: N I Y 
Diet : N  I Y since 
Dietician visited : N  I Y 
Self monitoring : N  I Y since 
Latest gauging dd. : 









Retinal exam N / Y 
Latest visit ophthalmologist 
Retinal photograph :  
D Independent D chiropodist D Podiatrist 







Check-up injection sites : Y I n.a 




Conclusion internist based on national guideline: Comment internist 
Good Accegtable Poor 
Glycaemic regulation: a 0 0 
Lipid profile: 0 0 D 
Blood pressure: 0 0 0 
B.M.I. :  0 0 0 
Comment diabetes specialist nurse: 
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Macrovascular complications: 
0 Myocardial infarction 
O CABG: 
O PTCA 





( . . . . . . . . .  ) 0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  : ( . . . . . . . . .  ) 
( . . . . . . . . .  ) 
( . . . . . . . . .  ) 
( . . . . . . . . .  ) 
( . . . . . . . . . ) 
0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  : ( . . . . . . . . .  ) 
0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  : ( . . . . . . . . .  ) 
0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  : ( . . . . . . . . . ) 
Riaht Wounds: Y I N 
A.D.P. palpable? Y I N  Y I N  Localisation: 
A.T.P. palpable? 
Sensitivity abnormal? 
Y I N  Y I N  
Toes : Y I N Y I N  Other findings: 
Forefoot Y I N  Y I N  
Heel : Y I N  Y I N  
Other comments: 
"Good - Acceptable - Poor" according to the national guidelines 
Good Acceptabel Bad 
HbAl c  <7 7-8.5 >8.5 
Blood Pressure Systolic < 1 50 mm Hg Systolic 1 50-1 60 mm Hg Systolic > 1 60 mm Hg 
And/or And/or And/or 
Diastolic < 85 mm Hg Diastolic 85-90 mm Hg Diastolic > 90 mm Hg 
Chol/HDL-ratio <4 4-6 >6 
BMI <27 kg/m2 27-30 kg/m2 >30 kg/m2 
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Shared Diabetes Care 
General practitioner 
GP-working group 
General Data 2000 
All general practitioners Individual general practitioner 
Total number, by diabetes specialist nurse 
checked patients with OM type 2 










N = 1 002 
N - 8 1 6  










Diastolic blood pressure 
Systolic blood pressure 
Body Mass Index 
N = 1 8 1 4  
N .  344 
1 8 1 8  






5 %  
20 % 
1 0 %  
63% 
99 % 




1 44 mmHg 
29,5 kg/m2 
N = 43 
N :  46 
N : 
N =  
89 
1 0  
Reference Table 
Judgement good aCCI!J)table bad 
HbA1c < 7 7 - 8  5 > 8 5  
blood__m-essure < 1 50/85 1 50/85 - 1 60/90 > 1 60/90 
Choi/HDL < 4  4 - 6 > 6  








2 %  
44 % 
7 %  
44% 
100 % 
1 1 % 
6,62% 
4,08 
81,6 m m Hg 
1 47 m mHg 
28,3 kg/m2 
-
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General practitioner 
Clustered bars for HbA1 c for all general practitioners In Intervention A as 
compared to the Individual general practitioner: percentage of patients with an HbA1c 
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Mean Choi/HDL-rallo per general practitioner, with reference line for mean 
Choi/HDL-rallo for the total group. 
1 88 
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General practitioner 
Clustered bars for Choi/HDL-ratio for all general practitioners in intervention A as 
compared to the individual general practitioner: percentage of patients with a 
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<4 4 - 6 >6 
ChoVHDL-ratio 
Mean systolic blood pre55ure par general practitioner, with reference line for the mean 
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<3enenal pnactitioner 
Clustered bars for systolic blood pressure for all general practitioners in intervention A as 
compared to the Individual general practitioner: percentage of patients with a 
systolic blood pressure in the categories "good", "acceptable" and "bad". 
Cll ... 
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Mean diastolic blood pressure per general practitioner, with reference line for the mean 
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General practitioner 
Clustered bars for diastolic blood pressure for all general practitioners in intervention A as 
compared to the individual general practitioner: percentage of patients with a 
diastolic blood pressure in the categories "good","acceptable" and "bad"'. 
70 66 
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D iastolic blood pressure 
Mean body mass index per general practitioner, with reference Una for the mean 
body mass Index for the total group. 
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Clustered bars for body mass Index for all general practitioners In Intervention A as 
compared to the individual general practitioner: percentage of patients with a 
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D AII GPs 
D l-d.OO GP 
Appendix 2. 
1 9 1  
Benchmarking 
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Curr icu l u m  v itae 
Liclith Veltmaat werd �Jeboren op 1 0  m;Jart 1 972 in 
D<1lf�.en . Z i j  beh;:dclo i n  1 990 l1a<1r Gyrnnas1 U ill - f3  d 1 plorn8 
�Kill het Thome�s 6 Kempis Col le�Je in Zwolle. De studie 
geneeskuncle.  a;:Jn de U n iversiteit van Gron 1nge 1 1 .  mndde 
zij in 1 997 cum laude af. De i 1 1  hel  k;:Jder van de stud io 
verp l ichte wetensci Jappel iJI<e st:1ge we1 d bij de <Jfdel ing 
H u i s;:u-tsger reesl<uncle begelcicl cloor K laas Reenders en 
hac! a is onclerwerp : " Lleler l l rnercncle be tor en bij over­
scil 3 i<el i n�J op insu l ine lJ i j  patien len met d iabetes nwl l i tus 
type 2· · .  Voor cle publ icatie e i re h ien 1 i t  volgcle l<ree�J z r j .  
s;.unen met Krista M i cclern<J. i n  1 996 cle Hecrt Dolder­
prijs. Di t  �wheel bleel< een goedo st 1 1n u l ;�ns voor vercler  
wetenschappel i J I< onder:�oc l< .  De co-scl ;.tppe r J  wer den 
doorlopen in clc Deventer Zrel<cnhui:,:en en voor ha;�r 
keuzeco-schap gynaecolo9ie �J I I l�J 2:e nztar hct ··uvcr·pool 
Won wn 's NHS Trust Hospit<l l "  in  En�Jelal lCL 
Na ee1 1 arts-3ssr slentsch;lp rnt c'! m o ncnecsl<undc en 
cardiolo�J ie in z iel<en h t l is De Weezcn l;ulCien in Zwolle (nu 
l s�ti;J K l i n i e l<en) weri<tl'� ze tt r��sen 1 �198 en 2002 al�� 
artsoncler zoel<er op c!c cl i �J betespo l i  v::111 el i !  z ieken h u i s  
(beneleider: clr. H .clG .  B i lo) en voor de Disciplincg1 oep 
H ui�;:-�rts�wncesl<umle van cle Un ivers i leit v;m G r onin�)cn 
(hoofc l :  Prof. Dr. B. Mcyboor n - clc cl on�J).  Het Or lc!er zocl< 
cl�tt lciclde tot cl i t  p1 oeL;ch ntt wer d uitnt':)voer·cl b i n rwn he! 
MCC K l i k  Tr;>nsn Jur�t le Diahett:)sproject in de re�J io Zwol le .  
In ?002 startle ze met cle h u isartsopleicli rlrJ aa1 1 cle U r t i ­
vel  sitoit van Groni l l�Jei J .  Hct  ee1 ste cleel v�m cle opleitl ing 
voncl p laats i n  1-l u lsartsen pr�tkt ijk  ' t  Veen in H<Jttcm 
(opleicler :  R . O .  R i �;c hen) . De opleicl 1 n �1 we1 d vcr·voi�JCI bij 
het R IAGC i 1 1  Zwo l l e  (opleicler: F. G i m brcrc) en moiTH::nteel 
we1 kt ze vom l1et l:w t s te cleel van cle opleicl in�J lJij 
H u is:trtsenpral<t ijl< clc Tu1 frn�trkt  in Zwo l l e  (oplo icler :  
F� Spoelstra). 
Lielrth is getmuwcl r net Alcl r ecl U b i n l< en sind�-. 1 7  m�t�trt 
2003 de trotse moocler· v:m Anna Ro::�c1 .  
